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Foreword
During its long history, Methadone Maintenance has struggled with a reputation that conjures 
images of seedy Methadone clinics in rundown neighborhoods, inhabited by drug users who are 
merely substituting one drug for another. The emphasis seemed to be on “maintenance” rather 
than “treatment.”
Meanwhile, the substance abuse treatment field began to evolve, recognizing that substance use 
disorders are diseases that respond to treatment that can lead to recovery. The focus shifted to 
defining exactly what was needed to support recovery, and the idea of a more holistic approach 
began to take shape.
This recovery-oriented systems approach acknowledges the importance of a person-centered, 
community-involved recovery process–ideas that had not previously been associated with 
Methadone Maintenance. The question is why not?
Recovery-oriented Methadone Maintenance answers that question by presenting a dynamic and 
convincing picture of how recovery-oriented systems can be applied to Methadone Maintenance, 
bringing it into the recovery process. In doing so, the stigma that has surrounded Methadone 
Maintenance for much of its life is replaced by the recognition that Methadone has a legitimate 
place within the recovery-oriented system. 
When brought into the recovery process, the benefits of Methadone Maintenance are enhanced 
through linkages with other communities, resources, and systems. Methadone becomes part 
of the client’s recovery, rather than being perceived as a crutch. Through the integration of the 
recovery-oriented approach the Methadone Maintenance client becomes empowered to affect his 
or her recovery. The provider begins to treat the entire person, not just the addiction. The result is 
better and more accurate treatment management and reduced misuse and abuse.
The challenge becomes communicating this new approach to the Methadone Maintenance 
community. Recovery-oriented Methadone Maintenance meets that challenge, establishing an 
appropriate place for Methadone Maintenance within the recovery community. It is a volume that 
should be absorbed by medication-assisted treatment providers, whether or not they are currently 
involved in Methadone Maintenance, as well as all treatment providers. It is time to overcome 
the stigma associated with Methadone and focus on recovery. It is time to recognize that each 
person’s path to recovery is different and that Methadone Maintenance can and does have a 
legitimate place on that path for many.
H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM
Director, Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
U.S. Department of Health & Human Services
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Preface
Sit down and be prepared to feel the earth move beneath you. For nearly half a century, 
methadone has been used successfully—but never without controversy—as a medication in the 
treatment of opioid addiction. This latest recovery monograph by William L. White and Lisa Mojer-
Torres reviews the history and cultural context of methadone maintenance (MM) treatment in the 
United States, with an emphasis on the evolution of practices that directly influence long-term 
recovery outcomes. These pages offer a distinct understanding of medication-assisted recovery 
in general, and methadone-assisted recovery in particular. On page 7, the authors write:
Recapturing and extending methadone maintenance as a person-centered, 
recovery-focused treatment of opioid addiction—what we here refer to as 
recovery-oriented methadone maintenance (ROMM)—will require a realignment 
of addiction- and recovery-related concepts, a realignment of core clinical and 
recovery support practices, and a realignment of the context in which treatment 
occurs (e.g., policies, regulatory guidelines, funding mechanisms, community 
recovery support resources).
Too much to ask, one might say? Actually, not at all. It’s just the beginning. In this new recovery-
focused understanding, methadone maintenance is saved from being an end in itself and is 
instead portrayed as a medication that, when wrapped in an array of professional and peer-based 
support services, will offer many individuals their best opportunity for long-term recovery. Be-
cause it is recovery-focused and measured by more than drug stabilization, Recovery Oriented 
Methadone Maintenance (ROMM) becomes simultaneously an enhancement to medication 
maintenance alone, a defense against medication as personal pacification or social control, and 
a safeguard against non-rehabilitative approaches that perversely profit from the dependence of 
others. ROMM protects pharmacotherapy with an array of technically skilled, recovery-thinking 
professional and peer-based recovery supports; opportunities for family and community involve-
ment (often absent today); and measures and accountabilities. Together, these reach into the 
quality and wellness of the individual’s life and tie the gained recovery capital of the individual to 
the gained recovery capital of the community. 
Most critical in this new understanding is the realization that being “in recovery” may or may not 
mean being on methadone. Indeed, some readers will contest or challenge this view, insisting that 
only by being “drug-free” and off methadone can one even begin to say, “I am in recovery.” The 
authors chart the historical sources of that view, but herein advance that being on properly moni-
tored methadone is really no different from being on other medications (e.g., insulin for diabetics, 
antidepressants for depression, disulfirum for alcoholism, etc.) that support one’s recovery from 
other chronic illnesses. In this view, the MM patient attains recovery when he or she engages in a 
process of recovery that:
•	 leads	to	stabilization	on	his	or	her	optimal	dose,
•	 helps	the	patient	abstain	from	the	use	of	alcohol	and	other	intoxicating	drugs,	and	
•	 produces	evidence	of	improved	global	health	and	social	functioning.
As the authors contend, it is time that MM patients who meet this three-part definition of 
recovery are welcomed into American communities of recovery. It is also time that recovery from 
opioid dependence was recognized as more than the removal of drug use from an otherwise 
unchanged life. 
Perhaps the most important insights are related to the entwining of the social contexts and 
historical influences that the authors illuminate. White, a world leader in recovery-focused historical 
research and advocacy, and Mojer-Torres, an eminent lawyer and advocate for people involved 
in MM treatment, speak for the person and family first. In speaking of the quality of methadone 
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services and its cultural and professional status today, the authors open new frontiers by travers-
ing across time to present-day criticisms of MM, and delineate what ROMM in particular can do 
to help us transcend those concerns. In this, providers are asked to “go the distance” by adding a 
recovery focus, staff in recovery (with or without MM), recovery representation on their boards of 
directors, program recovery philosophy, and recovery-focused and -measured care. Regulators 
are directly challenged to ameliorate the overwhelming barriers to achieving a more humane, 
sensitive, and potentially effective system of opioid dependence treatment. Even the traditional 
role of MM dispensed only via Opioid Treatment Programs (OTPs) is challenged by the advocacy 
of office-based care for those well into recovery but still in need of methadone-assisted physical 
stabilization. The monograph concludes with a paper describing recovery in the city of Philadel-
phia that offers priceless added understanding of ways of recognizing, addressing, and reducing 
stigma in this population. This one is a classic in and of itself. 
Indeed, by now, if you are still in your chair, you have felt the earth move. William White and Lisa 
Mojer-Torres offer a new view, one which must be considered fully and which we as publishers 
believe will ultimately elevate and advance the quality of methadone treatment in the United States. 
Read on, dear reader, travel this monograph with its sweeping review of the history of MM, 
reframed and elevated today within a recovery focus and framework. You will hear much in this 
work from these two long-term recovery advocates, from other experts and critics, and from other 
voices in recovery—with and without current methadone assistance—who share their personal 
experience and insight. The articles, each also available as a stand-alone for separate use and 
publication, will stir thought and discussion, but they will also suggest that we do much more in 
implementation, if we are to evolve and individuals and communities are to find ROMM. Many 
examples are provided, and clinicians, seasoned addiction experts, and methadone practitioners 
are asked to take the next step—instilling and sustaining a recovery focus in treatment—that will 
restore purpose and invigorate the desire to treat the person and the addiction in general, rather 
than just treating addiction with a particular drug or defining a person by a particular medication.
In the end, we believe we are all enhanced by this work: authoritative, experiential, novel, and yet 
sensible—very sensible. Recovery, defined for medication-assisted treatments and methadone 
maintenance in particular, re-asserts a clear purpose and measurable and accountable outcomes. 
These pages offer hope that we can connect professionally directed biopsychosocial intervention 
to the process of long-term, self-maintained recovery. 
Michael T. Flaherty, PhD  Lonnetta Albright  Arthur C. Evans, PhD
Principal Investigator Executive Director Director
Northeast ATTC  Great Lakes ATTC  Philadelphia DBHMRS
Publishers’ Note: This latest monograph represents the seventh in a series of monographs by 
William White and co-authors, a series that explores the evolving understanding of addiction as a 
chronic illness best addressed through a focus on its recovery and on those seeking or in recov-
ery. All have been published by the Great Lakes Addiction Technology Transfer Center (ATTC), the 
Northeast Addiction Technology Transfer Center, and the Philadelphia Department of Behavioral 
Health and Mental Retardation Services. The publishers wish to gratefully acknowledge the 
SAMHSA Center for Substance Abuse Treatment for the support that makes this work possible, 
and to acknowledge our respective ATTC parent organizations: the University of Illinois – Chicago 
(UIC) and the Institute for Resarch, Education and Training in the Addictions (IRETA). In these 
publications we seek, not to be clinically proscriptive, but to challenge through insight and experi-
ence, so as to build from these works an even greater world of possibility for improved care and 
more effective and fulfilling recovery. The monographs are available for free viewing or download 
at www.williamwhitepapers.com, www.ireta.org, and www.attcnetwork.org/greatlakes. 
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Executive Summary
There are growing calls to shift the acute-care model of addiction treatment to a model of 
sustained recovery support analogous to the long-term management of other chronic diseases. 
The purpose of this monograph is to explore what this shift means to the design and delivery of 
methadone maintenance (MM) treatment and the status of MM treatment and MM patients in the 
United States. 
Recovery-oriented Methadone Maintenance has two primary audiences. For addiction treatment 
professionals and recovery support specialists who have not worked in methadone maintenance 
treatment, our goals are to: 
•	 provide	a	primer	on	the	historical	evolution	and	scientific	status	of	MM	treatment,
•	 explore	the	controversies	surrounding	recovery	status	and	methadone	maintenance,	and	
•	 enlist	readers’	support	for	a	model	of	recovery-oriented	methadone	maintenance	(ROMM).
For addiction treatment professionals, recovery support specialists, and patients and their families 
directly involved with MM treatment, our goals are to:
•	 document	the	dissipation	of	recovery	orientation	within	the	evolution	of	MM	treatment,
•	 engage	readers’	support	in	reviving	and	extending	such	a	recovery	orientation,
•	 discuss	MM	in	the	context	of	recent	efforts	to	define	and	measure	addiction	recovery,
•	 describe	core	clinical	practices	within	MM	that	would	change	in	the	shift	toward	a	model	of	
ROMM, and 
•	 outline	strategies	to	address	the	professional	and	social	stigma	attached	to	methadone,	MM	
treatment, and MM patients.
Recovery-oriented Methadone Maintenance is divided into four articles:
I. Historical Context
II. Recovery and Methadone
III. A Vision Statement
IV. Long-Term Strategies to Reduce the Stigma Attached to Addiction, Treatment, and Recovery 
within the City of Philadelphia 
These four articles are also available individually, each containing both the relevant Executive 
Summary material and the content from the body of the monograph. The intent is to provide tools 
for both broad and focused examinations of this critical topic.
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RecoveRy-oRiented Methadone Maintenance
Introduction
William L. White, MA 
Lisa Mojer-Torres, JD
n Summary of Key Points — I: Historical Context 
Recovery-oriented methadone maintenance (ROMM) is an approach to the treatment of opioid 
addiction that combines methadone pharmacotherapy and a sustained menu of professional and 
peer-based recovery support services to assist patients and families in initiating and maintaining 
long-term addiction recovery—recovery defined here as remission of primary and secondary 
substance use disorders, enhancement of personal/family health and functioning, and positive 
community reintegration.
distinctiveness of RoMM 
ROMM provides an alternative to acute care (heroin detoxification or short-term maintenance) and 
palliative care (medication maintenance as a strategy of personal pacification and social control). 
ROMM is a person-centered model of long-term recovery management. 
opioid addiction as a chRonic disease 
It was the dream of those who developed methadone maintenance that chronic opioid addiction 
would one day be addressed with the same treatment philosophies and strategies used to man-
age other chronic medical disorders. Within this framework, the methadone maintenance patient 
is viewed on par with patients requiring normalizing doses of insulin, anti-convulsive medication, 
or hypertensive medication and psychosocial support services. Fulfillment of that vision has been 
thwarted by the strong anti-medication bias that pervades the history of addiction treatment and 
recovery in the United States.
eaRly tReatMent histoRy 
The treatment of opioid addiction in the United States spans nineteenth-century institutional 
treatment (inebriate homes, inebriate asylums, and private addiction cure institutes); detoxification 
by private physicians; exotic and sometimes lethal medical withdrawal procedures; fraudulent 
proprietary home cures; early twentieth-century morphine maintenance clinics; mid-twentieth-
century prison-based treatment (“narcotics farms”); and experiments with aversive conditioning, 
electroconvulsive treatments, psychosurgery, and psychoanalysis. All were characterized by high 
rates of resumed opioid addiction following treatment cessation.
the context foR Methadone tReatMent 
Methadone maintenance was pioneered in the mid-1960s in the wake of a dramatic rise in heroin 
addiction following the Second World War. Therapeutic pessimism regarding traditional approach-
es to treatment prompted calls by major policy bodies for new experiments in the maintenance 
of persons chronically addicted to heroin. Methadone maintenance developed amidst competing 
approaches to this problem: mass incarceration, Narcotics Anonymous, ex-addict-directed 
therapeutic communities, hospital-based detoxification, alternative pharmacotherapies, experi-
ments with civil commitment, and faith-based outpatient counseling clinics. 
the oRigin of Methadone Maintenance 
Methadone maintenance (MM) was pioneered in 1964 by Dr. Vincent Dole, Dr. Marie Nyswander, 
and Dr. Mary Jeanne Kreek at Rockefeller Institute for Medical Research (now Rockefeller Uni-
versity) and Rockefeller Hospital. Following early studies on its safety and effectiveness, MM was 
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integrated into multi-modality treatment systems in New York, Illinois, Connecticut, Massachu-
setts, Pennsylvania, and Washington, D.C. and then more widely disseminated in the 1970s within 
a growing national network of addiction treatment programs in the United States.
eaRly theoRetical foundations 
MM was based on a metabolic theory of addiction that viewed heroin addiction as a genetically 
influenced, chronic brain disease requiring sustained medical management—a problem of sick-
ness rather than sinfulness. Metabolic stabilization and maintenance (via individualized, optimal 
daily oral doses of methadone) were viewed as essential for most patients to achieve successful 
long-term recovery. MM was defined as “corrective but not curative.” It was believed that many, 
if not most, MM patients would require prolonged if not lifelong pharmacotherapy to sustain their 
recoveries. In the early-stage theory of MM treatment, biological stabilization was expected to be 
followed by psychosocial rehabilitation and community reintegration—processes requiring a broad 
menu of ancillary services and supports. 
eaRly RecoveRy oRientation 
Recovery-oriented practices (those now known to be linked to elevated long-term recovery out-
comes) within the early MM model included: 1) rapid access to treatment in early sites (e.g., New 
York City, Washington, D.C.); 2) patient involvement in clinical decision-making; 3) methadone 
doses (usually 80-120 mgd with no dose ceilings) capable of suppressing withdrawal distress, 
reducing craving, and inducing a “blockade effect” to other opioids; 4) therapeutic responses to 
any continued drug use; 5) a chronic care perspective that placed no arbitrary limits on duration 
of MM participation; 6) emphasis on creating a strong therapeutic alliance with each patient; 7) 
use of recovering staff as role models; 8) development of programs for populations with special 
needs; and 9) the broader mobilization of community resources to respond to addiction, including 
long-term recovery support needs. 
diffusion of MM 
Public and political alarm about heroin-related crime and about heroin use by U.S. soldiers 
in Vietnam spurred federal investment in addiction treatment and the subsequent diffusion of 
methadone maintenance in the United States. The number of methadone patients in the U.S. grew 
from fewer than 400 patients in 1968 to more than 80,000 patients in 1976, with much of that 
expansion occurring in New York City. 
decReased RecoveRy oRientation 
The regulation and mass diffusion of MM in the 1970s and 1980s was accompanied by changes 
in treatment philosophy and clinical protocols. The most significant of these changes in terms of 
recovery orientation included a shift in emphasis from personal recovery to reduction of social 
harm; increased preoccupation with regulatory compliance; widening variation in the quality of MM 
programs; the reduction of average methadone doses to subtherapeutic levels; arbitrary limits on 
the length of MM treatment; pressure on patients to taper and end MM treatment; the erosion of 
ancillary medical, psychiatric, and social services; and a decreased emphasis on therapeutic alli-
ance between MM staff and MM patients. The definition of recovery during this period shifted from a 
focus on global health and functioning to an almost exclusive preoccupation with abstinence—then 
defined as including cessation of methadone pharmacotherapy. The public face of MM became 
defined by the worst MM clinics and the least stabilized MM patients. Professional, political, and 
public support for MM as a medical treatment for opioid addiction declined through the late 1970s 
and early 1980s until the value of MM was revived in the late 1980s as a public health strategy to 
address the spread of HIV/AIDS. In spite of these challenges, many MM treatment staff continued to 
promote a vision of recovery, and many MM patients achieved but were forced to hide their achieve-
ment of that vision to avoid the social and professional stigma attached to MM. 
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Methadone cRitics 
The inevitable backlash to early media reports of methadone as a miracle cure for heroin addiction 
spawned numerous critics of methadone maintenance treatment. Critics of medication-assisted 
treatment, many of whom were competing for cultural and economic ownership of the problem 
of heroin addiction, alleged that MM: 1) substitutes one drug/addiction for another; 2) conveys a 
societal attitude of permissiveness toward drug use; 3) fails to address the characterological or 
social roots of heroin addiction; 4) cognitively, emotionally, and behaviorally impairs MM patients; 
5) is a tool of racial oppression and genocide; 6) is financially exploitive; and 7) as a result of these 
factors, is morally unacceptable. 
the Revitalization of MM 
Since the early 1990s, there has been a revitalization of MM in the United States. This process 
has included: 1) the scientific reaffirmation of the effectiveness of MM by prominent scientific, 
professional, and governmental bodies; 2) increased advocacy efforts by MM patients; 3) an 
expansion of national MM treatment capacity—most notably within the private sector; 4) national 
efforts to professionalize and elevate the quality of newly rechristened and accredited Opioid 
Treatment Programs (OTPs); and 5) an expansion of pharmacotherapy choices in the treatment of 
opioid addiction, e.g., buprenorphine/Suboxone/Subutex. These developments occurred amidst 
renewed efforts to publicly and professionally portray opioid addiction as a brain disease that can 
be medically managed with the aid of methadone and other pharmacotherapies. In spite of such 
advancements, resistance and hostility toward methadone continue from many quarters. 
RecoveRy-oRiented Methadone Maintenance 
Two trends are reshaping the future of MM in the United States: 1) a clearer articulation of addiction 
as a chronic disorder that is best treated through methods used to manage other chronic disorders, 
and 2) the emergence of recovery as an organizing paradigm for the addictions field. If sustained, 
these trends will profoundly change the nature of all addiction treatment, including MM treatment. 
the futuRe of MM 
The future of MM in the United States rests on the collective ability of OTPs to forge a more 
person-centered, recovery-focused medical treatment for opioid addiction and to confront 
methadone-related social stigma through assertive campaigns of public education and political/
professional influence. It also rests on the mobilization of a grassroots advocacy movement of MM 
patients and their families. An important next step in the developmental history of MM is to define 
recovery within the context of methadone maintenance and within the broader pharmacothera-
peutic treatment of substance use disorders. 
n Summary of Key Points — II: Recovery And Methadone 
defining RecoveRy within the context of MM 
Controversy and stigma continue to surround the use of methadone maintenance as a medical 
treatment of opioid addiction, in spite of more than four decades’ worth of scientific evidence of its 
effectiveness. Methadone patients continue to be socially marginalized, and their recovery status 
continues to be debated—even within the professional field of addiction treatment and within 
communities of recovery. The question of the recovery status of methadone patients cannot be 
answered without a clear understanding of what constitutes recovery from opioid addiction. The 
definition of recovery applied to the patient in medication-assisted recovery from opioid addiction 
should be the same as that applied to recovery from any other substance use disorder. 
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RecoveRy as MoRe than intent 
Recovery from opioid addiction is more than exhibiting motivation to stop or decelerate drug 
use. Defining recovery in terms of “he/she is trying” sets a low bar for expectations related to the 
methadone maintenance patient’s health, functioning, and quality of life. Defining recovery only as a 
motivational state also contributes to the professional and social stigma attached to methadone, MM 
treatment, and the MM patient and inhibits MM patients’ positive reintegration into the community. 
RecoveRy as MoRe than ReMission 
Recovery from opioid addiction is also more than remission, with remission defined as the sustained 
cessation or deceleration of opioid and other drug use/problems to a subclinical level—no longer 
meeting diagnostic criteria for opioid dependence or another substance use disorder. Remission is 
about the subtraction of pathology; recovery is ultimately about the achievement of global (physical, 
emotional, relational, spiritual) health, social functioning, and quality of life in the community. 
coRe eleMents of RecoveRy 
Recent attempts to define addiction recovery (e.g., Betty Ford Institute Consensus Conference, 
CSAT Recovery Summit, United Kingdom Drug Policy Commission) have focused on three 
essential elements: a) the resolution of drug-related problems (most often measured in terms of 
sobriety/abstinence or diagnostic remission), b) improvement in global health, and c) citizenship 
(positive community re-integration).
Methadone and RecoveRy 
There is growing professional consensus that the stabilized methadone maintenance patient who 
does not use alcohol or illicit drugs, and who takes methadone and other prescribed drugs only 
as indicated by competent medical practitioners, meets the first criterion for recovery. MM patients 
stabilized on medically supervised, individualized, optimum doses do not experience euphoria, 
sedation, or other functional impairments from the use of methadone as a medication. For the 
stabilized MM patient, methadone is NOT a substitute for heroin: the motivations for, effects of, 
and cultural symbolism of using methadone as a medication are vastly different from those associ-
ated with heroin use. 
distinguishing physical dependence fRoM addiction 
Physical dependence and addiction are not the same: the stabilized methadone maintenance 
patient—here defined as the patient who does not use alcohol or illicit drugs and takes methadone 
and other prescribed drugs only as indicated by competent medical practitioners—does not, like 
many pain patients maintained on opioid medications, meet key definitional criteria for addiction 
(e.g., obsession with using, loss of volitional control over use, self-accelerating patterns of use, 
compulsive use in spite of escalating consequences). 
RecoveRy status of the MM patient 
Denying “abstinence” or “drug free” status to stabilized MM patients (who do not use alcohol or 
illicit drugs and who take methadone and other prescribed drugs only as indicated by competent 
medical practitioners) based solely on their status as methadone patients inhibits rather than 
supports their long-term recoveries. 
vaRieties of Medication-assisted RecoveRy 
For stabilized MM patients, continued methadone maintenance or completed tapering and 
sustained recovery without medication support represent varieties/styles of recovery experience 
and matters of personal choice, not the boundary between and point of passage from the status 
of addiction to the status of recovery. 
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MM patient and coMMunities of RecoveRy 
The stabilized MM patient is caught in an ambiguous world—separated from cultures of active 
drug use, denied full membership in cultures of recovery, and socially stigmatized in the larger 
community. It is time for recovering MM patients to be welcomed into full membership in the 
culture of recovery and afforded opportunities to pursue full citizenship in their local communities. 
faMily RecoveRy in the MM context 
Rarely has the concept of recovery been applied to the families of MM patients. Opioid addiction 
severely wounds family and kinship relationships—wounds that feed the intergenerational trans-
mission of drug-related problems. Family recovery involves healing those wounds; reconstructing 
family roles, rules, and relationships; and enhancing the resistance/resilience/health of all family 
members. The ultimate aim of family recovery is breaking the intergenerational transmission of 
drug-related problems. 
seeking a vanguaRd of MM patients 
It is unlikely that the recovery status of the MM patient will be fully embraced by policy makers, the 
public, addiction professionals, and recovery communities until a vanguard of present and former 
MM patients and their families stand together to offer living proof of the role methadone can play 
in long-term recovery from opioid addiction. The faces and voices of healthy, fully functioning 
MM patients will be the most powerful antidotes to the stigma attached to opioid addiction and 
methadone maintenance treatment. 
Multiple pathways of RecoveRy 
There are multiple pathways and styles of long-term addiction recovery, and all should be cause 
for celebration. The MM patient who is stabilized on his/her optimal dose of methadone, abstains 
from the use of alcohol and other intoxicating drugs, and shows evidence of improving global 
health and social functioning is in recovery or recovering. Long-term recoveries from opioid addic-
tion with or without the use of methadone (or naltrexone or buprenorphine/Suboxone/Subutex) 
represent personal styles of recovery and should not be framed in categories of superiority or 
inferiority, right or wrong, or recovery inclusion or recovery exclusion. Rather than a source of 
disqualification from recovery status, methadone, provided as a medication under competent 
medical supervision at proper dosages with appropriate ancillary psychosocial support services, 
aids long-term recovery from opioid addiction and should be so recognized. 
RecoveRy definition and the design of opioid tReatMent pRogRaMs 
Achieving this vision of recovery as remission, global health, and citizenship for the mass of MM 
patients will require expanding and elevating the range and quality of clinical and peer-based 
recovery support services available to MM patients and their families. It will also require creating 
the physical, psychological, and cultural space in local communities within which medication-
assisted recovery can flourish. 
n Summary of Key Points — III: A Vision Statement
the ManageMent of chRonic disease 
Addiction to heroin or other short-acting exogenous opioids shares many of the characteristics 
of other chronic illnesses. Principles and practices that characterize the effective management 
of other chronic primary diseases can be adapted to effectively manage and improve long-term 
recovery outcomes in the treatment of chronic opioid addiction. 
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Methadone Maintenance and RecoveRy ManageMent 
Recapturing and extending methadone maintenance as a person-centered, recovery-focused 
treatment of opioid addiction—referred to here as recovery-oriented methadone maintenance 
(ROMM)—will require a realignment of addiction- and recovery-related concepts, a realignment of 
core clinical and recovery support practices, and a realignment of the context in which treatment 
occurs (e.g., policies, regulatory guidelines, funding mechanisms, community recovery support 
resources). Eight arenas of service practice will be profoundly transformed in the move toward 
ROMM: 1) attraction, access, and early engagement; 2) assessment and service planning; 3) 
service team composition; 4) service relationships; 5) service quality and duration; 6) locus of 
service delivery; 7) assertive linkage to recovery community resources; and 8) long-term recovery 
check-ups, stage-appropriate recovery support, and, when needed, early re-intervention.
attRaction, access, and eaRly engageMent/Retention 
Methadone maintenance treatment attracts voluntary participation by more people addicted to 
heroin and other short-acting opioids than any other addiction treatment modality, but most people 
in need of treatment for opioid addiction are not currently in treatment, will seek treatment only at 
late stages of their addictions, will drop out of treatment before optimum therapeutic effects are 
achieved, and will experience prolonged addiction/treatment careers before recovery stability is 
achieved. A key strategy of ROMM is to attract, engage, and retain patients at the earliest stages of 
problem development, toward the twin goals of shortening addiction careers and extending recovery 
careers. Promising practices in enhancing treatment attraction include educational campaigns to 
reach injection drug users, designed to dispel myths and misconceptions about MM treatment, and 
assertive community outreach teams that provide visible role models of medication-assisted recov-
ery, engage active users in a “recovery priming” process, mobilize family and kinship support, and 
resolve obstacles to treatment participation. Access to MM could be increased via expanded public 
and private funding of MM treatment, distribution of coupons for free treatment, reduction of regula-
tory obstacles that inhibit rapid access, expedited admission (e.g., interim maintenance—methadone 
without counseling), and moving stabilized patients to medical maintenance (methadone provided 
by trained primary care physicians). Promising practices related to engagement and retention in 
MM include individualized and higher methadone doses (above 60 mgd), increased patient choices, 
telephone and email prompts following missed appointments, patient education related to the safety 
and benefits of MM, provision of sustained peer-based recovery coaching, and provision of mental 
health services for co-occurring mental illness.
assessMent and seRvice planning 
Practices aimed at increasing the recovery orientation of the assessment and service planning 
process within MM treatment include shifting from categorical to global assessment instruments 
and interview protocols; defining the family (as defined by the patient) rather than the individual as 
the unit of service; using a strengths-based assessment process to identify personal, family, and 
community/cultural assets that can be mobilized to support recovery initiation and maintenance; 
viewing assessment as a continual rather than a single-point-in-time intake process (based on 
the understanding that service needs change across the developmental stages of recovery); and 
transitioning from professionally directed treatment plans to patient-directed recovery plans.
coMposition of the seRvice teaM 
Treatment of chronic diseases, in contrast with the treatment of acute disease or trauma, involves 
a broader multidisciplinary team and a greater emphasis on peer support for long-term recovery 
management. Implementing models of ROMM will involve key staffing changes within OTP 
programs, including a greater role of addiction medicine specialists in patient/family/community 
education; increased involvement of primary care physicians; co-location of OTPs and primary 
health care clinics; greater inclusion of family/child therapists; increased use of current and former 
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patients in medication-assisted recovery as staff and volunteers; and the use of indigenous 
healers drawn from diverse cultural communities, e.g., leaders of recovery-focused religious and 
cultural revitalization movements. 
the seRvice Relationship 
Service relationships within chronic disease management are distinctive in their duration (mea-
sured in years or decades), the degree of intimacy that develops between the service providers 
and the patient and family, and the broader focus of the relationship—the global health and 
functioning of the patient and family rather than treatment of a particular health defect. Positive 
indicators of recovery-oriented service relationships include increased levels of recovery repre-
sentation at OTP governance, leadership, and service delivery levels; respect for patient opinions 
and preferences via a choice philosophy; changes in administrative discharge policies; reduced 
incidence of administrative discharges and other premature disengagements from service; elevat-
ing patients’ hopes and possibilities; transitioning patients from professionally directed treatment 
plans to patient-directed recovery plans; and an emphasis on sustained continuity of contact and 
support across the stages of long-term recovery. 
seRvice Quality/duRation 
ROMM involves ensuring six critical areas of service practice: 1) dosing policies that ensure safe 
induction (optimum, individualized, and effective dose stabilization); 2) addiction counseling that 
is focused on building and sustaining a recovery process/partnership rather than the mechanics 
of dosing or service contact documentation; 3) expanding ancillary resources to address co-
occurring medical, psychiatric, and other substance-related problems; vocational/employment/
education needs; need for peer-based recovery support; and the needs of patients’ families/chil-
dren; 4) ensuring an adequate period of dose stabilization and psychosocial rehabilitation before 
any efforts to taper from MM (at least 1-2 years to achieve the best long-term recovery outcomes) 
and offering increased supports during and following the cessation of methadone maintenance; 5) 
increasing the percentage of MM patients who successfully complete treatment; and 6) building a 
strong culture of recovery within the MM service milieu.
the locus of seRvice deliveRy 
ROMM anticipates a greater focus on delivery of recovery support services outside the clinic and 
the greater integration of medication and other recovery support services within non-stigmatized 
community environments. Promising practices in this area include shifting from siloed OTPs 
toward the integration of MM within comprehensive addiction treatment and recovery support 
centers, the expansion of office-based treatment and medical maintenance, and greater use of 
neighborhood- and home-based recovery support services. The focus of ROMM is on firmly 
nesting recovery within the natural environment of each patient or in helping develop an alternative 
environment in which long-term recovery can be nurtured. 
asseRtive linkage to RecoveRy coMMunity ResouRces 
Peer-based recovery support resources are growing rapidly in the United States via the expanding 
network of addiction recovery mutual aid groups, the philosophical diversification of these groups, 
the emergence of a new addiction recovery advocacy movement, new recovery community insti-
tutions, and the emergence of new peer-based service roles (e.g., the recovery coach). Promising 
practices for ROMM in this area include:
•	 active	liaison	between	OTPs	and	the	service	committees	of	local	recovery	mutual	aid	societies;
•	 encouraging/supporting	the	development	of	groups	specifically	for	persons	in	medication-
assisted recovery and assertive linkage of patients to the resources of local communities of 
recovery (including medication-friendly recovery support meetings);
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•	 using	volunteer	or	paid	peer	recovery	coaches	to	facilitate	patient	connections	to	recovery	
community resources, coaching patients on ways of addressing medication issues at recov-
ery support meetings, and hosting onsite peer recovery support meetings at or near OTPs;
•	 sponsoring	educational	events	on	medication-assisted	recovery	for	recovery	community	
members;
•	 inclusion	of	indigenous	healers	and	healing	practices	within	OTPs;
•	 using	patient/alumni	councils	to	visibly	celebrate	patient	recovery	milestones;	and
•	 visibly	participating	(OTP	staff	and	MM	patients/families)	in	local	recovery	celebration	events.
long-teRM RecoveRy check-ups; stage-appRopRiate RecoveRy 
education and suppoRt; and, when needed, eaRly Re-inteRvention 
Most people addicted to opioids experience prolonged addiction careers marked by cycles of 
treatment, periods of abstinence, resumption of opioid addiction, and treatment re-entry. Asser-
tive approaches to in-treatment and post-treatment monitoring significantly enhance long-term 
recovery outcomes. We envision a future in which a system of recovery check-ups, peer-based 
recovery support, stage-appropriate recovery education, assertive linkage to communities of 
recovery, and early re-intervention will reduce post-treatment mortality and enhance the long-term 
recovery outcomes of MM patients.
suMMaRy 
Put simply, ROMM seeks to: 
•	 attract people at an earlier stage of problem development via programs of assertive commu-
nity education, screening, and outreach;
•	 ensure rapid service access for individuals and families seeking help;
•	 resolve obstacles to initial and continued treatment participation; 
•	 achieve safe, individualized, optimum dose stabilization;
•	 engage and retain individuals and families in a sustained recovery-focused service and sup-
port process; 
•	 assess patient/family needs using assessment protocols that are global, family-centered, 
strengths-based, and continual;
•	 transition each patient from a professionally directed treatment plan to a patient-directed 
recovery plan;
•	 expand the service team to include primary care physicians, psychologists, social workers, 
peer recovery support specialists, and indigenous healers;
•	 shift the service relationship from a professional/expert model to a long-term recovery part-
nership/consultation model marked by mutual respect, hope, and emotional authenticity;
•	 ensure minimum (at least one year) and optimum (individualized) duration of treatment 
via focused retention strategies and assertive responses to early signs of disengagement;
•	 shift the treatment focus from an episode of care to the management of long-term addic-
tion/treatment/recovery careers; 
•	 expand the service menu to include ancillary medical/psychiatric/social services and non-
clinical, peer-based recovery support services;
•	 extend the locus of service delivery beyond the OTP to non-stigmatized service sites and 
neighborhood-based, church-based, work-based, home-based, and technology-based 
(phone/Internet) recovery support services; 
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•	 assertively link patients/families to recovery community support resources; 
•	 engage the community through anti-stigma campaigns and recovery community develop-
ment activities; 
•	 provide post-treatment monitoring and support and stage-appropriate education, 
support, and (if and when needed), early re-intervention for all patients regardless of 
discharge status; and 
•	 evaluate MM treatment using proximal and distal indicators of long-term personal and family 
recovery. 
Care will need to be taken to avoid potential unintended consequences of this heightened 
recovery orientation, e.g., the abandonment of patients who do not share this vision of a recovery-
transformed life.
n Summary of Key Points — IV: Long-Term Strategies to Reduce the 
Stigma Attached to Addiction, Treatment, and Recovery Within the 
City of Philadelphia
intRoduction 
This article, developed for the Philadelphia Department of Behavioral Health and Mental Retarda-
tion Services (DBHMRS): 1) reviews the historical and scientific research on the social/profes-
sional stigma related to addiction, with a particular focus on the stigma experienced by people in 
medication-assisted recovery; and 2) outlines strategies that could be used by DBHMRS and its 
many community partners to reduce addiction/recovery-related stigma. 
stigMa Basics 
Research on the social stigma related to addiction can be summarized briefly as follows. 
•	 Stigma	involves	processes	of	labeling,	stereotyping,	social	rejection,	exclusion,	and	extrusion,	
as well as the internalization of community attitudes in the form of shame by the person/family 
being discredited.
•	 The	social	stigma	attached	to	addiction	constitutes	a	major	obstacle	to	personal	and	family	
recovery, contributes to the marginalization of addiction professionals and their organizations, 
and limits the type and magnitude of cultural resources allocated to alcohol- and other drug-
related problems.
•	 Social	stigma	attached	to	addiction	is	influenced	by	perceptions	of	the	role	of	choice	versus	
compulsion in addiction, the motivation for initial drug use (a search for pleasure versus es-
cape from pain), and whether addiction is related to a socially defined “good” or “bad” drug.
•	 The	social	stigma	attached	to	addiction	is	greatest	for	those	experiencing	multiple	discredit-
ing conditions, e.g., combinations of addiction, psychiatric illness, HIV/AIDS, minority status, 
poverty, homelessness, and the perception that a woman has failed to meet her gender-role 
expectations due to addiction. 
•	 Addiction-related	social	stigma	elicits	social	isolation,	reduces	help-seeking,	and	compro-
mises long-term physical and mental health outcomes of those with severe alcohol and other 
drug problems. 
•	 Heroin	addiction	and	its	treatment	have	been	trapped	between	medical	and	moral/criminal	
models of problem definition and resolution for nearly a century.
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•	 Methadone	maintenance	has	never	achieved	full	legitimacy	as	a	medical	treatment	by	the	
public, health care professionals, and the recovery community, in spite of the overwhelming 
body of scientific evidence supporting its effectiveness.
•	 The	person	enrolled	in	methadone	maintenance	has	never	received	full	status	as	a	“patient,”	
and the methadone clinic has yet to be viewed as a place of healing on a par with hospitals or 
outpatient medical clinics. 
•	 The	professional	status	of	methadone	treatment	has	suffered	from	the	absence	of	theoretical	
models of treatment and recovery that transcend a focus on the medication to address the 
larger movement toward global health and community integration. 
•	 Personal	strategies	to	deal	with	stigma	include	secrecy/concealment,	social	withdrawal,	se-
lective disclosure, over-compensation in other areas, and political activism. 
•	 Three	broad	social	strategies	have	been	used	to	address	stigma	related	to	behavioral	health	
disorders: 1) personal or mass protest (advocacy), 2) public and professional education, and 
3) strategies that increase interpersonal contact between stigmatized and non-stigmatized 
groups.
histoRical/sociological peRspectives 
The social stigma attached to certain patterns of psychoactive drug use has a long history in the 
United States and is inseparable from cultural strain related to such issues as race/ethnicity, religion, 
social class, gender roles, and intergenerational conflict. The social stigma attached to methadone is 
rooted in a larger anti-medication bias within the history of addiction treatment. Social stigma toward 
alcohol and other drug (AOD) addiction may be defined as a negative social force (an obstacle to 
problem resolution) or as a positive social force (discouragement of drug use; social pressure for 
help-seeking). A key question for local communities is: how do addiction treatment professionals, 
recovery advocates, and preventionists avoid working at cross-purposes in their educational efforts 
in local communities? Any campaign to counter addiction/treatment/recovery-related stigma must 
ask two related questions: 1) “What is the source of stigma?” and 2) “Who profits from stigma?”
conceptual undeRpinnings of the social stigMa attached to 
Medication-assisted tReatMent (Mat) 
Social and professional stigma, particularly stigma associated with methadone treatment, is but-
tressed by a set of core assumptions or beliefs. These assumptions and beliefs include the follow-
ing: 1) excessive drug use is a choice, 2) methadone is a “crutch,” 3) methadone simply replaces 
one drug/addiction for another, 4) methadone prolongs rather than shortens addiction careers, 5) 
low doses and short periods of methadone maintenance result in better rates of long-term recov-
ery, and 6) methadone maintenance patients should be encouraged to end methadone treatment 
as soon as possible. These propositions have been and are being challenged by a growing body 
of scientific research on methadone and medication-assisted treatment and recovery. 
seMantic and visual iMages undeRpinning Mat-Related stigMa 
The stigma attached to heroin addiction has been extended to methadone treatment and intensi-
fied through language and images within the professional and popular media that represent the 
least stabilized methadone patients and the lowest quality methadone clinics as the norm. The 
stigma attached to heroin addiction is internalized and results in an elaborate pecking order within 
the illicit heroin culture. Such pecking orders can be acted out with negative consequences within 
the milieu of methadone maintenance treatment. Any campaign to address the social stigma 
attached to medication-assisted treatment and recovery must transform the ideas, words, and 
images attached to this approach to treatment and this pathway of recovery.
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stReet Myths and stigMa 
Stigma attached to methadone maintenance treatment has been embedded within the illicit drug 
culture of the United States in ways that inhibit treatment seeking and contribute to early treatment 
termination. These myths topically span the origin of methadone, methadone’s pharmacological 
properties and long-term effects, and the source of the proliferation of methadone maintenance 
clinics in poor communities of color. Any effective anti-stigma campaign aimed at establishing the 
legitimacy and effectiveness of medication-assisted treatment and recovery must include the wide 
and sustained dissemination of myth-challenging information within local cultures of addiction and 
local communities. 
exaMples of addiction-Related stigMa/discRiMination 
Addiction/treatment/recovery-related stigma manifests itself in a broad range of attitudes, 
behaviors, and policies that range from social shunning to discrimination, e.g., loss of access to 
medical/dental care, governmental benefits, training/employment opportunities, and housing and 
homelessness services. Stigma/discrimination related to participation in methadone maintenance 
includes: denial of access to methadone maintenance or medically supervised withdrawal in jail, 
denial of admission to other addiction treatment modalities and recovery support services, denial 
of pain medication, denial of the right to speak and assume leadership roles in local recovery 
mutual aid meetings, and loss of child custody due to participation in MMT. Stigma-influenced 
methadone maintenance treatment practices include arbitrary dose restrictions, restrictions on 
the duration of MM, lowering methadone dose as a punishment for rule infractions, disciplinary 
discharge for drug use, and shaming rituals (public queues to receive methadone, supervised 
consumption, separate bathrooms for staff and patients, observed urine drops for drug testing, 
discouragement of peer fraternization).
conceptual undeRpinnings of a caMpaign to eliMinate stigMa 
Related to Methadone 
A campaign to lower stigma related to medication-assisted treatment/recovery must involve a 
set of messages related to the nature of addictive disorders, the nature of addiction recovery, the 
potential benefit of medication to the recovery process, and a statement of the harmful effects 
of stigma on treatment/recovery outcomes and on the family and larger community. These core 
ideas must be science-based, clear, capable of translation into educational slogans, and effective 
in altering perceptions, attitudes, and actions (as measured by pilot testing).
an addiction/tReatMent/RecoveRy caMpaign 
The guiding vision of the proposed campaign is to create a city and a world in which “people with 
a history of alcohol or drug problems, people in recovery, and people at risk for these problems 
are valued and treated with dignity, and where stigma, accompanying attitudes, discrimination, 
and other barriers to recovery are eliminated.”1 The campaign goals are to: 1) enhance public and 
professional perceptions of the value of medication-assisted treatment, 2) enhance the perceived 
value of medication-assisted treatment within the heroin-using community, 3) put a face and voice 
on medication-assisted recovery and portray the contributions of people in medication-assisted 
recovery to their communities, and 4) increase the participation of medication-assisted treatment 
providers within local community activities. The strategies proposed for the campaign span the 
following areas: 1) recovery representation and community mobilization; 2) community education; 
3) professional education; 4) non-stigmatizing, recovery-focused language; 5) treatment practices; 
6) local, state, and national policy advocacy; and 7) campaign evaluation. The implementation of 
these strategies will require that people in methadone-assisted recovery take their places at the 
vanguard of the larger recovery advocacy movement. Efforts must be made to encourage and 
support that vanguard. 
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A Brief Note On Language 
The terms opiate and opioid both appear in this monograph. Opiate refers to drugs derived 
from the poppy plant, whereas opioid is a more encompassing term that includes synthetic and 
semi-synthetic drugs. Medication-assisted treatment (MAT), as used in this monograph, refers to 
the use of medications to facilitate detoxification, suppress withdrawal symptoms, reverse cravings 
(normalize physiological functions), neutralize or create an aversion to the effects of particular 
drugs, or treat symptoms of a co-occurring medical/psychiatric disorder (normalize psychological 
functions). MAT is most frequently applied to the use of medications in the treatment of alcohol-
ism (e.g., antabuse, naltrexone, nalmefene, acamprosate) and heroin addiction (e.g., methadone, 
buprenorphine, naltrexone). Medication-assisted Recovery (MAR) refers to the use of medications 
as an aid in recovery initiation and/or recovery maintenance. MAT refers to professional interven-
tions; MAR refers to the activities and experience of patients whose recoveries have been sup-
ported by medications such as methadone, Buprenorphine/Suboxone, or naltrexone. Methadone 
maintenance (MM) is the use of the medication methadone in individualized, optimum doses, in 
tandem with counseling and other recovery support services, as a treatment for opioid addiction 
(primarily addiction to heroin and prescription opioids). While methadone may be prescribed by 
private physicians as an analgesic, MM as a treatment of opioid dependence is provided in the 
United States primarily by the 1,215 (as of March 5, 2010) accredited Opioid Treatment Programs 
(OTPs).2 Patients who have achieved prolonged dose stabilization and psychosocial rehabilitation 
may also be eligible for medical maintenance—a program that allows them to see a physician once 
per month and receive four weeks of medication without the requirement of continued participa-
tion in an OTP. Office Based Opioid Treatment (OBOT) is medication-assisted treatment for opioid 
dependence provided in a setting other than an OTP—an option that is legal but currently limited 
in its availability. 
1. Substance Abuse and Mental Health Services Administration (SAMHSA). 
(2002). National Recovery Month helps reduce stigma. Rockville, MD: Sub-
stance Abuse and Mental Health Services Administration. Retrieved June 
17, 2009 from http://www.hazelden.org/web/public/ade20909.page.
2. N. Reuter, personal communication, March 5, 2010.
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RecoveRy-oRiented Methadone Maintenance
I. Historical Context 
William L. White, MA 
Lisa Mojer-Torres, JD 
There are growing calls to shift the acute care model of addiction treatment to a model of 
sustained recovery support analogous to the treatment and management of other chronic 
diseases.3 Efforts are underway at federal, state, and local levels to define and implement 
models of sustained recovery management and to nest these approaches within larger 
recovery-oriented systems of care.4 
Recovery management (RM) is a philosophical framework for organizing addic-
tion treatment services aimed at early pre-recovery identification and engage-
ment, recovery initiation and stabilization, long-term recovery maintenance, and 
enhancement of quality of life for individuals and families affected by severe 
substance use disorders.5 
Recovery-oriented systems of care (ROSC) are networks of formal and informal 
services developed and mobilized to sustain long-term recovery for individu-
als and families impacted by severe substance use disorders. The “system” 
in ROSC is not a local, state, or federal treatment agency but a macro level 
organization of a community, a state, or a nation.6 
The theoretical and scientific foundations of RM and ROSC and their implementation processes 
are outlined in a series of monographs developed by the Substance Abuse and Mental Health 
Service Administration’s Center for Substance Abuse Treatment and the Philadelphia Department 
of Behavioral Health and Mental Retardation Services.7 Those seminal documents provided a 
vision for the future of addiction treatment and recovery support services, but they only peripher-
ally addressed medication-assisted treatment (MAT) and, more specifically, the role of methadone 
maintenance (MM) in RM and ROSC. 
3. Dennis, M. L., & Scott, C.K. (2007). Managing addiction as a chronic 
condition. Addiction Science & Clinical Practice, 4(1), 45-55.  DuPont, R.L., 
McLellan, A.T., White, W.L., Merlo, L.J., & Gold, M.S. (2009). Setting the 
standard for recovery: Physician Health Programs. Journal of Substance 
Abuse Treatment, 36, 159-171. Institute of Medicine. (2006). Improving the 
quality of health care for mental and substance-use conditions. Washington, 
D.C.: The National Academies Press. McLellan, A.T., Lewis, D.C., O’Brien, 
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In this monograph, the authors outline a model of recovery-oriented methadone maintenance. 
Recovery-oriented methadone maintenance (ROMM) is an approach to the 
treatment of opioid addiction that combines medication and a sustained menu 
of professional and peer-based recovery support services to assist patients and 
families in initiating and maintaining long-term addiction recovery. 
ROMM provides an alternative to acute care (heroin detoxification) and palliative care (long-term 
medication maintenance as a form of social pacification, e.g., control of crime and disease). 
ROMM is a person-centered model of long-term recovery management whose primary goals are 
defined in terms of remission of primary and secondary substance use disorders, enhancement 
of personal/family health and functioning, and positive community reintegration. The ultimate aim 
of ROMM is an enhanced quality of life for each MM patient and his or her family, with larger social 
benefits viewed as flowing from this primary achievement. 
This article will review the evolution of service practices within MM in the United States that have a 
direct relationship to long-term recovery outcomes. 
Medication and chRonic diseases 
Chronic diseases are distinguished by their prolonged if not lifelong course. Medications have 
long played a role in the stabilization and management of such disorders. Today, medications play 
a central role in the treatment of cancer, diabetes, thyroid disease, asthma, chronic obstructive 
pulmonary disease, hypertension, migraine, hemophilia, anemia, AIDS, lupus, multiple sclerosis, 
rheumatoid arthritis, Hepatitis C, osteoporosis, Crohn’s disease, epilepsy, Alzheimer’s disease, 
severe mental health issues, psoriasis, glaucoma, sleep disorders, and chronic pain. Medications 
used in the stabilization and management of chronic conditions share five defining characteristics. 
1.  They eliminate, reduce, or manage symptoms of the disorder but do not “cure” (permanently 
alter the root cause of) the disorder. 
2.  They “work” only as long as the medication is being consumed at optimally effective doses 
and frequencies. 
3.  Their maximum benefits are often, and to varying degrees, achieved only in tandem with 
changes in the patient’s daily lifestyle. 
communities of recovery: A primer for addiction counselors and recovery 
coaches. Pittsburgh, PA: Institute for Research, Education and Training in 
Addictions. White, W., Kurtz, E., & Sanders, M. (2006). Recovery manage-
ment. Chicago, IL: Great Lakes Addiction Technology Transfer Center. 
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4.  Recurrence of symptoms can occur even with medication adherence, most often when larger 
aspects of the patient’s bio/psycho/social/spiritual health are disrupted. 
5.  When combined with broader strategies of bio/psycho/social/spiritual support, these medica-
tions can transform potentially lethal and profoundly disabling diseases into conditions that 
can be actively managed to sustain and enhance quality of life.8 
It was the dream of those who developed methadone maintenance that chronic opioid addiction 
would one day be treated with the same philosophies and service technologies used to treat 
other chronic medical disorders and that the methadone maintenance patient would be viewed no 
differently than patients requiring daily doses of insulin, anti-convulsive medication, or hypertensive 
medication.9 While there is little debate about the prolonged or lifelong use of medications in the 
management of other common chronic health conditions, the use of methadone in the manage-
ment of chronic heroin addiction has stirred considerable professional and public controversy.10 
A strong anti-medication bias pervades the history of addiction treatment and recovery in the 
United States. This antipathy toward medications is rooted in efforts to treat addiction with drugs 
that later were revealed to have great addictive potential. This history spans the treatment of 
morphine addiction with cocaine (1870s and 1880s) and the treatment of alcohol dependence 
with opium, morphine, cocaine, amphetamines, sedatives, and tranquilizers. The practice of 
defining recovery or abstinence as incompatible with the use of any mood-altering medications 
flows from this history.11 It is within this context that we will explore the development and evolution 
of methadone maintenance as a medical treatment for opioid dependence in the United States. 
the histoRy of Methadone Maintenance 
There are excellent histories of the development and evolution of methadone maintenance.12 
The purpose of this article is not to retell the story of methadone maintenance, but to draw from 
existing accounts to illustrate two ideally complimentary but often contrasting visions of MM: one 
focused on long-term personal recovery and the other on the reduction of personal and social 
harm. The prominence of one or the other of these visions has exerted a profound influence on 
the evolving nature of MM treatment, patients’ perception and experience of MM, and public and 
professional attitudes toward MM. We will pay particular attention to changes in key MM clinical 
practices that have a clear connection to recovery initiation, recovery maintenance, and quality of 
personal and family life in long-term recovery. 
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Internal Medicine, 118, 304-309. Joseph, H., & Dole, V.P. (1970). Methadone 
patients in probation and parole. Federal Probation, 34(2), 42-48. 
10. Stimmel, B. (1999). Heroin addiction and methadone maintenance: 
When will we ever learn? Journal of Addictive Diseases, 18(2), 1-4. White, 
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11. White, W. (1998). Slaying the dragon: The history of addiction treat-
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who survived (pp. 331-343). Knoxville, TN: The University of Tennessee 
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Nyswander, M.E., & Kreek, M.J. (1966). Narcotic blockade. Archives of In-
ternal Medicine, 118, 304-309. Kreek, M.J. (1993). Epilogue—a personal 
retrospective and prospective viewpoint. In M. W. Parrino, State methadone 
guidelines: Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: 
Center for Substance Abuse Treatment. Kreek, M. J., & Vocci, F. (2002). 
History and current status of opioid maintenance treatments. Journal of 
Substance Abuse Treatment, 23(2), 93-105. Joseph, H., Stancliff, S., & 
Langrod, J. (2000). Methadone maintenance treatment: A review of his-
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agonist pharmacotherapy for heroin addiction: History, recent molecular 
and neurochemical research and future in mainstream medicine. Annals 
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opioid addiction tReatMent BefoRe Methadone Maintenance 
Opioid addiction in the United States grew in tandem with a series of innovations: the isolation of 
the alkaloids morphine (1806) and codeine (1820) from opium, the introduction of the hypodermic 
syringe (1853), the sophisticated marketing of opiate-based patent medicines (late 1800s), and the 
introduction of heroin as an alternative to morphine (1898). Nineteenth century opium and morphine 
addicts seeking recovery were preyed upon via opiate-laced miracle cures promulgated by the 
same patent medicine industry that had long supplied them with opiate-based medicines. Medical 
treatments for opiate dependence in the U.S. during this early era focused on the best procedures 
and pacing of withdrawal and strengthening the patient’s physical, emotional, and moral constitu-
tion. Such treatment was provided via prolonged institutional care in specialized inebriate asylums 
(e.g., the DeQuincey Home, the Brooklyn Home for Habitués), brief outpatient treatment in private 
addiction cure institutes (e.g., the Keeley, Neal, Gatlin, or Openheimer Institutes), or by private physi-
cians, some of whom specialized in the treatment of opiate addiction. Treatment across all of these 
settings was usually followed by relapse. Intractable addicts—most with accompanying chronic 
medical problems—were maintained on opium or morphine by their physicians or, more commonly, 
were subjected to ineffective and potentially lethal withdrawal schemes.13  
Following passage of the Harrison Tax Act14 in 1914 and a 1919 Supreme Court decision (Webb 
v. United States) that interpreted such maintenance as criminal, 44 communities established 
morphine maintenance clinics (1919-1923). The clinics were criticized by the medical establish-
ment and were subsequently closed under threat of criminal indictment. Private physicians were 
allowed to legally detox patients using diminishing doses of opiates, but those who attempted 
a maintenance treatment approach faced arrest and prosecution by the Bureau of Narcotics. 
Through the early twentieth century, cultural responsibility for the management of opioid addiction 
was transferred from the medical community to the criminal justice system. 
When prisons became inundated with addicts who had violated the Harrison Act, Congress 
passed legislation (1929) that provided for the construction of two federal “narcotics hospitals” 
(prisons/”farms”)—one in Lexington, Kentucky (1935) and one in Fort Worth, Texas (1938). Beyond the 
Lexington and Forth Worth facilities, few resources existed for the treatment of opioid addiction. The 
exceptions included a small number of state facilities (e.g., State Narcotics Hospital in Spadra, Califor-
nia, 1928-1941), private hospitals, and psychiatrists who catered to addicted persons of affluence. 
in the treatment of opiate dependence: A personal perspective. Journal of 
Psychoactive Drugs, 23(2), 103-107. Platt, J.J., Widman, M., Lidz, V., & 
Marlowe, D. (1998). Methadone maintenance treatment: Its development 
and effectiveness after 30 years. In J.A. Inciardi & L. Harrison (Eds.), 
Heroin in the age of crack-cocaine (pp. 160-187). Thousand Oaks, CA: 
Sage. Senay, E.D., Lewis, D.C., & Millar, D.G. (1997). The history and 
current status of drug substitution therapy for narcotic addiction in the 
United States. In Medical prescription of narcotics (pp. 189-200). Seattle: 
Hogrefe & Huber.
13. Kleber, H., & Riordan, C. (1982). The treatment of narcotic withdrawal: 
A historical review. Journal of Clinical Psychiatry, 43(6), 30-34. White, 
W. (1998). Slaying the dragon: The history of addiction treatment and 
recovery in America. Bloomington, IL: Chestnut Health Systems. 
14. The Harrison Tax Act in effect made physicians the cultural gatekeep-
ers of access to narcotic drugs by levying a tax on narcotic distribution 
and providing licenses for such distribution only to physicians. Musto, D. 
(1973). The American disease: Origins of narcotic controls. New Haven: 
Yale University Press.
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Noteworthy in this early history is the limited availability and access to treatment, the risk of harm-
ful treatment (prolonged sequestration, injury from medications and medical procedures, financial 
exploitation), and the absence of models of sustained, community-based support for addiction 
recovery—no sustained professional treatment or support protocols, no opioid addiction recovery 
mutual aid societies, and no visible role models of recovery from opioid addiction. The pathways 
to recovery from narcotic addiction, if they existed in this era, were hazardous and poorly marked. 
the context foR Methadone Maintenance
The development of methadone maintenance in the early 1960s occurred within a unique histori-
cal context. First and foremost was the dramatic rise in heroin addiction following World War II 
and the Korean War, particularly among adolescents and transition-age youths. This triggered a 
number of responses, including church-sponsored counseling clinics, hospital detoxification units, 
and the first specialized adolescent addiction treatment unit in the country—a 141-bed facility 
opened in 1952 at Riverside Hospital.15 Also of note were efforts to adapt the program of Alcohol-
ics Anonymous as a framework of sustained recovery for heroin addicts, e.g., Addicts Anonymous 
(1947), Habit Forming Drugs (1951), Hypes and Alcoholics (early 1950s), and Narcotics Anony-
mous (1950, 1953), but these groups were small, geographically limited, and often short lived. NA 
nearly died as an organization in 1959 and did not generate a viable service structure or sizeable 
membership until after MM was pioneered. 
Psychiatric treatment of heroin addiction in the mid-twentieth century spanned electroconvulsive 
therapies, psychosurgery, aversion therapy, and psychotherapies from multiple theoretical 
schools, but none of these revealed any sustained promise of long-term recovery from heroin ad-
diction. Criminal penalties for drug possession and sales were dramatically increased in 1951 and 
1956, further filling the nation’s prisons with heroin addicts. Follow-up studies of addicts treated 
at the two federal “narcotics farms” revealed relapse rates exceeding 90% following community 
re-entry. Riverside Hospital was closed in 1961 after a report documented exceptionally high post-
treatment relapse rates. Synanon was founded in 1958 as the first ex-addict-directed therapeutic 
community (TC), but a thriving TC movement had not yet arisen in the U.S. when work on the 
development of MM began. States were experimenting with different approaches, including the 
use of civil commitments, to find some solution to the problem of opioid addiction. 
15. White, W. (2004). Riverside Hospital: The birth of adolescent treatment. 
Counselor, 5(2), 18-20.
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Therapeutic pessimism regarding the treatment of opioid addiction spurred the American Medical 
Association, the American Bar Association, and other groups to call for renewed experiments in 
the treatment of heroin addiction, including experiments in opioid maintenance. Despite calls from 
such prominent groups, the Federal Bureau of Narcotics aggressively opposed all maintenance-
based proposals for the treatment of heroin addiction on the grounds that such drug substitution 
was morally wrong and would lead to increased drug use.16 But forces were coalescing to tip the 
social scales toward experimentation with maintenance. 
the BiRth and eaRly RefineMent of Methadone Maintenance as a 
Model tReatMent  
In 1964, Dr. Vincent Dole (an internist), Dr. Marie Nyswander (a psychiatrist), and Dr. Mary Jeanne 
Kreek (a medical resident) led a research project at Rockefeller Institute for Medical Research 
(now Rockefeller University) and Rockefeller Hospital to develop a medical treatment for heroin 
addiction. Collectively, they were involved in every aspect of the research, but they each made 
special contributions, with Dole taking the lead on the funding, policy, and politics of the project, 
Nyswander serving as the lead clinician, and Kreek leading the scientific studies and data 
collection. Controversy surrounded the project from its inception, including threats of criminal 
indictment. They avoided prosecution due to Dr. Dole’s exceptional medical prominence prior to 
his work on heroin addiction and because of legal briefs prepared by the Rockefeller attorneys 
arguing that the Bureau of Narcotics’ harassment of physicians offering medical maintenance of 
addicts was based on a misinterpretation of the Harrison Act—an argument the Bureau did not 
want tested in the courts. The fruits of the Rockefeller project set the stage for the diffusion of 
methadone maintenance treatment throughout the world. 
The original pilot studies of MM in the mid-1960s occurred at a time when there was no national 
treatment system. A 1968 national survey revealed only 183 drug treatment programs in the United 
States, with more than 75% of these having been in existence for less than 5 years. By 1984, 
the number of drug treatment programs in the U.S. had grown to more than 3,000.17 Methadone 
maintenance as a new medical treatment for addiction had to compete with alternative medications 
(e.g., narcotic antagonists-naltrexone) and treatment approaches using very different theoretical 
frameworks and clinical approaches (psychiatric treatment, therapeutic communities, faith-based 
counseling clinics). The birthing and earliest clinical replications of MM were marked by: 
16. Musto, D. (1973). The American disease: Origins of narcotic controls. 
New Haven: Yale University Press. White, W. (1998). Slaying the dragon: 
The history of addiction treatment and recovery in America. Bloomington, 
IL: Chestnut Health Systems. White, W. L. (2002). Trick or treat? A century 
of American responses to heroin addiction. In D. Musto (Ed.), One hundred 
years of heroin (pp. 131-148). Westport, CT: Auburn House. 
17. Jaffe, J. (1987). Footnotes in the evolution of the American national 
response: Some little known aspects of the first American strategy for drug 
abuse and drug traffic prevention. The Inaugural Thomas Okey Memorial 
Lecture. British Journal of Addiction, 82, 587-600.
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•	 clinical	studies	concluding	that	short-acting	opioids	such	as	heroin	and	morphine	were	un-
suitable as maintenance agents;18
•	 the	discovery	of	methadone’s	unique	effects	on	metabolic	stabilization	and	its	ability	to	induce	
cross-tolerance to other opioids (“blockade effect”);19 
•	 the	publication	of	the	original	MM	treatment	protocol	(a	three-phase	process	of	stabilization,	
counseling and rehabilitation, and maintenance) and clinical findings from the first pilots;20
•	 elaboration	of	a	metabolic	disease	theory	of	addiction;21 
•	 scientific	studies	of	the	actions	and	safety	of	methadone;22 
•	 scientific	confirmation	that	the	physical,	social,	and	occupational	performance	of	stabilized	
patients was not impaired by methadone;23 
•	 the	extension	of	MM	pilots	to	New	York	City	hospitals/clinics/jails	under	the	leadership	of	Drs.	
Freeman, Khuri, Lowinson, Millman, Newman, Primm, Trigg, Trussell, and New York City’s 
Health Services Administrator Gordon Chase;24 
•	 the	transition	from	hospital-based	induction	into	MM	to	ambulatory	induction	within	outpatient	
clinics;25
•	 the	integration	of	MM	into	multi-modality	treatment	systems	in	New	York,	Illinois,	Connecti-
cut, Massachusetts, Pennsylvania, and Washington, D.C. under the early leadership of Drs. 
Ramirez, Newman, Jaffe, Senay, Weiland, Kleber, and DuPont;26 
•	 the	early	professionalization	of	MM	as	an	addiction	treatment	specialty,	e.g.,	the	first	National	
Methadone Conference (1968); and 
•	 the	increased	scientific	legitimacy	of	MM,	including	the	first	long-term	outcome	study	of	MM.27 
Historically, MM marked the remedicalization of opioid addiction and the re-involvement of 
physicians and nurses in the medical treatment of opioid addiction. The innovation of MM was not 
the fact that it provided drug maintenance as a medical intervention for opioid dependence. As 
noted above, 44 clinics in the U.S. had provided morphine maintenance during the early twen-
tieth century.28 The core innovations were the unique properties that methadone brought to the 
maintenance process and the service milieus within which methadone was nested within the pilot 
sites. When Dr. Vincent Dole died in 2006, patients around the world were receiving methadone 
as a medical treatment for heroin addiction.29 
18. Kreek, M.J. (1993). Epilogue: A personal retrospective and prospective 
viewpoint. In M. W. Parrino, State methadone treatment guidelines 
Treatment Improvement Protocol Series 1. Rockville, MD: Center for 
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viewpoint. In M. W. Parrino, State methadone treatment guidelines 
Treatment Improvement Protocol Series 1. Rockville, MD: Center for 
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M.E. (1967). Heroin addiction—a metabolic disease. Archives of Internal 
Medicine, 120, 19-24. 
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One early change in the design of MM is very important to the theme of this monograph. Before 
the MM pilot began, Dr. Dole conceptualized medication maintenance as a palliative care model 
that focused on reduction of personal and social harm—“a medication that would keep addicts 
content without causing medical harm and that would be safe and effective for use over long 
periods in relatively stable doses… The goal of social rehabilitation of addicts was not part of the 
original plan.”30 What shifted this theoretical perspective of palliative care almost immediately was 
the patients’ unexpectedly positive response to methadone as a stabilizing medication and the 
active involvement of Drs. Dole, Nyswander, Kreek, and other staff in the rapidly changing lives of 
their patients. Within weeks of initiating MM, patients who on other opioid medications had been 
obsessed only with the schedule of drug administration began to pursue other activities and talk 
about their futures.31 The goal of MM then shifted from palliation to an active and highly individual-
ized process of recovery management. The elevated expectations accompanying this shift proved 
quite empowering to patients who in the past had been defined more by their problems than their 
possibilities. A large portion of the patients during this early era of MM in the United States were 
older heroin addicts whose lives had been consumed by heroin in spite of multiple treatment 
efforts and who now saw methadone as a new life-transforming treatment. 
It was these [methadone maintenance] patients that gave all of us in those hal-
cyon days such hope and enthusiasm as to the possibility of eventually cutting 
heroin addiction down to a small problem [in the United States].32
eaRly theoRetical foundation foR clinical pRactices 
An analysis of the early and subsequent writings of Dole, Nyswander, Kreek, and other early MM 
pioneers reveals ten theoretical premises that shaped the core clinical practices within the original 
model of MM. 
1.  Heroin addiction is a genetically-influenced, chronic brain disease (a metabolic disorder 
on par with diabetes) marked by the prolonged or permanent derangement of the patient’s 
endogenous opioid receptor system. MM pioneers viewed heroin addiction not as a problem 
of deviance or “badness” but as a problem of “sickness”—a “brain disease with behavioral 
manifestations.”33 Recovery from heroin addiction thus required sustained medical super-
vision and medication management. MM rested on the proposition that primary cultural 
ownership of the problem of heroin addiction should rest with medical institutions rather than 
30. Dole, V.P. (1988). Implications of methadone maintenance for theories 
of addiction. The Albert Lasker Medical Awards. Journal of the American 
Medical Association, 260, 3025-3029. 
31. Dr. Mary Jeanne Kreek, personal communication, April, 2010. 
32. Kleber, H. (1977). Methadone maintenance treatment—a reply. 
American Journal of Drug and Alcohol Abuse, 4(2), 267-272. 
33. Dole, V.P., & Nyswander, M.E. (1967). Heroin addiction—a metabolic 
disease. Archives of Internal Medicine, 120, 19-24. Dole, V.P., Nyswander, 
M.E., & Kreek, M.J. (1966). Narcotic blockade. Archives of Internal Medicine, 
118, 304-309. Kreek, M.J. (2000). Methadone-related opioid agonist pharma-
cotherapy for heroin addiction: History, recent molecular and neurochemical 
research and future in mainstream medicine. Annals of New York Academy of 
Science, 909, 186-216. For recent updates, see Trigo, J.M., Martin-Garcia, 
E., Berrendero, F. Robledo, P. & Maldonado, R. (2010). The endogenous opioid 
system: A common substrate in drug addiction. Drug and Alcohol Dependence, 
108, 183-194, and Kreek, M.J. (2010). Overview and historical perspective of 
four papers presented on research related to the endogenous opioid system. 
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institutions that view addiction in terms of sin, vice (moral depravity), misbehavior, or crime.34 
MM as originally developed was a physician-directed, hospital-based model of medical care.35 
2.  Methadone-facilitated metabolic stabilization is essential for most patients to achieve suc-
cessful long-term recovery from heroin addiction; full biopsychosocial recovery is possible 
but is “corrective but not curative.”36 Effective dose stabilization was posited as the foundation 
of biopsychosocial recovery within MM. It was assumed that efforts to treat heroin addiction that 
failed to account for the need for metabolic stabilization would fail for most patients. 
3.  In the mid-1960s, methadone was discovered to have unique properties as a medical 
treatment for heroin addiction: no increase in tolerance over time (although stress-induced 
neurobiological changes may require dose increases or decreases over time); no impairment 
from euphoria or sedation; success in relieving withdrawal distress and cravings; long dura-
tion of effect (24-36 hours); high relative safety; minimal side effects; and low cost.37 Metha-
done was viewed as analogous to the use of insulin in the metabolic stabilization of diabetes. 
“With a relatively steady concentration [of methadone] in the blood, the narcotic receptors in 
critical cells remain continuously occupied and the patient becomes functionally normal.”38 
In this view, the foundation of methadone-assisted recovery is the oral administration of an 
individualized effective dose of methadone on a daily basis.
4.  Effective metabolic stabilization and achievement of blockade effects (e.g., prevention 
of effects from injected heroin) is contingent upon the individual receiving his/her op-
timal daily dose of methadone. This belief led to average daily doses of methadone within 
the MM pilot programs ranging from 80-120mgd.39 Subsequent research confirmed the wide 
range of dosages required to produce the same therapeutic blood levels as a result of patient 
variability in methadone metabolism.40 
5.  The dosage of methadone required for effective stabilization varies considerably from 
patient to patient and can vary modestly for the same patient over time. This find-
ing led to an early emphasis on individualized methadone dosing and adjustments in each 
patient’s methadone dose over time as needed. There were no arbitrary floors or ceilings on 
methadone dosage; average methadone doses were also expected to change over time in 
response to changes in heroin purity and in response to new patterns of use (e.g., increased 
use of prescription opioid medications within the illicit drug culture).
34. Platt, J.J., Widman, M., Lidz, V., & Marlowe, D. (1998). Methadone 
maintenance treatment: Its development and effectiveness after 30 years. 
In J.A. Inciardi & L. Harrison Eds.), Heroin in the age of crack-cocaine (pp. 
160-187). Thousand Oaks, CA: Sage.
35. It is historically noteworthy that the metabolic theory of heroin addiction, 
later reformulated as receptor system dysfunction, anticipated the discovery 
of specific opioid receptors. Dr. Dole undertook the first study to look for 
opiate receptors, but this discovery would not be made until 1973 by three 
independent research teams, led respectively by Candace Pert and Solomon 
Snyder, Eric Simon, and Lars Terenius. Pert, C.B. & Snyder, S.H. (1973). 
Opiate receptor: demonstration in nervous tissue. Science, 179, 1011-
1014. Simon, E.J., Hiller, J.M. & Edelman, I. (1973). Sterospecific binding 
of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. 
Proceedings of the National Academy of Science USA, 70, 1947-1949. 
Terenius, L. (1973). Characteristics of the “receptor” for narcotic analgesics 
in synaptic plasma membrane fraction from rat brain. Acta Pharmacologica 
et Toxicologica, 33, 377-384. J. Woods, personal communication, March 
15, 2010. See Ingolia, N.A., & Dole, V.P. (1970). Localization of d and 
l-methadone after intraventricular injection into rat brains. Journal of 
Pharmacology and Experimental Therapeutics, 175, 84-87. Woods, J. 
(1994). The discovery of endorphins. Retrieved April 22, 2010 from http://
www.methadone.org/library/woods_1994_endorphin.html. 
36. Dole, V.P. (1988). Implications of methadone maintenance for theories 
of addiction. The Albert Lasker Medical Awards. Journal of the American 
Medical Association, 260, 3025-3029. 
37. Dole, V.P. (1988). Implications of methadone maintenance for theories 
of addiction. The Albert Lasker Medical Awards. Journal of the American 
Medical Association, 260, 3025-3029. Dole, V.P., Nyswander, M.E., & 
Kreek, M.J. (1966). Narcotic blockade. Archives of Internal Medicine, 118, 
304-309. Kreek. M.J. (1973). Medical safety and side effects of metha-
done in tolerant individuals. Journal of the American Medical Association, 
223, 665-668. E. Senay, personal communication, February 16, 2010.
38. Dole, V.P. (1988). Implications of methadone maintenance for theories 
of addiction. The Albert Lasker Medical Awards. Journal of the American 
Medical Association, 260, 3025-3029. 
39. Kreek, M. J., & Vocci, F. (2002). History and current status of opioid 
maintenance treatments. Journal of Substance Abuse Treatment, 23(2), 
93-105.
40. Eap, C., Bourquin, M., Martin, J-L, Spagnoli, J., Livoti, S., Powell, 
K.,… Deglon, J. (2000). Plasma concentrations of the enantiometers 
of methadone and therapeutic response in methadone maintenance 
treatment. Drug and Alcohol Dependence, 61, 47-54. 
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6.  Chronic heroin addiction produces profound, persistent, recurring, and potentially 
permanent metabolic changes. Prolonged cellular cravings for heroin and the high relapse 
rates associated with heroin addiction are consequences of metabolic impairment rather than 
a function of inadequate motivation, psychopathology, or environmental stressors; individually 
optimal doses of methadone provide daily correction of this impairment. Some MM patients 
maintain their recoveries following cessation of methadone without relapsing, but most patients 
are at high risk of opioid relapse and development of other drug dependencies following termi-
nation of MM—particularly patients with long opioid addiction careers.41 Early studies found that 
relapse after discontinuation of MM was least likely for those with longer periods of time in MM, 
those who had achieved substantial rehabilitation, and those who had successfully completed 
treatment according to plan—a small minority of all MM patients.42 Early MM was delivered with 
an understanding that most patients would need prolonged if not lifelong methadone mainte-
nance.43 There were no arbitrary limits on duration of methadone treatment and no professional 
pressure for patients to taper. Patients were maintained on methadone as long as they contin-
ued to derive benefits from it. They were further encouraged to carefully weigh the risks/benefits 
of tapering and were provided increased support during the tapering process. Returning pa-
tients were welcomed and re-admitted without guilt or shame. Addiction recovery was defined 
in terms of health and functionality and not viewed as contingent upon cessation of MM.
7.  “Addict traits” are a consequence, not a cause of addiction.44 In the view of MM pio-
neers, chronic heroin addiction is a problem of neuropathology, not psychopathology. Ad-
diction was not viewed as a manifestation of mental illness, personality flaws, emotional pain 
related to trauma and loss, or inadequate coping skills. They argued that the biological roots 
of heroin addiction should not be confused with the psychological or social sources of heroin 
experimentation and use.45 The success of MM-assisted treatment/recovery was not believed 
to be contingent upon a specific psychiatric treatment. Counseling to maximize emotional sta-
bilization was directed primarily at lifestyle reconstruction, e.g., housing, family/social relation-
ships, education, work, leisure.46 In the words of Dr. Marie Nyswander, “… drug addicts, like 
other patients with medical illnesses, have attending or causative emotional problems, [but] 
they may neither need nor want psychiatric help.”47 
41. Des Jarlais, D.C., Joseph, H., Dole, V.P., & Schmeidler, J. (1983). 
Predicting post-treatment narcotic use among patients terminating from 
methadone maintenance. Journal of Advances in Alcoholism and Sub-
stance Abuse, 2(1), 57-68. Dole, V.P. (1988). Implications of methadone 
maintenance for theories of addiction. The Albert Lasker Medical Awards. 
Journal of the American Medical Association, 260, 3025-3029. Kreek, 
M.J. (2000). Methadone-related opioid agonist pharmacotherapy for 
heroin addiction: History, recent molecular and neurochemical research 
and future in mainstream medicine. Annals of New York Academy of Sci-
ence, 909, 186-216.
42. Stimmel. B., & Rabin, J. (1974). The ability to remain abstinent upon 
leaving methadone maintenance: A prospective study. American Journal of 
Drug and Alcohol Abuse, 1, 379-391. 
43. Jaffe, J. (1972). The maintenance approach to the management of 
opioid dependence. In C. Zarafonetis (Ed.), Drug abuse: Proceedings of the 
international conference (pp. 161-170). Philadelphia: Lea and Febiger.
44. Dole, V.P., & Nyswander, M.E. (1967). Heroin addiction—a metabolic 
disease. Archives of Internal Medicine, 120, 19-24. Dole, V.P., Nyswander, 
M.E., & Kreek, M.J. (1966). Narcotic blockade. Archives of Internal 
Medicine, 118, 304-309. 
45. Nyswander, M. (1956). The drug addict as a patient. New York: Grune 
& Stratton.
46. Dole, V.P., & Nyswander, M.E. (1967). Heroin addiction—a metabolic 
disease. Archives of Internal Medicine, 120, 19-24.
47. Nyswander, M. (1956). The drug addict as a patient. New York: Grune 
& Stratton.
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8.  Metabolic stabilization produced by MM does not, by itself, constitute recovery from 
heroin addiction; methadone-mediated metabolic stabilization of heroin addiction 
makes broader biopsychosocial rehabilitation possible.48 Early MM included a broad 
menu of services designed to promote global health and community reintegration, includ-
ing provision of or linkage to resources for treatment of co-occurring medical/psychiatric 
problems and secondary drug dependencies.49 The provision of ancillary services must be 
individualized by need, from no such services needed to multiple and prolonged services. 
9.  MM-assisted recovery initiation and maintenance is enhanced within a supportive 
service milieu—a vibrant recovery culture and a sustained recovery support partner-
ship between MM staff and their patients. The service milieu and service relationship 
are potent ingredients, valuable components that help maximize the potential of methadone 
maintenance in achieving/sustaining recovery. There was an emphasis in early MM programs 
on compassion and professional respect and rapport. Early units remained small (maximum 
of 75 patients) to ensure a close connection between staff and each patient.50 Peer supports 
were provided by stabilized patients who were hired as “research assistants” who could 
“speak from the authority of personal experience,” inspire hope in new patients, and serve as 
guides in the service process.51 There was intense support for education, employment, and 
pursuit of personal goals. Service relationships were marked by listening, encouragement, 
and continuity of contact over time, with patients actively involved in clinical decision-mak-
ing—including determination of personally optimal doses.52 
10.  The structure of daily clinic participation that enhanced early biopsychosocial stabiliza-
tion within MM can constitute an obstacle to full recovery once patients begin to recon-
struct a prosocial life in the community. There was growing recognition that the requirement 
for daily clinic contact could inhibit later-stage recovery by sustaining contact with recent and 
active drug users and by interfering with opportunities for education, employment, career 
advancement, family life, and travel. There was also an understanding that sustained recovery 
management of stable patients by a personal physician could improve overall medical care of 
patients (comparable to management of other chronic diseases), provide greater assurance of 
confidentiality, reduce stigma-related problems, and enhance quality of life in long-term re-
covery. Interest in non-clinic options for MM grew in tandem with the number of patients who 
had achieved complete social rehabilitation. Medical maintenance provision of monthly visits 
48. Dole, V.P. (1989). Interview. In D. Courtwright & J. H. Des Jarlais, 
Addicts who survived (pp. 331-343). Knoxville, TN: The University of Ten-
nessee Press. 
49. Kreek, M.J. (1993). Epilogue: A personal retrospective and prospective 
viewpoint. In M. W. Parrino, State methadone treatment guidelines, 
Treatment Improvement Protocol Series 1. Rockville, MD: Center for 
Substance Abuse Treatment. McLellan, A. T., Arndt, I. O., Metzger, D. S., 
Woody, G. E., & O’Brien, C. P. (1993). The effect of psychosocial services in 
substance abuse treatment. Journal of the American Medical Association, 
269, 1953-1957.
50. Hentoff, N. (1967). A doctor among the addicts. New York: Rand 
McNalley & Company.
51. Hentoff, N. (1967). A doctor among the addicts. New York: Rand 
McNalley & Company.
52. Ashton, M. (2005). Methadone maintenance: The original. Drug and 
Alcohol Findings, 14, 20-21. Joseph, H., & Woods, J. S. (2006). In the 
service of patients: The legacy of Dr. Dole. Heroin Addiction and Related 
Clinical Problems, 8(4), 9-28. 
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for take-home methadone (in diskette or tablet form) from physicians’ offices rather than the 
individual portions of juice provided in plastic bottles at MM clinics—was pioneered in the early 
1980s as a viable alternative for highly stabilized patients, but its availability remains extremely 
limited.53 
Theory was important to the development of particular clinical practices within MM, and several 
of these practices reflect what we will later define in this monograph as recovery-oriented clinical 
practices, e.g., transitioning from acute biopsychosocial stabilization to support for long-term 
biopsychosocial recovery, a relationship marked by personal encouragement and continuity 
of contact over an extended period of time, and availability of peer supports. There were two 
aspects to the biological emphasis in the metabolic theory of addiction and the central innovation 
of methadone that limited the recovery orientation in the evolution of MM. (We will explore these 
issues in greater depth in article three of this monograph.) 
First, opioid dependence was viewed as a specialized disorder, and, as a result, MM treatment 
was aimed at and explicitly evaluated in terms of remission/reduction/cessation of heroin use as 
opposed to focusing on a larger construct of recovery from addiction. As a result, Opioid Treat-
ment Programs (OTPs) historically have not provided for their patients a coherent rationale for 
abstinence from alcohol and other drugs, as has occurred in other addiction treatment modalities, 
nor have OTPs integrated the core technologies used in other treatment modalities to address 
patterns of and vulnerabilities to multiple drug use. At a systems level, this also created MM clinics 
that were isolated from the larger addiction treatment and recovery communities—isolation that 
left both MM staff and patients marginalized from these larger communities.
Second, the metabolic disease theory placed primary emphasis on the importance of pharmaco-
logical stabilization. Missing was a larger theoretical outline of how the addiction process poisoned 
personal character and interpersonal relationships and, as a result, how recovery involves not just 
a cessation of heroin use but a reconstruction of personal values, personal identity, and one’s 
relationship to family, friends, and community. The biological rationale for MM also provided little in 
the way of a framework to consider spirituality (including life meaning and purpose) as a potentially 
important dimension of the recovery process. What that has meant throughout the history of MM 
is that mainstream MM patients have never been afforded the scope and intensity of educational 
and counseling experiences routinely provided to those in other addiction treatment modalities. 
53. Novick, D.M., & Joseph, H. (1991). Medical maintenance: The treat-
ment of chronic opiate dependence in general medical practice. Journal 
of Substance Abuse Treatment, 8, 233-239. Novick, D.M., Joseph, H., 
Salsitz, E.A., Kalin, M.F., Keefe, J.B., Miller, E.L., & Richmond, B.L. (1994). 
Outcomes of treatment of socially rehabilitated methadone patients in 
physicians’ offices (medical maintenance): Follow-up at three and a half to 
nine and a fourth years. Journal of General Internal Medicine, 9, 127-130. 
Salsitz, E.A., Joseph, H., Frank, B., Perez, J., Richmond, B.L., Salomom, 
N., & Novick, D.M. (2000). Methadone medical maintenance treating 
chronic opioid dependence in private medical practice: A summary report 
(1983-1998). The Mount Sinai Journal of Medicine, 67, 388-397. Senay, 
E.D., Barthwell, A.G., Marks, R., Bokos, P., Gillman, D., & White, R. (1993). 
Medical maintenance: A pilot. Journal of Addictive Diseases, 12(4), 59-76.
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The counseling bar has been set low in MM, dominated by mechanics of medication manage-
ment and regulatory compliance within counselor caseloads that would be unthinkable in other 
modalities. Services aimed at assertive recovery management and lifestyle reconstruction have 
generally been viewed within MM programs as “ancillary” or optional “wrap-around” services to 
the pharmacotherapy that was viewed as the primary mechanism of MM treatment. 
eaRly challenges 
There is a tendency to portray the mid- to late 1960s and early 1970s as the Camelot period or 
“Golden era” for MM,54 but the realities are much more complex. There were many problems 
that plagued the earliest years of MM—and some of them endure to the present. These included 
challenges in:
•	 determining	optimum	therapeutic	dosages	of	methadone,	optimum	duration	of	methadone	
maintenance, effective tapering procedures, and post-tapering support protocols to reduce 
relapse risks;
•	 defining	the	optimal	multidisciplinary	team	to	operate	a	MM	clinic;
•	 competing	with	private	physicians	who	claimed	to	be	providing	addiction	treatment	but	who	
only prescribed methadone;55 
•	 minimizing	the	number	of	deaths	from	methadone,	e.g.,	deaths	from	high-dose	induction,	
overdoses among neophyte users from diverted methadone, and accidental ingestion by 
children—problems compounded early (1969-1970) by private physicians financially profiting 
from prescribing liberal quantities of methadone;56
•	 determining	the	most	clinically	effective	procedures	for	central	intake	units	to	match	individual	
patients to particular treatment options, e.g., pharmacotherapies such as methadone detoxi-
fication, methadone maintenance, and narcotic antagonists; therapeutic communities (TCs); 
and other residential programs and outpatient psychosocial programs;
•	 managing	the	intense	conflict	and	competition	among	programs,	particularly	between	MM	
and TC advocates;57 
•	 developing	clinical	and	administrative	responses	to	continued	opioid	use	and	other	drug	and	
alcohol use after MM induction;
54. Kleber, H. (2002). Methadone: The drug, the treatment, the contro-
versy. In D. Musto (Ed.), One hundred years of heroin (pp. 149-158). 
Westport, CT: Auburn House. White, W. (1998). Slaying the dragon: The 
history of addiction treatment and recovery in America. Bloomington, IL: 
Chestnut Health Systems.
55. J. Jaffe, personal communication, March 10, 2010.
56. DuPont, R.L. (2002). Heroin addiction in the nation’s capital, 1966-
1973. In D. Musto (Ed.), One hundred years of heroin (pp. 67-90). West-
port, CT: Auburn House. Jaffe notes: “Some [private physicians prescribing 
methadone doses as high as 300 mg] used a different algorithm in which 
the methadone dose was related to the size of the fee paid by the patient.” 
J. Jaffe, personal communication, March 10, 2010.
57. Kleber, H. (2002). Methadone: The drug, the treatment, the 
controversy. In D. Musto (Ed.), One hundred years of heroin (pp. 149-158). 
Westport, CT: Auburn House.
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•	 formulating	protocols	to	respond	to	co-occurring	medical	and	psychiatric	disorders	among	
MM patients; 
•	 garnering	sufficient	financial	resources	to	sustain	methadone	clinic	operations—a	process	
that required finding a balance between cost effectiveness and clinical effectiveness in defin-
ing the billable units of MM clinic services; and 
•	 responding	to	professional	and	community	criticism	of	MM,	including	great	difficulties	in	find-
ing locations for MM clinics acceptable to the community—a subject we will return to shortly.
Perhaps the most challenging demand was the need to refine a new addiction treatment modality 
while simultaneously responding to a demand for treatment that far outstripped available capacity. 
The early MM programs in cities like New York City, Washington, D.C., Chicago, New Haven, and 
Philadelphia could respond to only a small fraction of those needing treatment, and most cities 
had few if any resources to respond to a heroin epidemic that was peaking across the country. 
eaRly RecoveRy oRientation of MM
In 1968-1970, the emerging multimodality treatment systems spoke of rehabilitation rather than 
recovery and defined rehabilitation in terms of three goals: reduced drug use, reduced criminal 
activity, and increased employment. Although there was not a “recovery consciousness” per 
se in the early MM clinics, there were several key clinical practices that the present authors will 
later define in this monograph as essential elements of a recovery-oriented model of methadone 
maintenance. These elements included:
•	 Rapid Service Access: Within the early MM clinics in New York City and Washington, 
D.C., every effort was made to expand treatment availability, speed service initiation, and 
stay connected to those on waiting lists for treatment as MM availability increased. The 
extent of early demand is evident by the two-year waiting list for admission into New York 
MM clinics in 1967.58 In 1969, the Narcotics Treatment Administration (NTA) in Washington, 
D.C. admitted 2,000 heroin addicts into 12 treatment programs within its first two months of 
operation59: “At that time NTA would rather treat two people half as well than one person in 
the best way possible. We did not want to leave anybody on a waiting list… We always had 
room for another heroin addict to come in off the street.”60 
58. Hentoff, N. (1967). A doctor among the addicts. New York: Rand 
McNalley & Company.
59. DuPont, R.L. (2002). Heroin addiction in the nation’s capital, 1966-
1973. In D. Musto (Ed.), One hundred years of heroin (pp. 67-90). 
Westport, CT: Auburn House.
60. DuPont, R.L. (2005). Conversation with Robert L. DuPont. Addiction, 
100, 1402-1411.
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•	 Patient Choice: Patients most often entered treatment through a central intake unit that con-
sidered patient preference in linking patients to a particular treatment modality/organization. 
The assessment process was independent from the treatment process and provided options 
and respect for patient choices. It was clear from the beginning that some persons addicted to 
heroin were achieving recovery in treatment modalities other than MM, but it was (and remains) 
unclear which patients can recover with these other options, which will benefit from short-term 
maintenance, and which will require prolonged and potentially lifelong maintenance.61 
•	 Effective/Individualized Dose Stabilization: Methadone doses were individually set based 
on patient need without arbitrary ceilings on doses that could be prescribed. Most early pro-
grams maintained the average 80-120 mg per day “blockade levels” originally pioneered by 
Dole, Nyswander, and Kreek. 
•	 Therapeutic Response to Continued Drug Use: Drug testing was integrated into the MM 
clinical protocol as soon as it became available. It served multiple purposes, including the 
inhibition of methadone diversion and a means of providing timely therapeutic responses to 
continued drug use (e.g., dose adjustments, intensified counseling). Testing conveyed the 
message that the continued use of illicit drugs was incongruent with personal recovery and a 
potential threat to clinic participation. 
•	 Chronic Care Perspective: Heroin addiction was viewed as a chronic, relapsing disorder 
whose treatment required prolonged if not lifelong medical and psychosocial support. There 
were no limits placed on length of MM treatment, nor was there pressure from staff for pa-
tients to taper. Sustainable recovery was viewed as requiring continued or intermittent treat-
ment of most patients over a number of years.62 
•	 Therapeutic Alliance: There was emphasis on forging a sustained, respectful relationship 
between MM clinic staff and each patient. This relationship was viewed as a critical dimension 
of the success of MM.63 
•	 Recovery Role Models: People in stable medication-assisted recovery from heroin addiction 
were integrated into the treatment milieu in multiple roles, to affirm the potential for long-term 
recovery from heroin addiction and to serve as recovery guides for new patients.
61. J. Jaffe, personal communication, March 10, 2010.
62. Jaffe, J. (1969). Possible solutions to the drug dependence and abuse 
problem. Presented at the Michigan Governor’s Conference on Drug 
Dependence and Abuse, December 18, 1969. 
63. Kreek, M.J. (1993). Epilogue: A personal retrospective and prospective 
viewpoint. In M. W. Parrino, State methadone treatment guidelines 
Treatment Improvement Protocol Series 1. Rockville, MD: Center for 
Substance Abuse Treatment.
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•	 Focus on the Whole Person: Methadone pharmacotherapy was wrapped in a larger menu 
of medical, psychiatric, and social support services (housing, employment, legal) aimed at 
enhancing global health and quality of life. 
•	 Safety Net: MM clinics developed special programs for patient populations whose needs 
exceeded the services available in mainstream clinics (e.g., specialty programs for women, 
younger patients, patients with serious psychiatric illness, patients with co-occurring severe 
alcohol problems, chronically relapsing patients). Referral to other programs/modalities was 
used as a safety net based on the assumption that the lack of optimal response was some-
times a function of the program or bad chemistry in the program-patient relationship rather 
than a function of patient pathology.64 
•	 Community as Patient: The organizations that first extended the MM model (e.g., those in 
New York City, Washington D.C, Chicago, New Haven) viewed themselves not as health care 
businesses but as public health agencies. In a very real sense, they viewed the community as 
their patient and sought mobilization of a community-wide response to problems of addic-
tion.65 
Other recovery-focused elements (e.g., recovery-focused patient and family education, collaboration 
with and assertive linkage to local recovery mutual aid groups, assertive follow-up of patients follow-
ing successful tapering or disengagement) were weak or missing from early MM treatment models. 
funding, diffusion, and Regulation of Methadone Maintenance 
The mid-twentieth-century heroin epidemic peaked (in terms of incidence of new heroin use) 
between 1969 and 1971.66 On the domestic front, there was alarm about rising drug use (particularly 
heroin use) and its most visible manifestation: escalating crime rates. That alarm intensified in 1971 
when two members of Congress returned from a visit to Vietnam and reported that “10-15% of GIs 
were addicted to heroin.”67 Fears of ever-escalating, drug-fueled crime and legions of addicted sol-
diers returning from Vietnam (which never materialized) triggered unprecedented action. On June 17, 
1971, President Richard Nixon declared a “war on drugs” and announced the creation of the Special 
Action Office for Drug Abuse Prevention (SAODAP) to coordinate a national response to the growing 
drug problem. The resulting federal strategy balanced traditional drug supply-reduction efforts with 
expanded activities related to drug demand reduction (e.g., prevention and treatment).68
64. White, W. (1998). Slaying the dragon: The history of addiction treat-
ment and recovery in America. Bloomington, IL: Chestnut Health Systems.
65. DuPont, R.L. (2005). Conversation with Robert L. DuPont. Addiction, 
100, 1402-1411.
66. DuPont, R.L. (2002). Heroin addiction in the nation’s capital, 1966-
1973. In D. Musto (Ed.), One hundred years of heroin (pp. 67-90). 
Westport, CT: Auburn House.
67. Jaffe, J. (1987). Footnotes in the evolution of the American national 
response: Some little known aspects of the first American strategy for drug 
abuse and drug traffic prevention. The Inaugural Thomas Okey Memorial 
Lecture. British Journal of Addiction, 82, 587-600. Jaffe. J. (2002). One 
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Westport, CT: Auburn House.
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This unprecedented federal investment in addiction treatment was led by two individuals, Drs. 
Jerome Jaffe and Robert DuPont, each of whom had led multimodality treatment systems—Jaffe 
in Chicago and DuPont in Washington, D.C. Based on their collective experience, they convinced 
the White House that methadone maintenance was an essential element of any comprehensive 
strategy and that it could exert a direct, rapid effect on urban crime rates. The resulting infusion of 
federal dollars led to the rapid expansion of addiction treatment programs—MM clinics, therapeu-
tic communities, outpatient counseling programs—across the country. The speed of MM diffusion 
was staggering—from 22 patients in 1965 and less than 400 patients in 1968 to more than 80,000 
patients in 1976.69 It should be noted that much of the expansion of MM was in New York City 
(36,000 by 1972), and that many American cities with significant opioid dependence problems 
did not provide MM, in part due to political controversies surrounding maintenance treatment. 
The New York City Health Department under the leadership of health czar Gordon Chase pushed 
the rapid expansion of MM in spite of cautions from even the most ardent MM defenders to avoid 
replicating MM too quickly. Chase acted on his belief that the prevalence of heroin addiction in 
New York City required a significant treatment response and that the most effective means of 
engaging those in need of treatment was through methadone maintenance.70 
This rapid expansion of MM programs led to federal and state regulatory structures, program 
licensure requirements, and new funding guidelines that exerted a profound and oft-debated 
influence on MM clinical practices. These new regulatory guidelines contributed to the dramati-
cally enhanced availability, quality, credibility, and acceptability of MM. They restricted who 
could provide MM to approved clinics and hospital pharmacies—an effort that deterred private 
physicians from profiteering from methadone prescriptions. They also restricted who could have 
access to MM—a response to allegations that physicians were prescribing methadone to non-
dependent heroin users.71 Without such requirements and guidelines, funding for MM would have 
been unlikely, and unacceptable practices in the worst-managed MM clinics could have triggered 
a backlash that would have threatened the very existence of MM. In a comparison of MM diffusion 
with such requirements to MM diffusion in countries that lacked such structures, it becomes clear 
that these requirements did serve to limit methadone diversion and methadone-related deaths.72 
The 1980s were marked by two successive presidential administrations (Carter and Reagan) in 
which White House Policy advisors were first lukewarm to MM and then distinctly anti-methadone. 
Diminished public funding support for MM—by more than 50%73—changes in the core philosophy 
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71. Jaffe, J., & O’Keefe, C. (2003). From morphine clinics to buprenor-
phine: Regulating opioid agonist treatment of addiction in the United 
States. Drug and Alcohol Dependence, 70, S3-S11.
72. J. Jaffe, personal communication, March 10, 2010.
73. Jaffe, J., & O’Keefe, C. (2003). From morphine clinics to buprenor-
phine: Regulating opioid agonist treatment of addiction in the United 
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of MM, and erosion of quality within many MM programs troubled early MM pioneers, as did the 
increasingly hostile attitudes toward MM at local and national levels.74 Indicative of such erosion 
was the 1988 White House Conference for a Drug Free America, which called for the abolishment 
of MM and an investigation of NIDA for its support of MM. Dr. Herbert Kleber75 describes 1988 
as the “lowest point methadone reached, in terms of national policy.” These years were marked 
by decreased public funding of MM, increased reliance on patient fees to support MM, and the 
dramatic growth of privately owned for-profit MM clinics.76 But even at this low benchmark, some 
200,000 patients were enrolled in MM in the United States.77
The most significant factor that brought MM back into policy favor was the spread of HIV/AIDS by 
injection drug users and growing evidence that MM significantly lowered the risk of HIV infection.78 
Public and professional alarm about rising rates of HIV infection and AIDS-related deaths pushed 
the primary rationale for methadone from a medical treatment for heroin addiction to a public 
health strategy of HIV/AIDS prevention. A more calculated harm-reduction approach to MM led to 
proposals for stripped-down versions of “interim MM” and “low-threshold MM.” MM pioneer Vin-
cent Dole was quite clear that such approaches to MM lacked the core technology and personal 
focus—what we refer to in this monograph as recovery orientation—of the original MM model. 
 … ”harm reduction” is an improvement in the sterile policy of simply blaming the 
addict for having a chronic, relapsing disease. At present methadone is being 
dispensed liberally in various harm reduction programs throughout the world, 
with doses and schedules being guided by the wishes of the addicts. This is not 
entirely bad, but it is a poor way to practice medicine and is not the “methadone 
maintenance treatment” described in the early literature.79 
changing clinical pRactices in MM in the 1970s and 1980s 
As MM programs spread in the 1970s and 1980s, several factors contributed to changes in core 
MM practices, their degree of effectiveness, and the cultural and professional perception of MM 
programs. First was the sheer level of demand for MM treatment. As waiting lists to enter MM 
lengthened, many programs responded by shortening treatment. They accomplished this by 
encouraging stabilized patients to taper/terminate MM and by administratively discharging patients 
for continued drug or alcohol use or for infraction of clinic rules.80 Characteristics of patients 
entering MM evolved toward a younger, less motivated population that was more prone to view 
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methadone as just another drug, or a control device, rather than a medication that could aid 
addiction recovery. The quality of staff also changed with mass expansion. Second-generation 
staff were sometimes less capable and less enthusiastic about MM and more likely to view their 
work as “just a job.” MM programs became increasingly characterized by inadequate staffing 
levels, hiring of staff philosophically opposed to maintenance, and relegating physicians (often in 
part-time positions) to conducting physicals and writing prescriptions rather than providing clinical 
leadership. Some of the newer expansion programs were also plagued with poor leadership and 
weak infrastructure (e.g., inadequate capitalization, facilities, and information technology) and were 
often perceived to be motivated more by financial gain than by community service. 
Many of the new methadone programs and regulatory bodies governing MM grew without a 
foundational knowledge of the pharmacology and theoretical framework that had guided MM’s 
early development. Dr. Dole later reflected on this period of mass MM diffusion.
With the growth of the programs, there was an adoption of methadone by people 
who still fundamentally believed that [heroin addiction] was a psychological problem. 
They were only using methadone as a means to engage somebody in treatment, 
with the ideas that ultimately the cure would be through psychotherapy… This type 
of attitude was adopted and expanded into an official view by the federal govern-
ment, and it was incorporated in their regulations by 1974. The goal of [methadone 
maintenance] treatment was [from that period on] not rehabilitation but abstinence.81 
Dole was particularly incensed at the shift away from the use of methadone doses high enough 
to achieve a blockade effect and at arbitrary limits on length of MM treatment—trends he viewed 
as being based on political considerations rather than medical science or clinical judgment.82 
Dole83 viewed each episode of tapering as “an experiment with the life of a patient” with potentially 
ominous outcomes that should not be undertaken without a sustained period of stability, the 
patient’s request, and prolonged follow-up by the physician. In later interviews, Dole continued to 
criticize the mass diffusion of what he considered to be a watered down approach to MM:
There is no sense in multiplying [methadone maintenance] programs that are 
administered by people who do not understand the pharmacology of metha-
done, or who lack compassion and a grasp of what it is to be an addict.84 
Drs. Dole and Nyswander were critical of the loss of key ingredients of MM throughout the late 1970s 
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and 1980s. They argued that “Bureaucratic control of methadone programs has given us ‘slots,’ a rule 
book, and an army of inspectors, but relatively little rehabilitation.”85 Dole’s and Nyswander’s criticism 
of the effects of federal regulation obscure the fact that some of the most restrictive of such regulations 
came not from the federal level but from states, counties, and cities. These criticisms also failed to 
acknowledge the fact that many methadone treatment providers resisted loosening MM regulations on 
the grounds that current regulations were essential for continued state funding of MM services.86 
Dr. Dole later spoke of the “stagnation of treatment” that occurred throughout the 1970s and 
1980s.87 He was particularly incensed at the depersonalization of MM and the loss of partnership 
with patients in MM: “the contempt with which many regulators and program administrators have 
treated their patients seems to me scandalous.”88 
The strength of the early programs as designed by Marie Nyswander was in their 
sensitivity to individual human problems. The stupidity of thinking that just giving 
methadone will solve a complicated problem seems to me beyond comprehen-
sion.89
Dole was not the only early MM pioneer who criticized the evolution of MM in the 1970s. In 1976, 
Dr. Robert Newman, who led the expansion of MM in New York City, declared: 
Methadone maintenance treatment, with its unique, proven record of both ef-
fectiveness and safety, no longer exists. One can only hope that it is not too late 
to reassess that which has been cast aside, and to resurrect a form of treatment 
which has helped so many, and which could help many more.90 
Other critics, including Dr. Stephen Kandall, concurred with Newman and further argued that:
Political forces reduced methadone to an inexpensive, stripped down way to 
“control” a generation of addicts without having to provide essential rehabilitative 
services… 91
Whether one believes the mass diffusion and regulation of MM was a curse or a positive and 
essential stage in the maturation of modern addiction treatment, it is clear that key changes 
occurred in the philosophy and practice of MM in the 1970s and 1980s. Changes that have had 
the greatest impact on long-term medication-assisted recovery include the following, as reported 
in the literature and observed by the authors:
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•	 Purpose: MM’s primary focus shifted from personal rehabilitation to reduction in social harm 
(e.g., crime, violence, disease transmission); at policy levels, and sometimes at clinical levels, 
the whole person and the personal recovery process became an afterthought.92 Protection of 
public safety/health and personal recovery are not incompatible, but emphasis on the former 
to the exclusion of the latter led to depersonalized and degrading treatment in some OTPs.93 
Increased privatization of MM (via for-profit methadone clinics) in response to cuts in public 
funding focused institutional missions on financial margins and led to cuts in ancillary servic-
es, as well as subsequent exposés of excessive profits in some clinics94—a situation that not 
only continues but has worsened.95
•	 Variation in Quality: There was widening variation in program adherence to accepted guide-
lines and best practices, and decreases in optimal care, as indicated by increased reports of 
adverse events and quality concerns raised by funding, licensing, and accreditation authorities. 
•	 Decreased Access: Cuts to publicly funded methadone programs, program closings, and 
reduced MM treatment capacity increased MM waiting lists, prompted prolonged delays in 
treatment entry, created pressure for premature and involuntary tapering, and led to service 
fees that forced some patients into criminal activity to pay for MM96—all at a time when de-
mand for MM treatment was increasing.97 
•	 Inadequate Dose Stabilization: Arbitrary limits were imposed on methadone doses, with 
average MM dosages dropping from their original optimal range of 80-120mgd to 88% of 
MM patients receiving suboptimal doses (below 60mgd) in 1988.98 Patient success became 
measured in terms of achievement of lower methadone doses and in getting patients off of 
methadone.99
•	 Concerns about Patient Safety: Some private clinics used exceptionally high doses (above 
120mgd) to attract patients, in spite of the lack of research on long-term effects and effective-
ness of such dosage levels.100
•	 Shortened Treatment Duration: Arbitrary limits were set for duration of MM, e.g., require-
ments for medical justification for sustaining treatment beyond two years, staff pressure for 
patients to progressively reduce methadone dosage and cease maintenance, extrusion of 
“troublesome” patients (i.e., those with the most severe and complex problems) via admin-
istrative discharge. One-year retention rates in MM in New York City dropped from an initial 
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98% to 59% ten years later.101 With growing professional, family, and community expectations 
that MM should be as short as possible, opioid addiction became the only chronic disease 
in which patients were shamed and stigmatized for long-term medication adherence. With 
these changes, MM patients were denied pride in the achievement of sustained recovery 
stabilization—in marked contrast to those celebrating the length of their recoveries in AA, NA, 
and treatment alumni association meetings. 
•	 Lowered Expectations: The shift from a rehabilitation to a harm-reduction philosophy led to 
tolerance of continued drug and alcohol use in some clinics.
•	 Contraction of Service Menu: There was a reduction in the range and intensity of medical, 
psychiatric, psychological, counseling, and social rehabilitation services provided, as funds to 
operate MM tightened and private programs discovered that providing fewer services gener-
ated greater profits.102 
•	 Regulator and Funder as the Patient: Increased preoccupation with regulatory compli-
ance and its ever-escalating paperwork burden: “[MM] Programs quickly learned that survival 
depended on the condition of the records and not the patients.”103 Close observers of MM 
throughout the 1970s and 1980s noted a shift in the character of the MM milieu from one of 
care, compassion, and choice to one of power, surveillance, and control. 
The very understanding of recovery within the context of MM changed during the 1970s and 
1980s. Whereas recovery was initially defined in the MM context in terms of global health and 
functioning irrespective of one’s medication status, recovery later became defined as beginning 
only at the point of cessation of MM. This newly imposed goal of “abstinence” from the use of 
methadone created a definition of recovery that precluded the use of methadone as a medication. 
(The subject of the relationship between methadone and recovery status and the controversies 
surrounding this question will be the topic of the second article in this monograph). Ironically, a 
study by Des Jarlais, Joseph, Dole, and Schmeidler104 found that the likelihood of sustaining absti-
nence from heroin after tapering from MM was greater in patients entering treatment in 1966-1967, 
when methadone doses were higher and sustained for longer time periods than in 1972, when 
methadone doses and maintenance duration were decreasing. 
Many MM clinics valiantly struggled to maintain the core clinical practices and personal recovery 
focus of the early MM model, but others became little more than methadone dosing stations 
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stripped of the rehabilitation services and recovery cultures that had once been essential parts of 
their character. As drug cultures flourished within and around these dosing stations (e.g., medica-
tion diversion, drug sales, prostitution), neighborhood acceptance of MM clinics, which was mar-
ginal at best, declined and was replaced by heightened opposition to MM. The worst-managed 
methadone clinics became the media-shaped face of methadone, and the best-managed clinics 
became virtually invisible. Myths and misconceptions about methadone flourished in this environ-
ment even among MM patients. Patient surveys found that while many believed methadone had 
positively affected their lives, they also believed that methadone could hurt their health and that its 
use should be terminated as soon as possible.105 
Studies of patients clinically or administratively pushed out of MM revealed high rates of post-
treatment heroin use, deaths, hospitalizations, arrests, incarcerations, and re-admission to MM. 
These findings led to calls for sustained retention of patients in MM.106 Ethnographic studies of 
local drug cultures revealed that the early vision of MM-facilitated social rehabilitation became 
replaced by a lifestyle for many MM patients marked by visits to the MM clinic, supplemental 
alcohol and drug use (e.g., cocaine and fortified wine), panhandling and other criminal activity, and 
welfare dependence.107 The erosion in quality of methadone maintenance, and its lost status as an 
effective, safe, and life-altering treatment for persistent heroin addiction, helped fuel the growing 
stigma and discrimination attached to MM. In spite of these limitations, a significant core of MM 
patients negotiated an increasingly oppressive system and forged their individualized recovery 
paths. Many of these otherwise invisible MM patients also became involved in advocacy, so that 
others could benefit from their experience, knowledge, wisdom, and tenacity. These patients and 
patient advocates are among the hidden heroes within the modern history of MM treatment.108
eaRly Methadone cRitics 
One aspect of the story of MM we have not yet discussed is the heightened stigmatization of 
methadone as a medication, methadone maintenance treatment (particularly high-dose treat-
ment), MM patients, and MM providers at cultural, governmental, and professional levels as well 
as within American communities of recovery.109
Media reports following the initial announcement of MM’s development characterized methadone 
as a panacea—a “Cinderella drug” that induced miraculous changes in addicts. Methadone was 
portrayed in the popular press as the magic bullet that would solve the country’s heroin addiction 
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problem.110 Efforts by Dr. Jerome Jaffe and others to explain that the positive outcomes of MM 
programs were the result of a total rehabilitative effort and not just the use of methadone went 
unheeded. The public and professional focus remained on the perceived power of methadone as 
a medical “cure” for heroin addiction. 
Early critics of MM (1970s and 1980s), including competing approaches to addiction recovery 
(e.g., therapeutic communities, Narcotics Anonymous) and government personnel whose views 
about maintenance had long been influenced by Bureau of Narcotics Chief Harry Anslinger, prof-
fered 10 key criticisms of MM. 
1.  MM reinforces the illusion that there are chemical answers to complex human and social prob-
lems. This criticism came particularly from those who viewed the cause of heroin addiction to 
be rooted in poverty and racism and who feared this new medication would be a “technologi-
cal fix” that diverted direct action on those underlying issues.
2.  Methadone merely substitutes a legal addiction for an illegal addiction; it is a form of “legalized 
euphoria” that does not eliminate craving for heroin. 
3.  Addicts maintained on methadone suffer from cognitive, emotional, and behavioral impairment: 
MM is a “crutch”—a pharmacological shield that prevents addicts from adjusting to reality.111 
4.  Government distribution of methadone reflects an attitude of permissiveness that contributes 
to youthful drug experimentation.
5.  The positive effects attributed to MM in published research studies are over-stated. 
6.  The source of addiction is rooted in the addict’s character/personality, not his or her cells.
7.  Treating heroin addiction with another opioid like methadone is morally unacceptable. 
8.  Methadone maintenance is a tool of genocide and racial oppression.
9.  The methadone treatment industry financially exploits those it has pledged to serve.112 
10. MM is a “hostile exercise in disciplining the unruly misuses of pleasure and in controlling 
economically unproductive bodies” through enforced dependency.113 
Widely publicized criticisms of MM became part of the growing body of myths and misunder-
standings that have plagued MM since its inception.114 Such misconceptions exerted considerable 
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influence on how MM clinics and MM patients viewed themselves and how allied professionals, 
the public, and policymakers viewed MM treatment. At a most practical level, starting or relocat-
ing new MM clinics became increasingly difficult from the mid-1970s forward in a cultural climate 
filled with such views.115 Most poignantly, MM patients faced stigma and discrimination from many 
quarters based on these perceptions, including within the larger addiction treatment field and local 
recovery mutual aid societies.116 
towaRd the Revitalization and elevation of Methadone 
Maintenance 
In 2003, Mark Parrino, President of the American Association for the Treatment of Opioid Depen-
dence (AATOD), suggested that methadone maintenance was entering a renaissance period of 
renewal, revitalization, and potential transformation. This renaissance began in the late 1980s and 
early 1990s with the reaffirmation of the effectiveness of MM by prominent scientific, professional, 
and governmental bodies, including the: 
•	 Lasker	Foundation	(1988),117
•	 Institute	of	Medicine	(1990),118 
•	 American	Society	of	Addiction	Medicine	(1990),119
•	 Government	Accounting	Office	Report	(1990),120
•	 Office	of	Technology	Assessment	of	the	United	States	Congress	(1990),121
•	 Ball	and	Ross	systematic	review	of	MM	outcomes	(1991),122
•	 American	Medical	Association	Council	on	Scientific	Affairs	(1994),123
•	 New	York	State	Office	of	Alcoholism	and	Substance	Abuse	Services	(1994),124
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•	 Office	of	National	Drug	Control	Policy	(1990,	1999),127
•	 National	Institute	on	Drug	Abuse	(1999),128
•	 World	Health	Organization	(2001),	and
•	 Cochrane	Review	(2003).129
These well respected reviews confirmed that methadone delivered at sustained optimal daily 
dosages and combined with ancillary psychosocial services delivered by competent practitioners: 
•	 decreases	the	death	rate	of	opioid-dependent	individuals	by	as	much	as	50%;	
•	 reduces	the	transmission	of	HIV,	Hepatitis	B	and	C,	and	other	infections;	
•	 eliminates	or	reduces	illicit	opioid	use;	
•	 reduces	criminal	activity;	
•	 enhances	productive	behavior	via	employment	and	academic/vocational	functioning;	
•	 improves	global	health	and	social	functioning;	and	
•	 is	cost-effective.130 
The effectiveness of MM was affirmed, and MM became the primary method used worldwide in 
the medical treatment of heroin addiction “despite regulatory constraints and suboptimal perfor-
mance by many programs.”131 
Today, the safety, effectiveness, and value of properly applied MMT is no more 
controversial [from the standpoint of science] than is the assertion that the earth 
is round.132
As the international body of scientific studies supporting MM grew, Dr. Dole continued to com-
municate what MM could and could not do as a treatment for heroin addiction. 
The treatment therefore, is corrective but not curative for severely addicted persons. 
A major challenge for future research is to identify the specific defect in receptor 
function and to repair it. Meanwhile, methadone maintenance provides a safe and 
effective way to normalize the function of otherwise intractable narcotic addicts.133
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Recent gRowth of Methadone Maintenance 
The number of patients admitted to OTPs in the United States grew dramatically between 1998 
and 2008—influenced by the growth in for-profit OTPs and new patterns of opioid addiction, e.g., 
increased addiction to pharmaceutical opioids. There are now 1,203 opioid treatment programs 
in 46 states (and the District of Columbia, U.S. Virgin Islands, American Samoa, and Puerto Rico), 
treating more than 260,000 patients on any given day.134 A 2009 analysis provides the latest profile 
of OTPs in the United States:
•	 OTPs	constitute	only	8%	of	all	U.S.	addiction	treatment	facilities,	but	OTP	patients	constitute	
23% of all patients in addiction treatment.
•	 67%	of	OTPs	serve	only	patients	in	medication-assisted	treatment—reflecting	the	isolation	of	
OTPs and their patients from the mainstream treatment system.
•	 50%	of	OTPs	are	operated	by	for-profit	organizations.
•	 Of	265,716	patients	in	OTP	treatment	in	2008,	99%	were	treated	with	methadone,	and	1%	
were treated with buprenorphine. 
•	 Half	of	all	OTP	patients	pay	out-of-pocket	for	their	own	treatment,	at	an	average	annual	cost	
of $4,176 per year.
•	 40%	of	OTP	patients	in	the	United	States	have	been	in	methadone	maintenance	treatment	for	
more than two years.135
the Quality of Methadone Maintenance
As the safety and effectiveness of MM was being reaffirmed, three additional findings in the 1990s 
triggered efforts to elevate the quality of methadone treatment.136 The first centered on the sci-
entific studies of Dr. John Ball and his colleagues suggesting that program factors (e.g., program 
policies, management capabilities, workforce stability, and staff training) play a greater role in MM 
clinical outcomes than do patient factors.137 The second was the 1990 General Accounting Office 
(GAO) report that exposed the high frequency of heroin and other drug use by MM patients as 
resulting from subtherapeutic doses of methadone.138 The third factor was growing awareness of 
the wide variability in quality of MM treatment programs in the United States and the lack of clear 
standards or guidelines for best clinical practices in MM.139 
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The revived scientific orientation and reaffirmation of the clinical effectiveness of MM, and concerns 
about quality of care across MM programs, led to the formation of a Commission established by the 
Institute of Medicine140 to study the Federal regulation of methadone. One of the Study Panel’s major 
recommendations led to the 2001 shift in regulatory authority over MM from the Drug Enforcement 
Administration (DEA) and the Food and Drug Administration (FDA) to the Center for Substance 
Abuse Treatment (CSAT), one of the arms of the Substance Abuse and Mental Health Services 
Administration (SAMHSA). One of CSAT’s first acts was a conceptual shift in the identity of MM from 
that of the methadone clinic to that of an Opioid Treatment Program (OTP). CSAT supported the 
independent accreditation of OTPs, refined and disseminated OTP guidelines and best-practices 
protocol, and provided OTP-related training and technical assistance. The shift from a regulatory 
oversight model to an accreditation and technical assistance model reflected the desire for greater 
emphasis on quality improvement and elevated outcomes in MM.141 Consistent with this quality 
emphasis, CSAT developed a series of updated Treatment Improvement Protocols (TIPs) related to 
MM: State Methadone Treatment Guidelines, 1993; Assessment and Treatment of Cocaine-Abusing 
Methadone-Maintained Patients, 1994; Matching Treatment to Patient Needs in Opioid Substitution 
Therapy, 1995; LAAM in the Treatment of Opiate Addiction, 1995; and Medication-Assisted Treat-
ment for Opioid Addiction in Opioid Treatment Programs, 2005.
cultuRal and pRofessional status of Methadone Maintenance
Other changes influenced the cultural and professional status of MM. First, there was an increase 
in public education efforts that portrayed addiction as a treatable brain disease. These noteworthy 
programs, including the PBS special, Moyers on Addiction: Close to Home (1998) and the HBO 
special, Addiction (2007) heightened public awareness of new neurobiological understandings 
of drug addiction and effective treatments. The educational programming was accompanied by 
efforts by the American Bar Association Standing Committee on Substance Abuse, Join Together, 
Legal Action Center, and other organizations to address the stigma and discrimination faced by 
MM patients142 and the growing political interest in protecting the rights of MM patients (e.g., work 
of the Congressional Caucus on Addiction, Treatment and Recovery). Among these efforts was a 
combined initiative by the American Bar Association and Join Together soliciting testimony about 
the current state of stigma and discrimination toward those who are addicted, those who have loved 
ones who are addicted, those in or seeking treatment and recovery, and those who have tried to put 
addiction behind them only to encounter discrimination based on their history of addiction. 
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A second force was the political awakening of people in medication-assisted recovery, as evi-
denced by the creation of new recovery advocacy groups as well as the inclusion of people in 
medication-assisted recovery in leadership roles in mainstream recovery advocacy organizations, 
such as Faces & Voices of Recovery.143 The medication-assisted groups included Advocates for 
the Integration of Recovery and Methadone (AFIRM, founded 1995), the National Alliance for 
Medication Assisted Recovery (formerly the National Alliance of Methadone Advocates, founded 
1988), Advocates of Recovery through Medicine (ARM, founded in 1999-2000), and the Opioid 
Dependence Resource Center. One outcome of this awakening was the growth in patient advisory 
boards and patient run groups within OTPs, as well as increased representation of MM patients on 
various federal, state, and local policy committees. 
The heightened professionalization of the MM treatment field also served to elevate the status of 
MM. Such professionalization spanned the evolution of the Northeast Regional Methadone Treat-
ment Coalition (1984) into the American Methadone Treatment Association (1990), the American 
Association for the Treatment of Opioid Dependence (AATOD, 2001), and the more recent 
founding of the World Federation for the Treatment of Opioid Dependence (2007). These as-
sociations emerged in direct response to the contraction of publicly funded methadone treatment 
and public attacks on methadone maintenance (e.g., the 1983 “Deadly Cure” series in the South 
Florida Sun-Sentinel). The drive to both defend and elevate the quality of MM contributed to the 
transformation of “methadone clinics” into “Opioid Treatment Programs” (OTPs), the development 
of OTP accreditation standards, and the subsequent accreditation of all 1,215 OTPs in the United 
States.144 
These achievements co-exist with regressive forces that continue to tarnish the image of metha-
done as a medication, methadone treatment patients, and America’s OTPs. In spite of scientific 
and professional advancements, cultural stigma and professional and political hostility toward 
methadone maintenance continue.145 
RecoveRy-oRiented Methadone Maintenance 
There is growing interest in recovery-oriented OTPs in the U.S. In 2005, the National Quality Forum 
(NFQ), through support from the Robert Wood Johnson Foundation and the Center for Substance 
Abuse Treatment, created national standards for addiction treatment that called for treating 
persons with severe substance use disorders via a “chronic care model” focused on long-term 
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recovery management support. The NFQ further supported the availability of integrated pharma-
cotherapy and psychosocial treatment for all adults diagnosed with opioid dependence. Efforts 
are underway to move beyond harm reduction toward an enhanced recovery orientation146 and 
to conceptually and clinically bridge medication-based strategies aimed at reduction of personal 
and social harm and psychosocial models of addiction treatment.147 Proponents argue that these 
efforts to bring dichotomized approaches into an integrated framework are particularly promising 
because they provide a means of working with individuals at different stages of their addiction and 
recovery careers. The New York State Office of Alcoholism and Substance Abuse Services (OA-
SAS) is working to transform its methadone clinics into comprehensive addiction recovery centers 
offering multiple levels and modalities of care. In New York, a peer-based recovery support 
services model was developed in 2006 for patients in methadone treatment via the CSAT-funded 
Recovery Community Services Program. The Medication Assisted Recovery Services (MARS) 
project in New York City is likely to be widely replicated.148 
In 2009, Southwest Behavioral Health Management, a large behavioral health management orga-
nization in Pennsylvania, and the Institute for Research, Education and Training in the Addictions 
(IRETA) developed the first recovery-focused practice guidelines for methadone maintenance treat-
ment.149 Other evidence of the movement toward a recovery orientation in OTPs includes the number 
of recovery-themed plenary presentations at the 2009 AATOD annual conference and the growing 
number of OTPs and recovery advocacy organizations providing Methadone Anonymous meetings. 
The Center for Substance Abuse Treatment has also been influential in this movement through its 
funding of several MM recovery support initiatives, including a new CSAT monograph, Introduction 
to Recovery-Oriented Systems of Care for Opiate Treatment. Also promising are renewed efforts 
to reduce the cultural and professional stigma that has permeated methadone as a medication, 
methadone maintenance patients, and methadone maintenance treatment providers.150
These broad initiatives are influencing particular aspects of recovery-oriented service practice 
within MM. Some of the more promising of these include: 
•	 Recovery Representation: OTPs are attempting to increase recovery representation at 
board, leadership, staff, and volunteer levels, e.g., growing interest in consumer councils and 
other patient-centered advisory and governance structures.151
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•	 Recovery-Linked Quality Indicators: Substantial progress is being made in meeting con-
sensus guidelines for methadone treatment, e.g., increases in the percentage of OTPs using 
optimal methadone dosages, increased retention/duration of participation in OTPs, and HIV 
testing, counseling, and outreach.152
•	 Patient Choice: There is increased emphasis on the importance of patient participation in 
decision-making within OTPs.153 The introduction of buprenorphine as an alternative medical 
treatment for opioid dependence via the 2002 approval of Subutex® and Suboxone® is also 
giving patients additional medication and delivery site options, although this is severely limited 
due to its cost.154
•	 Service Relationship: There is growing interest in elevating the quality of service relation-
ships in OTPs—relationships free of contempt and grounded in a sustained partnership 
marked by respect, emotional authenticity, and continuity of support. MM advocates are 
calling for a reaffirmation of the MM patient’s status to that of a “patient” whose concerns are 
heard rather than an addict whose every complaint represents “drug seeking behavior” and 
who must be controlled in a paternalistic fashion. 
•	 Peer-Based Recovery Support: There are new experiments with MM-specific approaches 
to peer-based recovery support services, improved relationships between OTPs and exist-
ing recovery mutual aid groups, development of new medication-assisted recovery support 
groups, and development of assertive procedures for linking MM patients to mutual aid 
groups and other recovery community institutions. Patients who daily stand in the queue to 
receive their dose of methadone have little contact with highly stabilized and high function-
ing MM patients in recovery, and few patients beginning MM treatment know of former MM 
patients who have tapered from MM and successfully sustained long-term recovery. What 
they do see are the least stabilized patients as well as patients who are returning to MM fol-
lowing earlier post-treatment relapse; they see neither successful long-term maintenance 
nor sustained recovery after medication maintenance.155 The goal of OTP-based or -linked 
peer-based recovery support services is to offer living proof of long-term medication-assisted 
recovery and the variation in styles of such recoveries. 
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•	 Alternative Frameworks for Recovery Maintenance Support: Early pilots of medical 
maintenance—medication maintenance via a monthly visit to a physician’s office—hold great 
promise as a support option for highly stabilized patients.156 Medical maintenance represents 
a means of nesting recovery within each patient’s natural environment as well as a means of 
more completely severing ties with the drug culture. 
•	 Post-treatment Monitoring, Support, and Early Re-intervention: Regardless of the theo-
retical orientation underlying MM, the reality is that few MM patients are continuously enrolled 
in MM for life. In 2005, the average time in treatment for patients discharged from opioid re-
placement therapy in the United States was 245 days.157 Models of sustained post-treatment 
recovery checkups and outreach-based re-intervention with disengaged MM patients are 
available for wide replication and adaptation, to support the ongoing treatment and recovery 
of these patients.158 
We will explore recovery-oriented service practices in great detail in the third article in this mono-
graph. There are significant but not insurmountable challenges to achieving greater recovery 
orientation within OTPs. The cultural and professional climates remain hostile toward MM. Patients 
and service providers were reminded of this when public billboards proclaiming “Methadone Kills” 
appeared across the country in 2008. Attacks on MM from other addiction treatment profession-
als continue amidst allegations of financial profiteering by MM clinics and tort lawyers who view 
OTPs as a new source of potential plunder. Like that of other addiction services, public funding of 
MM is precarious in these difficult financial times because of municipal and state budget crises. 
Also, third-party payors (private and public insurance) are exerting an ever greater influence on 
MM through their decisions regarding what MM-related services they will and will not pay for, and 
for how long. 
Acknowledging such challenges does not imply that OTPs lack ownership of their own fate. The 
future of OTPs will rest primarily on their own collective ability to forge a more person-centered, 
recovery-focused medical treatment for opioid addiction and to confront methadone-related social 
stigma through assertive campaigns of education and political/professional influence. The degree 
of success of such campaigns will determine the safety and quality of MM as a person-centered, 
recovery-focused medical treatment. It will also determine the future of the “peculiar American 
ambivalence about the opioid addict as not quite a patient and not quite a criminal.”159 
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suMMaRy
Methadone maintenance as originally conceived and practiced constituted one of the few treat-
ments based explicitly on an understanding of addiction as a chronic disease. The original model 
of MM posited that full recovery from, but not a cure of, heroin addiction was possible and that 
such recoveries were best nourished within a supportive and service-rich treatment milieu marked 
by a sustained recovery support partnership between MM staff and their patients. Throughout the 
1970s and 1980s, many core beliefs and practices of MM programs changed in ways that eroded 
their personal recovery orientation, the scope of services offered, and their overall effectiveness 
(as measured by attraction, retention, and personal recovery outcomes). The work to revitalize 
today’s OTP programs in the United States and to recapture their focus on long-term recovery 
should be welcomed by all addiction professionals. 
The OTP system of care in the United States may itself be in need of a recovery process. This 
would involve acknowledging that, as a system of care, OTPs have lost their recovery orientation, 
and that patients are being harmed in some OTPs by sub-standard services and by service mi-
lieus that fail to visibly model and nurture long-term personal and family recovery. The gross power 
inequities between the patient and clinic must be acknowledged, abuses of such power admitted, 
and new service relationships forged on a long-term recovery partnership model. Substandard 
care must be exposed and confronted, amends must be made where possible, and OTPs must 
be transformed into recovery-oriented systems of care.  
In the next two articles, we will attempt to lay a foundation for such systems-transformation 
processes by defining recovery within the context of methadone treatment (and the broader arena 
of medication-assisted treatment) and discussing strategies of sustained recovery management in 
the OTP context. 
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RecoveRy-oRiented Methadone Maintenance
II. Recovery and Methadone 
William L. White, MA 
Lisa Mojer-Torres, JD 
Essentially the question is whether the emphasis in treatment should be directed 
to the patient or to the medication.
—Dr. Vincent Dole160
I am not my disease, and I am not my medication.
—Excerpt from methadone patient’s email to the authors, 2009
The only places my recovery is known of and respected is at my MMTP and 
among my family. To others, my recovery remains nonexistent, it’s a part of my 
life I sometimes feel ashamed of, not because of my ignorance, but that of oth-
ers. I have worked hard over the years to achieve my optimal dose stabilization & 
to sustain my recovery.
—Excerpt from methadone patient’s email to the authors, 2010 
The use of medications such as methadone, naltrexone, and Buprenorphine/Suboxone/Subutex 
in the treatment of opioid addiction, and questions related to the recovery status of patients 
taking these medications, continue to be debated vigorously at professional and cultural levels. 
Such discussions have intensified in tandem with recent efforts in the United States and the 
United Kingdom to define recovery from substance use disorders and with the emergence 
of recovery as a central organizing construct for the addictions field and the larger arena of 
behavioral health care.161 
Can a methadone patient who has achieved long-term dose stabilization, uses no other non-
prescribed opioids or other intoxicants (including alcohol), and has achieved significant improve-
ments in psychosocial health and positive community integration be considered in recovery 
or recovering? The authors offer a clear, affirmative answer to that question as we outline 24 
160. Dole, V.P. (1973). Detoxification of methadone patients, and public 
policy. Journal of the American Medical Association, 226(7), 780. 
161. Betty Ford Institute Consensus Panel. (2007). What is recovery? 
A working definition from the Betty Ford Institute. Journal of Substance 
Abuse Treatment, 33, 221-228. Center for Substance Abuse Treat-
ment (CSAT). (2007). National Summit on Recovery: Conference Report 
(DHHS Publication No. SMA 07-4276). Rockville, MD: Substance Abuse 
and Mental Health Services Administration. Laudet, A. B. (2007). What 
does recovery mean to you? Lessons from the recovery experience 
for research and practice. Journal of Substance Abuse Treatment, 33, 
221-228. United Kingdom Drug Policy Commission. (2008). A consensus 
definition of recovery. Accessed June 24, 2010 at http://www.ukdpc.org.
uk/resources/A%20Vision%20of%20Recovery.pdf . White, W. (2005). 
Recovery: Its history and renaissance as an organizing construct. Alcohol-
ism Treatment Quarterly, 23(1), 3-15. White, W. (2007). Addiction recovery: 
Its definition and conceptual boundaries. Journal of Substance Abuse 
Treatment, 33, 229-241. White, W. (2008). Recovery: Old wine, flavor 
of the month or new organizing paradigm? Substance Use and Misuse, 
43(12&13), 1987-2000. 
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propositions related to the role of methadone maintenance in long-term addiction recovery, 
propositions that we believe are supported by the available historical, scientific, and clinical 
evidence. 
Methadone and RecoveRy status 
1. Productive explorations of the effects of methadone or other medications on ad-
diction recovery status hinge on a clear definition of recovery.
2. The recovery status of methadone maintenance (MM) patients should be evaluated 
using the same definition of recovery that applies to the resolution of all substance 
use disorders.
Controversy and stigma continue to surround the use of methadone in the treatment of opioid 
addiction, in spite of more than four decades’ worth of scientific evidence of its effectiveness. 
Methadone patients continue to be socially marginalized, and their recovery status is debated 
even within the professional field of addiction treatment and various recovery communities. 
Answering the controversy regarding the recovery status of methadone patients requires a clear 
understanding of what constitutes recovery from opioid addiction. Recovery from opioid addiction 
and other substance use disorders is a historically ill-defined concept that is often viewed differ-
ently by policymakers, the public, addiction and allied health professionals, and affected individu-
als and families. 
RecoveRy as intention 
3. Public understanding of addiction recovery as a motivational state rather than a 
stable behavioral health status contributes to therapeutic pessimism and the so-
cial stigma attached to addiction and addiction treatment.  
4. Recovery is more than “trying” to decelerate or stop opioid and other drug use.  
The “trying” definition sets a low bar for expectations related to global health 
and functioning, contributes to the stigma attached to methadone treatment, and 
restricts opportunities for the methadone patient to participate positively in com-
munity life. 
When Faces & Voices of Recovery commissioned a survey of how the American public under-
stood the word “recovery,” one of the findings was particularly surprising. The majority of those 
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surveyed thought the term recovery referred to someone who was “trying to stop using alcohol or 
drugs.”162 Bombarded by daily scenes of celebrities heading back to “rehab,” the public has come 
to see recovery as a fragile motivational state rather than as the durable experience of the millions 
of individuals in the U.S. who are in stable long-term addiction recovery.163 
The understanding of recovery as intention shapes differing views of MM based on how the public 
perceives methadone and motivations for its use. If methadone is viewed as an intoxicating drug (a 
“legal high”) and patient motivation for MM is viewed as a search for intoxication, then MM patients 
will not be afforded recovery status due to their failure to meet the “trying to stop” criterion. If, on 
the other hand, methadone is viewed as a non-intoxicating, normalizing medication taken by MM 
patients to promote social rehabilitation and eliminate the symptoms that lead to drug-seeking, 
MM might well be embraced within the public’s current conception of recovery. The danger even 
in this latter scenario is that the bar for recovery would be set so low that those achieving it would 
still be stigmatized and estranged from mainstream community life.
RecoveRy as ReMission
5. Recovery is more than remission (defined as the sustained cessation or decelera-
tion of drug use/problems to a point at which the person no longer meets diagnos-
tic criteria for opioid dependence or another substance use disorder).  
6. Remission is about the subtraction of pathology;  recovery is ultimately about the 
achievement of global (physical, emotional, relational, spiritual) health, social func-
tioning, and quality of personal/family life.
Remission is a clinical term used in psychiatry and addiction medicine to convey that the diag-
nostic elements for a substance-related disorder have diminished completely (key symptoms no 
longer present) or partially (presence of some symptoms, but not sufficient in number or severity 
to meet diagnostic criteria).164 If recovery is defined as remission, then the primary measure of 
recovery is not abstinence from drug use but the absence of drug-related clinical pathology. This 
approach is reflected in opioid addiction treatment outcome studies that have defined recovery 
as a state in which “drug abuse and related behavior are no longer problematic in the individual’s 
life.”165 Simpson and Marsh,166 for example, define recovery from opioid addiction in terms of the 
indicators of “reduction of drug use, criminal involvement and unemployment”—a definition that 
does not explicitly require abstinence from heroin or other drugs. 
162. Peter D. Hart Research Associates. (2004). Faces and Voices of 
Recovery Public Survey. Washington, D.C.: Peter D. Hart Research As-
sociates.
163. Compton, W.M., Thomas, Y.F., Stinson, F.S., & Grant, B.F. (2007). 
Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse 
and dependence in the United States. Archives of General Psychiatry, 
64(5), 566-576. Dawson, S.A., Grant, B.F., Stinson, F.S., Chou, P.S., Huang, 
B., & Ruan, W.J. (2005). Recovery from DSM-IV alcohol dependence: United 
States, 2001-2002. Addiction, 100(3), 281-292. Hasin, D.S., Stinson, F.S., 
Ogburn, E., & Grant, B. F. (2007). Prevalence, correlates, disability and comor-
bidity of DSM-IV alcohol abuse and dependence in the United States: Results 
from the National Epidemiologic Survey on Alcohol and Related Conditions. 
Archives of General Psychiatry, 64(7), 830-842. . . . .  
164. American Psychiatric Association. (1994). Diagnostic and statistical 
manual of mental disorders (4th ed.). Washington, DC: Author.
165. Leukefeld, C.G., & Tims, F.M. (1986). Relapse and recovery: Some 
directions for research and practice. In F. Tims & C. Leukefeld (Eds.), 
Relapse and recovery in drug abuse (NIDA Monograph 72, pp. 185-190). 
Rockville, MD: National Institute on Drug Abuse. . . . . 
166. Simpson, D.D., & Marsh, K.L. (1986). Relapse and recovery among 
opioid addicts 12 years after treatment. In F. Tims & C. Leukefeld (Eds.), 
Relapse and recovery in drug abuse (NIDA Monograph 72, pp. 86-103). 
Rockville, MD: National Institute on Drug Abuse.
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Some MM advocates have argued that MM treatment should be evaluated by one criterion only: 
its ability to bring heroin dependence into stable remission.167 Others have argued against the 
recovery-as-remission definition. 
… cultural and professional misunderstandings and stigma attached to 
methadone led to justifications of MM that focused on what methadone could 
subtract from an addicted individual’s life in terms of crime and broader 
threats to public safety and health. It is time we told the story of what the use 
of methadone and other medications combined with comprehensive and 
sustained clinical and recovery support services can add to the quality of life of 
individuals, families and communities.168 
As long as well-intentioned people go around saying that “methadone is 
recovery,” it is going to continue to be misunderstood. Methadone is a medica-
tion, a tool, even a pathway, but it is not recovery. Recovery is a way of living 
one’s life. It doesn’t come in a bottle.169
When recovery is defined solely in terms of remission, stabilized MM patients who are no longer 
addicted to opioids meet the criteria for achieving the status of recovery without accounting for 
other drug (including alcohol) use patterns or whether or not they have achieved larger improve-
ments in quality of life and social functioning. 
The American Society of Addiction Medicine has taken a step beyond the recovery-as-remission 
definition by defining recovery as “overcoming both physical and psychological dependence 
to a psychoactive drug while making a commitment to sobriety.”170 ASAM added the criterion 
of intentionality via a commitment for future sobriety, perhaps to distinguish recovery from the 
artificially imposed periods of enforced abstinence that are often part of prolonged addiction 
careers. Based on this definition, the stabilized person in MM who is no longer addicted to 
heroin and who is committed to continued abstinence from heroin would meet this definition 
of recovery. One weakness of the ASAM definition is that it doesn’t specify what other kinds of 
drug use would fall outside the boundaries of this definition of sobriety.
167. Newman, R.G. (1991). What’s so special about methadone 
maintenance? Drug and Alcohol Review, 10, 225-232.
168. White, W. (2009a). Long-term strategies to reduce the stigma at-
tached to addiction, treatment and recovery within the City of Philadelphia 
(with particular reference to medication-assisted treatment/recovery). 
Philadelphia: Department of Behavioral Health and Mental Retardation 
Services. 
169. W.Ginter, personal communication, June 22, 2009.
170. American Society of Addiction Medicine. (2001). Patient placement 
criteria for the treatment of substance use disorders (2nd Ed.). Chevy 
Chase, MD: ASAM.
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RecoveRy as aBstinence
7. Recovery from opioid addiction is more than the removal of drug use from an 
otherwise unchanged life.
8. Optimum, individualized doses of methadone do not produce intoxication in 
stabilized MM patients; as such, methadone prescribed under these circum-
stances should be viewed as a medication rather than a “drug.”
9. Methadone pharmacotherapy enhances rather than interferes with the reduction/
cessation of drug use and the broader processes of psychosocial rehabilitation.  
The predominant abstinence orientation of addiction treatment in the United States is reflected 
in abstinence-based treatment goals and in reporting treatment follow-up studies in terms of the 
percentage of patients who have been continuously abstinent since discharge or abstinent at 
the time of follow-up—abstinence here referring to abstinence from the substance(s) to which 
the patient was once addicted. Recovery as abstinence is also reflected in the use of “sobriety 
birthdays” and “clean time” within recovery mutual aid groups. Recovery as the cessation of all 
“alcohol and other drug use” is similarly the centerpiece of the anti-stigma messaging campaigns 
of recovery advocacy organizations.171 Historically, a broad spectrum of addiction professionals 
and recovery community leaders have posited concepts such as “dry drunk,” “mental sobriety,” 
“emotional sobriety,” “wellbriety,” and “stage II recovery”172 to convey that addiction recovery is 
more than the absence of drug use. Yet the question remains, “Does the use of methadone as a 
medication violate the abstinence requirement that many would posit as a component of addiction 
recovery?” Answering that question involves two related questions.
The first of these questions is: Does the consumption of a medically supervised, optimum oral dose 
of methadone by the stabilized MM patient produce intoxicating effects? Or put another way, “From 
the standpoint of recovery status, should methadone used in these circumstances be viewed as 
equivalent to the use of heroin or other intoxicants?” The anti-methadone stance within NA has at 
its roots the experiential knowledge of many NA members who used methadone as an intoxicant 
during their addiction careers, who used MM for purposes other than recovery, who jockeyed for 
high methadone doses and combined those doses with other drugs for purposes of intoxication, 
and who had little if any contact with highly stabilized, high-functioning MM patients. Through the 
lens of that experience, it is easy to see methadone as just another drug and any methadone use as 
precluding status as a person in recovery. But there is another side to this story. 
171. Faces and Voices of Recovery (2006). New messaging from Faces 
& Voices of Recovery: Talking about recovery. Retrieved January 5, 2010 
from http://www.facesandvoicesofrecovery.org/publications/recovery_
messaging/about_recovery.php.
172. For a review, see White, W., & Kurtz, E. (2006). The varieties of 
recovery experience. International Journal of Self Help and Self Care, 
3(1-2), 21-61. 
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Stabilized doses of methadone that are individualized, optimal, and ingested orally as a medication 
in MM do not usually produce euphoria in stabilized patients. For most patients, the tolerance to 
methadone resulting from prolonged daily administration of optimum dosages neutralizes the po-
tentially intoxicating properties of the medication and other opioids when properly administered.173 
Three pioneers of MM in the United States—Drs. Mary Jeanne Kreek, Ed Senay, and Robert 
DuPont—elaborate on this point: 
When initial methadone treatment doses are appropriately chosen and then 
increased at a sufficiently slow rate so that tolerance develops following each 
increment, no narcotic-like effects should be perceived by a patient in metha-
done maintenance treatment.174
There are sedating and intoxicating doses of any opioid, methadone included, 
but in a well-run clinic one does not see sedation or intoxication because dose 
effects are monitored and therapy deals with the issue of intoxication [from 
other substances].175
A patient receiving a stable, once-a-day oral dose of methadone is not intoxi-
cated or impaired by the methadone because of virtually complete tolerance 
to the sedating effects of the medication. For patients taking stable daily oral 
dosages of methadone, the effect is the functional equivalent of a depressed 
patient taking a daily dose of Prozac. However, when that same dose of 
methadone is injected intravenously, it elicits an equivalent “brain reward” as 
would be experienced with injected heroin or Oxycodone. For the nontolerant 
person—a person who has not taken a stable oral dose of methadone for 
days, weeks or longer—the commonly prescribed methadone dosages are 
intoxicating and often fatal. MM patients who exhibit signs of intoxication or 
sedation while taking a therapeutic dose of methadone have either not yet 
achieved dose stabilization (usually during the induction period or when the 
dose is raised significantly), or they are exhibiting signs of other recent alcohol 
or other drug use. Any methadone patient showing signs of impairment needs 
to be promptly evaluated: intoxication and impairment are not an expected part 
of the therapeutic experience of methadone treatment.176 
173. Dr. Vincent Dole did note the rare patient who failed to develop full 
tolerance to the sedating effects of methadone. Cushman, P., & Dole, V.P. 
(1973). Detoxification of rehabilitated methadone-maintained patients. 
Journal of the American Medical Association, 226(7), 747-752. Newman, 
R.G. (1991). What’s so special about methadone maintenance? Drug and 
Alcohol Review, 10, 225-232. 
174. Kreek, M.J. (1993). Epilogue: A personal retrospective and 
prospective viewpoint. In M.W. Parrino, State methadone treatment 
guidelines Treatment Improvement Protocol Series 1. Rockville, MD: Center 
for Substance Abuse Treatment.
175. Senay, E.C. (1985). Methadone maintenance treatment. International 
Journal of the Addictions, 20(6&7), 803-821.
176. R. DuPont, personal communication, February 17, 2010. 
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The second question is: Does the use of methadone aid or hinder the broader processes of 
psychosocial rehabilitation? Early tests of MM found that patients who had achieved effective 
dose stabilization were “functionally normal”177 and that methadone did not interfere with mental 
or physical performance.178 Continued participation in MM in spite of problems related to such 
participation (e.g., medication side-effects in some patients; limitations on education, work, and 
travel; social stigma) reflects the positive stability that MM offers and the experience of relapse to 
heroin that patients often experience following cessation of MM. MM studies consistently report 
decreased death rates (as much as 50%); reduced transmission of HIV, Hepatitis B and C, and 
other infections; and improvements in global health and social functioning.179 
In spite of this evidence, many MM patients experience sustained pressure to end methadone 
maintenance.
There is a constant theme experienced daily by MM patients—that they must be 
lowering their dose and proceeding toward detoxification. Only total abstinence 
from methadone is considered a methadone success story. The PA [physician’s 
assistant] who runs my program said to me at my physical last year that he 
“thought I’d be off this stuff” by now… In his eyes, I’m not a success because I 
am still on methadone. If the people who literally dispense methadone don’t view 
it in terms of recovery or even as medication, how can the patients? 180 
The professional controversies over the question of methadone, abstinence, and recovery status 
are well illustrated in the debate surrounding a study by Maddux and Desmond.181 The authors 
conducted a study to determine if MM prolonged addiction careers—defined as the time period 
from onset of drug use to achievement of sustained abstinence, with abstinence defined as also 
terminating the use of methadone as a medication. Dr. Robert Newman challenged this definition:
We do a disservice to methadone maintenance programs and their patients by 
suggesting that “completion” of treatment and subsequent abstinence are the 
sine qua non of therapeutic success in the treatment of opioid dependence.182 
Newman further argued that recovery should be understood solely in terms of “cessation of heroin 
use, sharply reduced morbidity and mortality, and restoration of the ability to lead a productive 
and self-fulfilling life.”183
177. Dole, V.P., & Nyswander, M.E. (1965). A medical treatment for 
diacetylmorphine (heroin) addiction. Journal of the American Medical 
Association, 193, 646-650. Dole, V.P., & Nyswander, M.E. (1967). Heroin 
addiction—a metabolic disease. Archives of Internal Medicine, 120, 
19-24. 
178. Gordon, N.B. (1973). The functional status of the methadone maintained 
person. In. L.R.S. Simmons & M.B. Gold (Eds.), Discrimination and the addic-
tion (pp. 101-123). Thousand Oaks, CA: Sage. 
179. Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone 
maintenance treatment: A review of historical and clinical issues. Mount 
Sinai Journal of Medicine, 67, 347-364. Kreek, M.J., & Vocci, F. (2002). 
History and current status of opioid maintenance treatments. Journal of 
Substance Abuse Treatment, 23(2), 93-105.
180. Methadone patient email to the authors, June, 2010. 
181. Maddux, J.F., & Desmond, D.P. (1992). Methadone maintenance and 
recovery from opioid dependence. American Journal of Drug and Alcohol 
Abuse, 18(1), 63-74. Maddux, J.F., & Desmond, D.P. (1992). Ten-year 
follow-up after admission to methadone maintenance. American Journal of 
Drug and Alcohol Abuse, 18(3), 289-303.
182. Newman, R.G. (1993). Methadone maintenance and recovery. Ameri-
can Journal of Drug and Alcohol Abuse, 19(1), 135-137.
183. Newman, R.G. (1993). Methadone maintenance and recovery. 
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Dr. Vincent Dole, co-developer of MM, was similarly critical of definitions of recovery that focused 
narrowly on abstinence without regard to health and social functioning: 
“… methadone patients are not necessarily committed to a lifelong dependence 
on the medication… The key to this result [sustained abstinence following 
termination of methadone maintenance] is the realization that the most important 
objective in treatment of an addict is support of good health and normal func-
tion. This may or may not require continuation of maintenance. An obsessive 
preoccupation with abstinence is self-defeating, leading to low-dose programs 
(which fail to stabilize the patient), premature discharge from treatment and low 
self-esteem if long-term abstinence seems unattainable… Available data suggest 
that the longer a patient continues in a maintenance program that provides 
adequate doses (e.g., five years or more), the greater his or her probability of 
permanent abstinence after termination of treatment… the neurochemical ad-
aptations produced by thousands of heroin injections… are capable of gradual 
repair in some cases under the steady conditions of methadone maintenance.184
Subsequent studies have confirmed Dole’s contention that higher methadone doses are linked to 
greater reductions in illicit opioid use than lower doses.185
Cessation of methadone use as a requirement for recovery status is contradicted by research 
linking methadone dose stabilization to decreased drug use and increased global health, and ces-
sation of MM to increased risk for clinical deterioration, resumption of heroin use, and death. Dole 
argued that there was no medical evidence that the majority of MM patients could be completely 
tapered from methadone without compromising recovery stability and that “the question of 
whether and when to discontinue methadone therapy can be answered in medical terms if the 
treatment is judged by the same standards as apply to other chronic diseases.”186 
There are recent efforts to explicitly define abstinence in the MM context and to abandon use of 
“abstinence” and “drug free” as a treatment program designation, as was recently recommended 
by the Clinical Training Program Caucus (NIDA’s Clinical Trials Network): 
We are writing to recommend that NIDA retire the terms “abstinence-based” and 
“drug free” to refer to programs that do not use or permit the use of methadone. At 
best, these terms are confusing, and at worst, they perpetuate the stigma against 
184. Dole, V.P. (1994). What we have learned from three decades of 
methadone maintenance treatment. Drug and Alcohol Review, 13, 3-4.
185. Strain, E.D., Bigelow, G.E., Liebson, I.A., & Stitzer (1999). Moderate- 
vs. high-dose methadone in the treatment of opioid dependence. Journal 
of the American Medical Association, 28(11), 1000-1005.
186. Dole, V.P. (1973). Detoxification of methadone patients, and public 
policy. Journal of the American Medical Association, 226(7), 781.
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methadone patients and treatment providers. “Abstinence” no longer precludes 
the appropriate use of prescribed medications. “Drug free” refers to patients who 
are no longer using illicit drugs…We do not suggest that someone on Prozac is 
not abstinent, so why do so with methadone? A methadone patient is abstinent if 
he/she is not using alcohol or illicit drugs, and is using legal ones as prescribed. 
This definition is accepted within the methadone treatment community, and is 
consistent with the stance that appropriately prescribed medication is compatible 
with recovery. Clinging to the obsolete terms perpetuates the stigma of methadone 
as something less noble than other treatments by suggesting that success is 
measured by the discontinuation of opioid agonist medication. Some patients and 
providers have internalized this stigma, to their detriment.187 
RecoveRy as gloBal health and functioning 
10. Recent attempts to define addiction recovery have focused on three essential ele-
ments:  a) the resolution of drug-related problems (most often measured in terms 
of sobriety/abstinence or diagnostic remission), b) improvement in global health, 
and c) citizenship (positive community reintegration).
11. MM patients stabilized on medically supervised, individualized, optimum doses 
do not experience euphoria, sedation, or other functional impairments from the 
methadone.
12. The stabilized methadone maintenance patient who does not use alcohol or illicit 
drugs and takes methadone and other prescribed drugs only as indicated by com-
petent medical practitioners meets the first criterion for recovery.  
13. Physical dependence on a medication and drug addiction are not the same:  like 
many pain patients maintained on opioid medications, the stabilized methadone 
maintenance patient who does not use alcohol or illicit drugs and takes methadone 
and other prescribed drugs only as indicated by competent medical practitioners 
does not meet key definitional criteria for addiction (e.g., obsession with using, 
loss of volitional control over use, self-accelerating patterns of use, compulsive 
use in spite of adverse and escalating consequences).
There is growing consensus across historical, cultural, and professional contexts that recovery 
from severe alcohol and other drug problems includes more than the subtraction of these sub-
187. J. Zweben, personal communication, February 5, 2010. 
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stances from one’s life. In 2007, the Center for Substance Abuse Treatment hosted a Recovery 
Summit in which participants defined recovery from alcohol and drug problems as “a process of 
change through which an individual achieves abstinence and improved health, wellness, and quality 
of life.”188 That same year, the Betty Ford Institute published a recovery definition drawn from a 
consensus conference of addiction researchers, addiction treatment professionals, and people 
in recovery. Conference members defined recovery from substance dependence as “a voluntarily 
maintained lifestyle characterized by sobriety, personal health, and citizenship.”189 The issue raised in 
these definitions that is most relevant to this monograph is whether stabilized methadone mainte-
nance patients are embraced within or excluded from the meaning of abstinence and sobriety. 
Methadone recovery status is at the center of evolving and conflicting perceptions of methadone 
use (recovery-enhancing medication versus addictive drug). It profoundly influences the lives of 
potential, current, and past MM patients who see attitudes toward methadone revealed in the: 
•	 cultural/professional	equation	of	methadone	and	heroin	(e.g.,	the	claim	that	MM	just	substi-
tutes one addicting drug for another—an equation reinforced by the characterization of MM 
as replacement therapy or substitution therapy); 
•	 pressure	experienced	by	MM	patients	from	family	members	to	stop	MM	treatment;
•	 prohibition	against	having	an	MM	patient	speak	at	a	meeting,	lead	a	service	committee,	or	
receive a sobriety chip within many local Narcotics Anonymous groups;
•	 refusal	on	the	part	of	addiction	treatment	programs	and	recovery	support	institutions	that	
do not use medications to admit MM patients in need of their services or to refer their own 
patients who could benefit from adjunctive, medication-assisted treatment;
•	 within	MM	clinic	cultures,	stigmatization	of	patients	on	higher	methadone	dosages;
•	 pressure	from	counselors	for	patients	to	terminate	MM;	
•	 the	discrimination	MM	patients	experience	in	such	arenas	as	education,	employment,	hous-
ing, health care, and government benefits; and
•	 ultimata	issued	by	family	members	and	drug	court	judges	who	order	the	parents/defendants	
to taper methadone intake or leave methadone maintenance treatment as a condition of 
retaining child custody or visitation rights, or as a condition of probation.190 
188. Center for Substance Abuse Treatment (CSAT). (2007). National 
Summit on Recovery: Conference Report (DHHS Publication No. SMA 
07-4276). Rockville, MD: Substance Abuse and Mental Health Services 
Administration.
189. Betty Ford Institute Consensus Panel. (2007). What is recovery? 
A working definition from the Betty Ford Institute. Journal of Substance 
Abuse Treatment, 33, 221-228. 
190. White, W. (2009). Long-term strategies to reduce the stigma attached 
to addiction, treatment and recovery within the City of Philadelphia 
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Philadelphia: Department of Behavioral Health and Mental Retardation 
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Such attitudes and overt acts of discrimination can leave even the most stable and healthiest of 
MMT patients hiding their “dirty little secret.”191 
The Betty Ford Institute (BFI) Consensus Panel specifically addressed the question of Opioid 
Treatment Program (OTP) medications and recovery status by defining recovery in terms of 
sobriety, global health, and citizenship, and then by clearly stating that: 
… formerly opioid-dependent individuals who take naltrexone, buprenorphine, 
or methadone as prescribed and are abstinent from alcohol and all other 
nonprescribed drugs would meet this definition of sobriety.192 
This declaration, coming from one of the institution most often associated with mainstream 
12-Step-infused addiction treatment in the United States, stands as a historical milestone in the 
addiction treatment field’s (and this country’s) perception of methadone maintenance. 
A variant of the Betty Ford Institute definition moves beyond remission and intention by defining 
long-term recovery as “an enduring lifestyle marked by: 1) the resolution of alcohol and other 
drug problems, 2) the progressive achievement of global (physical, emotional, relational) health, 
and 3) citizenship (life meaning and purpose, self-development, social stability, social contribu-
tion, elimination of threats to public safety).”193 The first of these criteria is synonymous with the 
medical definition of remission-symptom reduction/elimination to subclinical levels that might or 
might not include complete abstinence. Criteria two and three create additional inclusion/exclu-
sion measures that focus on the assertive management of collateral problems (e.g., secondary 
drug dependencies, co-occurring medical and psychiatric illnesses) in tandem with improve-
ments in multiple areas of life functioning and a reconstruction of the person-to-family/community 
relationship. The added criteria place emphasis on quality of personal and family life and social 
contribution in long-term recovery. 
Within this broader conceptualization of recovery, the question becomes how methadone as a 
medication, and the realities of the lived experience of methadone maintenance treatment, might 
enhance or inhibit the fulfillment of each of these three criteria. For example, methadone as a 
medication could provide a foundation for patients’ achievement of all three of the above criteria, 
while the rigorous demands of MM treatment within the existing clinic system might actually 
interfere with criteria two and three, e.g., inhibit one’s ability to pursue education, full-time em-
ployment, financial independence, family responsibilities, home ownership, community service, 
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travel, and leisure. Definitions of recovery that address issues of quality of personal/family life will, 
when applied to the MM patient, need to disentangle methadone as a medication from the lifestyle 
constraints imposed by MM treatment. 
Consistent with Newman’s and Dole’s views are definitions of recovery that focus on health and 
functionality without reference to cessation of medical use of methadone. The examples below 
illustrate such definitions:
Recovery is the process of pursuing a fulfilling and contributing life regardless of 
the difficulties one has faced. It involves not only the restoration but continued 
enhancement of a positive identity and personally meaningful connections 
and roles in one’s community. Recovery is facilitated by relationships and 
environments that provide hope, empowerment, choices and opportunities 
that promote people reaching their full potential as individuals and community 
members.194  
Recovery is a deeply personal, unique process of changing one’s attitudes, 
values, feelings, goals, skills and/or roles.195 
The process of recovery from problematic substance use is characterised by 
voluntary sustained control over substance use which maximises health and 
wellbeing and participation in the rights, roles and responsibilities of society.196 
Stabilized MM patients would meet these criteria for recovery if they were demonstrating progress 
toward increased health and functionality. The “sustained control over substance use” in the UK 
recovery definition is broad enough to include multiple pathways of alcohol and other drug (AOD) 
problem resolution—traditionally defined abstinence, decelerated patterns of AOD use that no 
longer meet criteria for a substance use disorder, and medication-assisted recovery—as long as 
the other criteria of health and positive community participation are met. Similar in spirit to the 
UK definition were suggestions to the authors from some methadone patients that a broadened 
definition of recovery is needed. 
The only way we will ever be able to move addiction treatment to a chronic 
disease model is if we take the “abstains from alcohol and other intoxicating 
drugs” our of the recovery definition, or at least stop making it the deciding factor 
194. Recovery Advisory Council, Philadelphia, PA 2005, Department of 
Behavioral Health and Mental Retardation Services. 
195. Anthony, W.A., Rogers, E.S., & Farkas, M. (2003). Research on 
evidence-based practices: Future directions in an era of recovery. Com-
munity Mental Health Journal, 39(2), 101-114.
196. United Kingdom Drug Policy Commision. (2008). A consensus 
definition of recovery. Accessed June 24, 2010 at http://www.ukdpc.org.
uk/resources/A%20Vision%20of%20Recovery.pdf . 
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for the status of being “in recovery”… I think we need to make it one of many 
goals rather than the focus. This would help us achieve the focus of every other 
chronic disease treatment: QUALITY OF LIFE and the reduction of symptoms… 
We have got to stop thinking of recovery as ALL or NOTHING.”  
the aMBiguous identity of the MM patient 
14. Denying “abstinence” or “drug free” status to stabilized MM patients (who do not 
use alcohol or illicit drugs and who take methadone and other prescribed drugs 
only as indicated by competent medical practitioners) inhibits rather than supports 
the long-term recoveries of MM patients.
15. For stabilized MM patients, continued methadone maintenance and successful 
tapering from methadone maintenance represent two varieties/styles of recovery 
experience, not the line of demarcation between addiction and recovery initiation.  
16. The highly stabilized MM patient is caught in an ambiguous world, separated from 
cultures of active drug use, denied full membership in cultures of recovery, and 
socially stigmatized in the larger community.  
17. It is time that MM patients who meet the three-part recovery definition were wel-
comed into full membership in the culture of recovery and offered opportunities to 
pursue full citizenship in their local communities.  
The widely varying definitions of recovery and the role of methadone as a disqualifying, qualifying, or 
neutral influence in determining recovery status is more than just a theoretical issue for addictionolo-
gists. MM patients live their daily lives amidst conflicting perceptions of methadone and MM patients. 
Stable MM patients have lost membership and status and have acquired stigma within the cultural 
world of drug users, where they are more likely to be disparaged for having compromised control of 
their opioid use by their submission to the MM clinic system. Those who should celebrate the MM 
patient’s budding recovery—family members, friends, acquaintances, co-workers, and even other MM 
patients—all too often still perceive the patient as “on drugs” and continue to ask when he or she is 
going to “get off methadone.” Seeking shelter within the worlds of addiction treatment and recovery, 
stabilized MM patients encounter continued indignities that demean the value of their accomplish-
ments—denying their right to speak, denying their right to lead, denying their very recovery status. 
MM patients are taught by addiction treatment professionals that opioid addiction is a brain disease, 
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but they are treated through institutional practices as if they were feeble-minded, insane, criminal, or 
recalcitrant children—treated as people who need control rather than care. MM patients face a wider 
community environment that defines methadone as “just another drug” and MM patients in terms of 
their perceived addiction rather than their recovery achievements. It is little wonder that the concept of 
recovery has had so little value in the ambiguous, conflicted world of the MM patient.
Addiction recovery is often the product of a highly personal synergy of pain and hope. Such 
catalytic turning points usually involve three complementary processes: renunciation (what is 
permanently expelled from one’s life—the recovery from process), retrieval (what has been lost 
through one’s addiction career—the recovery of process), and embrace (what is newly drawn 
into the center of one’s life—the recovery to process).197 If recovery for the MM patient involves a 
renunciation of drugs and the drug culture—a physical, psychological, and cultural escape from 
addiction and a search for new destinations for healing and hope—in what direction is the MM 
patient expected to step in order to be welcomed? 
Positing recovery as a journey of self-transformation, the methadone patient 
subsists in undetermined space—a hinterland beyond the clearly demarcated 
identity fissures of “addict” or “recovering addict.” In the absence of a proactive 
recovery culture, the methadone maintenance patient becomes tied to an ar-
chetypal “spoiled identity”198 to be managed and governed rather than retrieved, 
nurtured and healed.199 
To speak of recovery for the MM patient requires a world in which that recovery can be firmly 
nested and nurtured—a world where the ambiguous, fractured identity of the stable MM patient 
may be healed and made whole.200 The good news is that such a world may be struggling to 
emerge in communities across the United States. 
the Question of faMily RecoveRy201
18. Chronic opioid addiction severely wounds family and kinship relationships—
wounds that feed the intergenerational transmission of drug-related problems.  
19. Family recovery involves healing those wounds; reconstructing family roles, rules, 
and relationships; and enhancing the resistance/resilience/health of all family 
members.  
197. Amplified from: Horvath, A.T. (1998). Recovery of vs. recovery from. 
(Reflections on statement by Monica Harris). Smart Recovery® News & 
Views Newsletter, April, p. 1.
198. Goffman, E. (1963). Stigma: Notes on the management of spoiled 
identity. Englewood Cliffs: Prentice-Hall. 
199. S. Bamber, personal communication, March 22, 2010.
200. S. Bamber, personal communication, March 22, 2010.
201. We wish to thank Mark Parrino for suggesting the inclusion of this 
discussion within the paper.
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Chronic disorders take an inordinate toll on family life due to their duration, the unpredictable 
ebb and flow of acute episodes, and their potentially profound effects on functionality. The 
transformation of family life through the addiction and recovery processes include changes 
in the family system’s boundary permeability, the health and functioning of individual fam-
ily members, family subsystem relationships (e.g., adult intimate relationships, parent-child 
relationships, sibling relationships, relationships with the extended family and kinship network), 
and key dimensions of family life (e.g., roles, rules, and rituals).202 Families must develop their 
own defense structures to survive the effects of addiction, and the fragility of these defense 
structures can be threatened by the onset of a recovery process. Some research suggests that 
the restructuring of family processes in early recovery can be so traumatizing as to threaten the 
survival of the family as a system.203 
Family recovery is thus a process of the family surviving the insults inflicted by severe AOD 
problems as well as the adjustments required for the restoration of individual and family health 
during the stages of recovery initiation and maintenance. Family recovery also involves reducing 
the intergenerational risks for substance use disorders. At present, most OTPs do not provide 
services aimed at reducing these risks, e.g., child-focused prevention or early intervention ser-
vices, parenting training, or family counseling.
My daughter is now 15, but she was just seven when I went into treatment. I was 
very publicly outed (newspaper stories) as an addict, and I had no idea what to 
tell her about my addiction, let alone about the methadone treatment. Guidance 
from my counselor would have been wonderful, and I know it would have done 
my daughter a world of good to have someone to talk to at that time… 204
There are far fewer studies of family and parental functioning of MM patients than of patients in 
alcoholism treatment, but studies to-date confirm two key findings: 1) family/parental function-
ing is a significant problem for many MM patients, and 2) family-focused services enhance 
the health of MM patients, their families, and their children.205 As recovery re-emerges as an 
organizing construct within OTPs, involving the family members of MM patients in refining the 
concept of family recovery and in helping design family-focused recovery support services will 
be important agendas. 
202. White, W., & Savage, B. (2005). All in the family: Alcohol and other 
drug problems, recovery, advocacy. Alcoholism Treatment Quarterly, 23(4), 
3-38.
203. Brown, S., & Lewis, B. (1999). The alcoholic family in recovery: A 
developmental model. New York: Guilford.
204. Methadone patient email to authors, June 2010. 
205. Dawe, S., & Harnett, P. (2007). Reducing potential for child abuse 
among methadone-maintained parents: Results from a randomized 
controlled trial. Journal of Substance Abuse Treatment, 32(4), 381-390. 
Dawe, S., Harnett, P. H., Rendalls, V., & Staiger, P. (2003). Improving family 
functioning and child outcome in methadone maintained families: The 
Parents Under Pressure Programme. Drug and Alcohol Review, 22(3), 
299-307. Grella, C.E., Needell, B., Shi, Y., & Hser, Y-I. (2009). Do drug 
treatment services predict reunification outcomes of mothers and their 
children in child welfare? Journal of Substance Abuse Treatment, 36(3), 
278-293. 
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suMMaRy 
•	 The	MM	patient	who	is	stabilized	on	his/her	optimal	dose	of	methadone,	abstains	
from the use of alcohol and other intoxicating drugs, and shows evidence of improv-
ing global health and social functioning is in recovery or recovering.  
•	 Long-term	recoveries	from	opioid	addiction	with	or	without	the	use	of	methadone	(or	
naltrexone or Buprenorphine/Suboxone/Subutex) constitute different styles of recov-
ery and should not be framed in categories of inferiority or superiority.  
•	 Rather	than	a	source	of	disqualification	for	recovery	status,	methadone,	provided	
under competent medical supervision at proper dosages with appropriate ancillary 
psychosocial support services, aids long-term recovery from opioid addiction and 
should be so recognized.  
•	 It	is	unlikely	that	the	recovery	status	of	the	MM	patient	will	be	fully	embraced	by	
policy makers, the public, addiction professionals, and recovery communities until 
a vanguard of present and former MM patients and their families stand together as 
a collective witness to offer living proof of the role methadone can play in long-term 
recovery from opioid addiction.  
•	 There	are	multiple	pathways	and	styles	of	long-term	addiction	recovery,	and	all	
should be cause for celebration.
Social and professional stigma constitutes a major obstacle, if not the obstacle, to methadone-
assisted recovery. But these cultural winds are shifting. Scientific breakthroughs related to the 
neurobiology of addiction and addiction recovery are forcing a re-evaluation of methadone 
maintenance. Some local recovery mutual aid meetings are welcoming MM patients, and Metha-
done Anonymous and other medication-assisted recovery mutual aid groups are defining and 
legitimizing recovery within the MM context, as are new methadone-based peer-recovery support 
projects such as the CSAT-funded Medication Assisted Recovery Services (MARS) project in 
New York City operated in conjunction with the Division of Substance Abuse at the Albert Einstein 
College of Medicine.206 The 2007 Betty Ford Consensus Panel statement that the MM patient who 
takes methadone as prescribed and is abstinent from alcohol and other drugs meets the definition 
of sobriety may well constitute a “tipping point” in the field’s understanding of and attitudes toward 
methadone pharmacotherapy. The leading recovery advocacy organization in the United States 
206. W. Ginter, personal communication, June 22, 2009.
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(Faces & Voices of Recovery) celebrates diverse pathways of long-term addiction recovery (includ-
ing medication-assisted recovery), and medication-assisted recovery advocates have been a part 
of the governing board and committees of Faces & Voices since its inception in 2001. Increased 
recovery orientation within American OTPs is also evidenced by activities of the American Asso-
ciation for the Treatment of Opioid Dependence, efforts to forge recovery-focused models of MM 
in Philadelphia and New York State, and the Center for Substance Abuse Treatment’s Introduction 
to Recovery-Oriented Systems of Care for Opiate Treatment. 
The purpose of this article was to directly address the question: Can a methadone patient who 
has achieved long-term dose stabilization, uses no other non-prescribed opioids or other drugs 
(including alcohol), and has achieved significant improvement in psychosocial health and positive 
community integration be considered in recovery or recovering? After reviewing multiple definitions 
of recovery, the authors draw the following conclusion: 
The MM patient who is stabilized on his/her optimal dose of methadone, ab-
stains from the use of alcohol and other intoxicating drugs, and shows evidence 
of improving global health and social functioning is in recovery or recovering. 
Long-term recoveries from opioid addiction with or without the use of metha-
done (or naltrexone or Buprenorphine/Suboxone/Subutex) are issues of style 
of recovery and should not be framed in categories of inferiority or superiority. 
Rather than a source of disqualification for recovery status, methadone, provided 
under competent medical supervision at proper dosages with appropriate 
ancillary psychosocial support services, aids long-term recovery from opioid 
addiction and should be so recognized by the addiction treatment community, 
communities of recovery, and the public. There are multiple pathways and styles 
of long-term addiction recovery, and all should be cause for celebration.
Widespread acceptance of methadone maintenance is contingent upon elevating the quality of 
MM in the United States and on launching an effective and sustained campaign of professional 
and community education regarding methadone, methadone maintenance treatment, and 
methadone-assisted personal and family recovery.207 As a beginning, it is time that current and 
former MM patients and their families were invited to fully participate in the design, conduct, and 
evaluation of such a campaign. It is time all addiction professionals stood with Faces & Voices of 
207. White, W. (2009). Long-term strategies to reduce the stigma attached 
to addiction, treatment and recovery within the City of Philadelphia (with 
particular reference to medication-assisted treatment/recovery). Philadel-
phia: Department of Behavioral Health and Mental Retardation Services. 
— 64 —
Recovery in acknowledging that there are many pathways to recovery and that all are cause for 
celebration. It is time we as a national body of addiction professionals and recovery advocates 
fully acknowledged the legitimacy and value of methadone-assisted recovery and welcomed 
stabilized methadone patients as peers in the American culture of recovery. 
We are not saying that all or even most methadone patients are in recovery as defined in this 
monograph. (The prevalence of recovery within MM patients in the U.S. based on these new 
definitions of recovery has not been measured.) As a starting point, we are saying that there are 
methadone patients who meet this definition of recovery and that the percentage of MM patients 
who meet this definition could be significantly increased with a more recovery-focused approach 
to MM treatment. It is our further hope that this monograph will stimulate discussion about 
medication and recovery status and the extent to which new definitions of recovery will help or 
harm persons in methadone maintenance. 
In the next article, we will explore why changes in policies and clinical practices within Opioid 
Treatment Programs in the United States are needed to enhance long-term recovery outcomes. 
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RecoveRy-oRiented Methadone Maintenance
III: A Vision Statement 
William L. White, MA 
Lisa Mojer-Torres, JD 
If opioid dependence is a career, then therapeutic interventions must be mea-
sured in career terms.208
To recap the content of this monograph thus far, the first article reviewed the history of MM 
through three stages: 1) the personal recovery orientation of the early MM model, 2) a shift in the 
justification, design, and evaluation of MM toward reduction of social harm during the regulation 
and mass diffusion of MM across the United States, and 3) recent efforts to recapture and refine 
a person-centered, recovery-focused approach to MM. This third stage was seen as historically 
significant for its potential to revitalize and elevate the quality of MM treatment as a medical treat-
ment for opioid addiction.209 
The second article reviewed multiple definitions of recovery and discussed the question: Can a 
methadone maintenance patient who has achieved long-term dose stabilization, uses no other 
nonprescribed opioids or other drugs (including alcohol), and has achieved significant improve-
ment in psychosocial health and positive community integration be considered “in recovery” or 
“recovering”? We noted that emerging definitions of addiction recovery focus on three essential 
criteria: 1) the resolution of drug-related problems (defined in terms of sustained sobriety or 
clinical remission—the patient no longer meets diagnostic criteria for a substance use disorder), 
2) progress toward global (physical, mental, emotional, relational, and ontological) health, and 3) 
positive integration and contribution to the community.210 Using these criteria, we concluded: 
The MM patient who is stabilized on his/her optimal dose of methadone, 
abstains from the use of alcohol and other intoxicating drugs, and shows 
evidence of improved global health and social functioning should be considered 
to be in recovery or recovering. Rather than a source of disqualification for 
recovery status, methadone, provided under competent medical supervision at 
proper dosages with appropriate ancillary psychosocial support services, aids 
208. Senay, E.C. (1985). Methadone maintenance treatment. International 
Journal of the Addictions, 20(6&7), 803-821.
209. White, W., & Torres, L. (2010a). Recovery-oriented methadone 
maintenance: I. Historical context. 
210. Betty Ford Institute Consensus Panel. (2007). What is recovery? 
A working definition from the Betty Ford Institute. Journal of Substance 
Abuse Treatment, 33, 221-228. White, W. (2007). Addiction recovery: Its 
definition and conceptual boundaries. Journal of Substance Abuse Treat-
ment, 33, 229-241.
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long-term recovery from heroin addiction and should be so recognized by the 
addiction treatment community, communities of recovery, and the public.211 
We concluded in the first two articles that it was time we as a country and a professional field 
stopped debating the morality of methadone maintenance and focused our energies instead on 
elevating the quality of methadone maintenance treatment. In this third article, we will attempt to 
answer two overlapping questions: 1) How would opioid addiction be treated if we really believed 
that it was a chronic brain disease? 2) How would policies and clinical practices related to MM 
change if the primary goal of MM treatment were long-term personal recovery—defined as remis-
sion of the substance use disorder, improved global health, and community re-integration? 
One of the most definitive summaries of best practices in opioid addiction treatment is the Center 
for Substance Abuse Treatment’s Medication-Assisted Treatment for Opioid Addiction in Opioid 
Treatment Programs.212 Our intent is not to duplicate this exceptional effort, but to highlight par-
ticular clinical and support services that have a clear connection to short- and long-term recovery 
outcomes. Many of the key issues we address in this monograph were highlighted in CSAT’s first 
Treatment Improvement Protocol213 on methadone treatment. That TIP set forth a clear vision for 
the future of methadone maintenance:
Methadone maintenance providers will be under greater pressure to offer a 
richer mix of comprehensive services. Peer support groups will become a 
permanent part of the treatment system. More medical care will be offered at the 
clinic site as programs create better primary health care linkages to mainstream 
medical communities. Vocational referral and job placement will become more 
critical treatment components… More programs will begin to address the tragic 
realities of intergenerational drug abuse by implementing parenting skill work-
shops at or through the treatment setting.214 
More than fifteen years later, that vision remains unfulfilled, so it will be revisited in this article.
On a final introductory note, it is difficult to envision an article on the integration of medications 
within a recovery management paradigm without considering Buprenorphine/Suboxone/Subutex 
and other medications currently available (on and off label) and those in the pipeline of medication 
research on the treatment of opioid addiction. New medications for the treatment of heroin and 
other opioid addictions hold considerable promise, but that future potential does not alter the fact 
211. White, W., & Torres, L. (2010b). Recovery-oriented methadone 
maintenance: II. Recovery and methadone. 
212. Center for Substance Abuse Treatment. (2005). Medication-assisted 
treatment for opioid addiction in opioid treatment programs (Treatment 
Improvement Protocol (TIP) Series 43, DHHS Publication No. (SMA) 
05-4048). Rockville, MD: Substance Abuse and Mental Health Services 
Administration.
213. Center for Substance Abuse Treatment. (1993). State methadone 
treatment guidelines. Treatment Improvement Protocol (TIP) Series 1. 
Rockville, MD: U.S. Department of Health and Human Services. 
214. Center for Substance Abuse Treatment. (1993). State methadone 
treatment guidelines. Treatment Improvement Protocol (TIP) Series 1. 
Rockville, MD: U.S. Department of Health and Human Services. 
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that most patients in opioid treatment programs (OTPs) currently are treated with methadone.215 No 
other pharmacotherapeutic agent prescribed in the treatment of heroin addiction has demonstrated 
such consistently high efficacy, been more widely replicated and regulated, and yet been so linked 
to stigma and controversy.216 Therefore, our focus in this monograph is on methadone, and on the 
approach to treatment we refer to as recovery-oriented methadone maintenance (ROMM). 
the ManageMent of chRonic disease
Either addiction is a disease or it isn’t.217
Simply put, diseases of the human body are defined by the presence of an organ defect and 
predictable signs and symptoms of that defect.218 Methadone maintenance is based on the 
understanding that chronic heroin addiction is a metabolic brain disease whose core symptoms 
include drug tolerance, withdrawal, persistent craving, and continued drug-seeking in spite of 
adverse consequences and failed personal resolutions to cease drug use.219 Addiction to heroin 
or other short-acting exogenous opioids shares many characteristics with other primary chronic 
illnesses. These illnesses:
•	 are	influenced	by	genetic	as	well	as	personal,	family,	and	environmental	risk	factors;	
•	 are	linked	to	behaviors	that	begin	as	voluntary	choices	but	evolve	into	compulsive	behaviors	
fueled by neurobiological changes in the brain; 
•	 are	marked	by	sudden	or	gradual	onset	and	a	variable	though	often	prolonged	course;	
•	 are	accompanied	by	risk	of	profound	pathophysiology,	disability,	and	premature	death;	and	
•	 have	effective	treatments,	self-management	protocols,	peer	support	frameworks,	and	remis-
sion rates similar to those of other chronic illnesses, but no known cures.220
Opioid addiction has been defined as a chronic, progressive illness for more than a century, but 
the treatment of this disorder, like the treatment of other addictions, has been conducted primarily 
within an acute care (AC) model of service delivery. The AC model is marked by five distinguishing 
characteristics. First, care is provided within self-encapsulated, crisis-oriented episodes of care, 
each of which is marked by screening, admission, intake assessment, a short series of treatment 
procedures, discharge (with, at best, short-term follow-up), and termination of the service relation-
ship. Second, a professional expert directs and dominates the service delivery decision-making 
215. Kresina, T.F., Litwin, A., Marion, I., Lubran, R., & Clark, H.W. (2009). 
United States government oversight and regulation of medication assisted 
treatment for the treatment of opioid dependence. Journal of Drug Policy 
Analysis, 2(1), Article 2.
216. Joseph, H. (1995). Medical methadone maintenance: The further 
concealment of a stigmatized condition. Unpublished doctoral dissertation, 
City University of New York. Joseph, H., Stancliff, S., & Langrod, J. (2000). 
Methadone maintenance treatment (MMT): A review of historical and clini-
cal issues. Mount Sinai Journal of Medicine, 67, 347-364.
217. Methadone patient email to authors, 2010
218. McCauley, K. (2009). Pleasure unwoven: A personal journey about 
addiction. Salt Lake City, UT: The Institute for the Study of Addiction.
219. Dole, V. P., & Nyswander, M. E. (1967). Heroin addiction—A meta-
bolic disease. Archives of Internal Medicine, 120, 19-24. 
220. White, W., & McLellan, A.T. (2008). Addiction as a chronic disease: 
Key messages for clients, families and referral sources. Counselor, 9(3), 
24-33.
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process. Third, services transpire over a short (and historically ever-shorter) period of time. Fourth, 
the individual/family/community is given the impression at discharge (“graduation”) that long-term 
addiction recovery is now self-sustainable without further professional assistance. Fifth, post-
treatment relapse and re-admissions are viewed as the failure (non-compliance) of the patient 
rather than a failure of service design or execution.221 
Considerable effort is underway in primary medicine to develop models of chronic disease 
management,222 and there are growing calls to shift the acute care model of addiction treatment 
to a model of sustained recovery support analogous to the medical management of other chronic 
diseases.223 Efforts are underway at federal, state, and local levels to define and implement 
models of sustained recovery management (RM) and to nest these approaches within larger 
recovery-oriented systems of care (ROSC).224 
RM of chronic opioid addiction is based on the following four assumptions:
•	 Severe	and	chronic	opioid	addiction	is	a	brain	disease	characterized	by	neurobiological	de-
fects that are not corrected through acute detoxification.
•	 Exceptionally	high	rates	of	drug	seeking	and	re-addiction	following	detoxification	and	cessa-
tion of treatment are manifestations of these neurobiological defects.
•	 Acute	episodes	of	detoxification	and	biopsychosocial	stabilization	do	not	constitute	sustain-
able recovery from opioid dependence and are more likely to constitute predictable mile-
stones within a prolonged addiction career. 
•	 Principles	and	practices	that	characterize	the	effective	management	of	other	chronic	primary	
diseases can be adapted to effectively manage and improve long-term recovery outcomes in 
the treatment of chronic opioid (primarily heroin) addiction.
Methadone Maintenance and RecoveRy ManageMent 
Recapturing and extending methadone maintenance as a person-centered, recovery-focused 
treatment of opioid addiction—what we here refer to as recovery-oriented methadone mainte-
nance (ROMM)—will require a realignment of addiction- and recovery-related concepts, a realign-
ment of core clinical and recovery support practices, and a realignment of the context in which 
treatment occurs (e.g., policies, regulatory guidelines, funding mechanisms, community recovery 
support resources). The primary emphasis in this article will be on defining the core clinical and 
224. Halvorson, A., & Whitter, M. (2009). Approaches to recovery-oriented 
systems of care at the state and local levels: Three case studies (HHS Pub-
lication No. (SMA) 09-4438). Rockville, MD: Center for Substance Abuse 
Treatment, Substance Abuse and Mental Health Services Administration. 
White, W. (2008a). Perspectives on systems transformation: How visionary 
leaders are shifting addiction treatment toward a recovery-oriented system 
of care (Interviews with H. Westley Clark, Thomas A. Kirk, Jr., Arthur C. Ev-
ans, Michael Boyle, Phillip Valentine and Lonnetta Albright). Chicago: Great 
Lakes Addiction Technology Transfer Center. White, W. (2008b). Recovery: 
Old wine, flavor of the month or new organizing paradigm? Substance Use 
and Misuse, 43(12&13), 1987-2000. 
221. White, W., & McLellan, A.T. (2008). Addiction as a chronic disease: 
Key messages for clients, families and referral sources. Counselor, 9(3), 
24-33.
222. Bodenheimer, T., Wagner, E.H., & Grumbach, K. (2002). Improving 
primary care for patients with chronic illness. Journal of the American 
Medical Association, 288(14), 1775-1779. Wagner, E.H. (1998). Chronic 
disease management: What will it take to improve care for chronic illness? 
Effective Clinical Practice, 1, 2-4. Wagner, E.H., Austin, B.T., Davis, C., 
Hindmarsh, M., Schaefer, J., & Bonomi, A. (2001). Improving chronic 
illness care: Translating evidence to practice into action. Health Affairs, 
20, 64-78.
223. Dennis, M.L., & Scott, C.K. (2007). Managing addiction as a chronic 
condition. Addiction Science & Clinical Practice, 4(1), 45-55. Institute 
of Medicine. (2006). Improving the quality of health care for mental and 
substance-use disorders: Quality chasm series. Washington, DC: National 
Academy Press. McLellan, A.T., Lewis, D.C., O’Brien, C.P., & Kleber, 
H.D. (2000). Drug dependence, a chronic medical illness: Implications 
for treatment, insurance, and outcomes evaluation. Journal of the 
American Medical Association, 284(13), 1689-1695. White, W., Boyle, 
M., & Loveland, D. (2002). Alcoholism/addiction as a chronic disease: 
From rhetoric to clinical application. Alcoholism Treatment Quarterly, 
20(3/4), 107-130. White, W., & McLellan, A.T. (2008). Addiction as a 
chronic disease: Key messages for clients, families and referral sources. 
Counselor, 9(3), 24-33.
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recovery support practices that would distinguish a recovery management approach to the treat-
ment of opioid addiction: the who, what, when, where, and “how long” of MM treatment. 
Eight arenas of service practice distinguish RM from AC models of addiction treatment: 1) attraction, 
access, and early engagement; 2) assessment and service planning; 3) service team composition; 
4) the service relationship; 5) service quality and duration; 6) the locus of service delivery; 7) asser-
tive linkage to recovery community resources; and 8) long-term post-treatment recovery check-ups, 
stage-appropriate recovery support, and, when needed, early re-intervention.225 The current status 
of each of these areas related to methadone maintenance will be evaluated using available scientific 
studies and national treatment systems performance data. The authors will also explore potential 
changes in service design that would increase the focus of MM on long-term recovery outcomes. 
As we explore changes in clinical practices in MM, it is important to remain cognizant of the grow-
ing heterogeneity of MM patients. Today’s aging MM patients, a new generation of prescription 
opioid addicts, and the young polyaddicted heroin/cocaine addicts steeped in a street culture of 
ruthlessness, risk-taking, and violence226 all present needs much different from those of the mid-
twentieth-century “cool cats” and “righteous dope fiends” whose heroin use was nested within a 
lifestyle of carefully crafted slickness and street sophistication.227 Also of note is the wide variability 
of MM provider organizations. For example, few studies are available that illuminate potential 
differences between public and private MM programs, in spite of the growing privatization of MM 
in the United States over the past two decades.228 
attRaction, access, and eaRly engageMent/Retention 
Interventions at early stages in the development of chronic diseases improve long-term health 
outcomes. Such early intervention is crucial in addressing conditions such as heroin addiction 
that often become more severe, more complex, and more intractable over time. The keys to early 
intervention are public knowledge about the disorder; treatments that are perceived to be effec-
tive, accessible, and affordable by those affected; systems of intervention that encourage early 
treatment and resolve obstacles to participation; and mechanisms that enhance service engage-
ment and reduce early service attrition. Early intervention can be framed conceptually as including 
three distinct processes: 1) attracting those currently in need of treatment, 2) facilitating rapid 
access to services, and 3) enhancing therapeutic alliance and resolving intrapersonal, program, 
and environmental obstacles to continued participation.
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Attraction
Methadone maintenance treatment attracts voluntarily participation by more people addicted to heroin 
and other short-acting opioids than any other addiction treatment modality,229 but most people addict-
ed to heroin and other opioids are not currently enrolled in addiction treatment. There are an estimated 
750,000 to 1,000,000 opioid (primarily heroin) addicts in the United States,230 but only 337,342 persons 
with a primary drug choice of heroin (246,835; 13.6% of all admissions) or other opioids (90,489; 5% of 
all admissions) were admitted to addiction treatment in the United States in 2007.231 Of these admis-
sions, only 29% received methadone or buprenorphine as a planned part of their treatment.232 A 2008 
survey identified 1,132 certified OTPs in the United States (8% of the 13,688 treatment facilities in the 
U.S.).233 A March 31, 2008 survey of OTPs in the United States found that 268,071 patients were being 
treated with methadone and 4,280 were being treated with buprenorphine.234 
Methadone maintenance is considered the most effective treatment for chronic heroin depen-
dence,235 but the percentage of heroin-dependent people seeking treatment who receive metha-
done pharmacotherapy declined precipitously between 1992 and 2007 (from 42% to 22%).236 The 
systems in which heroin addicts are most likely to be encountered (the health care and criminal 
justice systems) refer only a small fraction (5.5%) of those currently enrolled in MM. Most patients 
entering methadone treatment get to MM by self/family referral (72.8%). Other addiction treatment 
providers make up only 9.6% of MM referrals, with other referral sources including health care 
providers (4.2%) and other community referrals (6.1%).237 Heroin users still linked to conventional 
society through living with family or an intimate partner are more likely to seek treatment than 
those living in isolation from such connections.238 Breaking such isolation may require special 
outreach services to elicit treatment seeking.
The most common pattern of treatment for injection drug users consists of multiple episodes of 
detoxification—the least effective of all treatments for opioid addiction.239 A recent Massachusetts 
study of first treatment entry for injection drug users revealed that 66% sought detoxification, 15% 
outpatient counseling, 14% methadone maintenance, and 5% residential treatment.240 The same 
study found that, throughout the six-year span of the study, 30% of injection drug users expe-
rienced multiple episodes of detoxification but did not participate in any additional treatment.241 
What is of most concern is the finding that those who seek heroin detoxification only and eschew 
further treatment have the fewest resources to support a process of long-term recovery.242 
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Popular and professional conceptions of methadone as a “legal substitute for heroin,” street myths 
about methadone (e.g., “it rots your bones”), and the view that MM is a “last resort” inhibit timely 
treatment seeking by those who could benefit from MM.243 Such views about methadone are 
particularly magnified within minority communities.244 
The myths, misconceptions, and stigma surrounding heroin addiction, methadone, and metha-
done treatment; the public visibility of the worst methadone clinics and the least stabilized MM 
patients; and the virtual invisibility of the best OTP clinics and the most successful MM patients 
create a climate in which people enter MM mostly under conditions of extreme desperation and 
only in the late stages of their addiction careers. The average duration of heroin use prior to first 
admission to treatment ranges from 6-10 years245 to 14.5 years,246 and an average span of 22 
years’ heroin use precedes the onset of long-term recovery from heroin addiction (with recovery 
defined in this study as 5 years’ continuous heroin abstinence).247 
Future efforts to attract people who are heroin dependent to enter MM include national and local 
professional education campaigns, targeted education of injection drug users, increasing the 
recovery orientation of syringe exchange programs, community intervention programs aimed at 
early problem identification and assertive linkage to MM or alternative treatments (via physicians, 
hospitals, health clinics, police, etc.), community education campaigns about opioid addiction and 
the effectiveness of MM as a medical treatment of heroin addiction, and street outreach programs 
conducted by people who offer themselves as “living proof” of the reality of long-term medication-
assisted recovery. 
Recovery catalysts (outreach workers) trolling the natural environments of prospective patients can 
reach, motivate, and engage individuals who resist entering MM due to their own ambivalence about 
giving up heroin and the associated lifestyle.248 Such workers challenge the myths about methadone 
and correct the view that MM is not accessible, effective, or affordable. They also avoid using inef-
fective pleas and threats such as those that warn of continued pain and the threat of death. People 
addicted to heroin and other opioids all too often are already drowning in pain, disregard death as 
a potential consequence of heroin use (e.g., by avoiding overdose protection measures), and even 
view the possibility of death as a seductive source of escape.249 Outreach in ROMM is often based 
on the recognition that sparking the recovery initiation process is more about hope (seeing the top) 
than about a heightened experience of pain (hitting bottom). And sometimes it is as simple as get-
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ting a clear message to those in need of services. Imagine a sign visible in every emergency room 
and ambulatory care center reading, “Dependence on narcotics is a medical problem that can be 
treated effectively. Ask our staff about taking the first step toward recovery.”250 
A study by Amodeo and colleagues251 offers another potential clue for outreach within ROMM. 
Their study found that female injection drug users who had previously received mental health 
services were 66% more likely to enter treatment beyond detoxification than female injection 
drug users who had not received such services. Outreach aimed at linking and providing mental 
health services to injection drug users may provide a novel window of opportunity for subsequent 
engagement in MM and other addiction treatment modalities.
Patient attraction to methadone maintenance would also be enhanced if all opioid-addicted patients 
seeking treatment were afforded objective choices about their treatment options regardless of 
the settings in which they were screened and evaluated. For example, patients who were seeking 
buprenorphine treatment but discover they cannot afford this treatment should be provided treat-
ment options that include MM as well as other treatment options that are more affordable. The 
clarification of patient expectations of treatment and a presentation of treatment choices through 
a more education-oriented consent-to-treatment process would enhance each patient’s capacity 
for informed decision-making. The goals would be to correct false expectations, enhance the best 
match between patient and treatment approach/setting, and ensure that each patient has sufficient 
information and understanding to appreciate the benefits and risks of MM and other addiction treat-
ment modalities. All addiction treatment programs should be required to provide regular opportuni-
ties for patients and family members to evaluate the treatments they are receiving and should make 
the results of these evaluations available to prospective patients/families and referral sources. 
A final issue related to patient attraction to MM involves the attractiveness, accessibility, perceived 
safety, and overall community reputation of the OTP. 
Access
Rapid access to addiction treatment is particularly critical for injection drug users due to their 
ambivalence about treatment and about ceasing heroin use, their low frustration tolerance, their 
likelihood of continued drug use, and the high risk of harm to self and others via overdose death, 
HIV transmission, and criminal behavior.252 Reports from MM counselors include vivid accounts of 
people dying while on waiting lists to enter treatment.253 Between 25-50% of persons on waiting 
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lists fail to enter addiction treatment,254 with as many as 40% of persons dropping out of the 
waiting list within the first two weeks.255 MM treatment access can be limited—even for the most 
highly motivated patient—by lack of geographical proximity, inadequate treatment capacity/wait-
ing lists for treatment admission, restrictive admission criteria, the demand for daily attendance, 
limited timeframes within which individuals can receive medication or pick up take-home medica-
tion, shaming rituals (e.g., standing in line on public streets, frontally-observed urination for drug 
testing), lack of insurance and prohibitive service fees, homelessness, child care, and language 
and cultural barriers.256 
Potential patients have also experienced lost access to MM through closure of public treatment 
programs or their inability to pay for public or private treatment. Studies of such patients who 
have lost access to MM have documented adverse personal and community consequences.257 It 
is critical that each OTP have an emergency plan that anticipates how each patient will be medi-
cated in the event of a brief, prolonged, or permanent disruption in services at the clinic—a current 
requirement of the OTP accreditation process. 
Future efforts to increase access to MM treatment include increased public and private funding 
to expand MM treatment capacity, distribution of coupons for free treatment, regulatory reform to 
minimize obstacles to treatment access, expedited admission (e.g., interim maintenance-meth-
adone without counseling), and moving stabilized patients to medical maintenance (methadone 
provided by a primary care physician).258 
For patients willing to enter MM only on a time-limited basis,259 MM programs could admit patients 
under such conditions; provide patient education about the benefits of longer periods of mainte-
nance; and, for those patients choosing to taper quickly, provide assertive post-treatment recovery 
check-ups to offer support, monitor recovery stability, and provide rapid re-engagement in treatment 
as needed (with or without methadone pharmacotherapy). Potential patients resistant to MM could 
be offered other treatment options, including alternative pharmacotherapies (e.g., buprenorphine). 
The goal of these efforts would be to shorten addiction careers and improve recovery outcomes 
by intervening in the progression of addiction at earlier stages of problem severity and complexity 
at a time when patients still have personal/family recovery capital that can be mobilized to enhance 
recovery initiation and recovery maintenance. 
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There is also an issue of MM patients’ access to other needed addiction treatment modalities. 
Historically, MM patients have been refused admission to abstinence-based addiction treatment 
and recovery support services, e.g., refused admission to alcohol detoxification, residential 
treatment, and sober living facilities.260 Efforts to involve MM patients in these services have shown 
positive results and should be expanded via professional education and the establishment of 
formal linkages between OTPs and other addiction treatment programs.261 OTPs can improve 
this situation by educating other treatment providers about the benefits of concurrent treatment, 
advocating on behalf of their patients (e.g., for state regulations that prohibit such discriminatory 
exclusion), and encouraging patients who have been denied access to treatment to seek legal 
redress. Some state addiction treatment authorities (e.g., Maine) explicitly prohibit (as a condition 
of licensing or funding) programs from refusing admission of patients who are also enrolled in 
medication-assisted treatment. 
Early Engagement and Retention
Another distinctive feature of recovery management approaches is their emphasis on enhancing 
early patient engagement in the treatment process. This is related to two issues we will discuss 
later—therapeutic alliance and duration of service involvement—and the critical role each plays in 
influencing long-term recovery outcomes. 
Recent reviews262 of patient retention studies lead to six critical conclusions:
•	 Sustained	treatment	retention	is	critical	to	long-term	recovery	outcomes:	“Addiction	is	a	
chronic relapsing disorder and short-term treatment is not likely to have any lasting impact.”263 
•	 MM	programs	retain	opioid-addicted	patients	at	higher	rates	than	all	other	treatment	modali-
ties, but retention remains a significant problem in MM treatment.264 
•	 Though	MM	was	originally	conceptualized	as	a	prolonged	if	not	lifelong	treatment,	the	major-
ity of newly admitted MM patients drop out within the first year. 
•	 Retention	and	dropout	rates	vary	widely	from	program	to	program.
•	 Retention	and	dropout	are	more	related	to	in-treatment	program	factors	than	pre-treatment	
patient factors.265
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•	 Early	dropout	is	related	to	four	factors:	1)	program-related	factors	(e.g.,	arbitrary	and	unequal-
ly enforced rules, conflict with one’s counselor, discharge for non-payment of fees, schedule 
conflicts that interfere with daily pickups), 2) dissatisfaction with methadone (e.g., fear of pro-
longed dependence on medication and the clinic), 3) life events/logistics (e.g., stressful events 
or other obstacles that interfere with treatment participation), and 4) incarceration due to past 
legal problems or new minor criminal charges (e.g., loitering). 
As we will review shortly, the optimum effects of MM in terms of full biopsychosocial recovery 
require a sustained period of treatment participation. Failure to establish a strong therapeutic 
alliance with each patient and early disengagement from treatment are key indicators that these 
optimum effects will not be achieved.266 Of those admitted to MM, 24% drop out in the first 60 
days,267 with new patients dropping out at higher rates than returning patients—31% versus 20% 
in the first 90 days of treatment.268 Studies have shown that the same factors that inhibit access 
also contribute to premature disengagement from MM, factors that include misconceptions and 
negative attitudes about methadone.269 A critical finding worth restating is that patient retention in 
treatment is predicted more by program characteristics, including degree of therapeutic engage-
ment, than by the patient’s demographic or clinical characteristics.270 
Among critical program factors that influence retention are medication dose, which we will discuss 
shortly, and each patient’s belief that he or she is being treated fairly and with dignity and that 
his or her preferences are being respected. The “patient-centered approach” advocated by the 
Institute of Medicine271 is the ideal for OTPs. Because of the amount of time the counselor spends 
with the patient compared to the time spent by other staff, the counselor plays a pivotal role in this 
process of patient engagement. Due-process assurances and the right of redress (e.g., grievance 
processes) are critical to resolving early problems in this engagement process. 
Promising practices related to early engagement and retention include interim MM, rapid admis-
sion, same-day dosing, expanded clinic hours, individualized methadone doses with no dose 
floors or ceilings, formal patient/family orientation sessions, increased numbers of patient op-
tions, patient participation in clinical decision-making, peer guides for new patients, telephone 
prompts following missed appointments, patient education related to safety and pharmacology 
(e.g., how methadone works to overcome withdrawal, suppress cravings, provide feeling of 
“normalcy,” create a blockade effect), provision of specialized services for co-occurring mental 
266. Broome, K.M., Simpson, D.D., & Joe, G.W. (1999). Patient and program 
attributes related to treatment process indicators in DATOS. Drug and Alco-
hol Dependence, 57, 127-135. Meier, P. S., Barrowclough, C., & Donmall, 
M.C. (2005). The role of the therapeutic alliance in the treatment of sub-
stance misuse: A critical review of the literature. Addiction, 100, 304-316.
267. Simpson, D.D., & Joe, G.W. (1993). Motivation as a predictor of early 
dropout from drug abuse treatment. Psychotherapy: Theory, Research and 
Practice, 30(2), 357-368. 
268. Deren, S., Goldstein, M.F., Des Jarlais, D.C., Richman, B.L., Kang, 
S-J., & Flom, P.L. (2001). Drug use, HIV-related risk behaviors and dropout 
status of new admissions and re-admissions to methadone treatment. 
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269. Zaller, N.D., Bazazi, A.R., Velazquez, L., & Rich, J.D. (2009). Attitudes 
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271. Institute of Medicine. (2006). Improving the quality of health care for 
mental and substance-use disorders: Quality chasm series. Washington, 
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illnesses, use of patient advocates to resolve conflicts with staff, and completion of patient 
satisfaction surveys/interviews.272 Another possible engagement strategy would be to reach out 
via intense peer-based educational interventions with patients who recycle through short heroin 
detoxification episodes without ever achieving an optimal therapeutic dose for maintenance 
pharmacotherapy.
Key recovery-focused systems performance measures related to attraction, access, and early 
retention include community-level measures of social and professional stigma related to MM, 
attitudes toward MM among persons who are in need of but not currently in treatment, referral 
source patterns (e.g., increases in self-referrals and referrals from systems traditionally hostile to 
MM), length of opioid use prior to first admission, percentage of admissions without prior addic-
tion treatment, percentage of admissions without prior MM treatment, average time lag between 
help seeking and treatment admission, percentage of patients admitted from waiting lists, and 
early treatment retention. 
assessMent and seRvice planning 
Assessment processes for patients with chronic diseases differ from assessment of acute disor-
ders due to the following principle: chronic diseases beget other acute and chronic disorders that 
collectively exert sustained and profound strain on the patient and family. Assessment of chronic 
disorders is therefore global in scope, family-inclusive, and continual. 
Assessment and service planning procedures within MM programs historically have paralleled 
those used in acute-care models of addiction treatment. A team of professionals conducts an 
initial screening and assessment, verifies and diagnoses opioid addiction, admits the patient, 
identifies primary and collateral problems, generates a professional treatment plan that delin-
eates how these problems will be addressed, and maintains progress notes related to service 
activities aimed at the identified problems. Efforts to increase the recovery orientation of these 
processes include:
•	 shifting	from	categorical	to	global	assessment	instruments	and	interview	protocols;
•	 conceptualizing	the	family	(as	defined	by	the	patient)	as	the	unit	of	service	rather	than	the	
individual patient;
272. Bao, Y-P., Liu, Z-M., Epstein, D., Du, C., Shi, J., & Lu, L. (2009). A 
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Health Services & Research, 32(1), 43-60. Maddux, J.F., Desmond, D. 
P., & Esquivel, M. (1995). Rapid admission and retention on methadone. 
American Journal of Drug and Alcohol Abuse, 21(4), 533-547. Reisinger, 
H.S., Schwartz, R.P., Mitchell, S.G., Peterson, J.A., Kelly, S.M., O’Grady, 
K.E., Agar, M.H. (2009). Premature discharge from methadone treatment: 
Patient perspectives. Journal of Psychoactive Drugs, 41(3), 285-296. 
Schwartz, R.P., Jaffe, J.H., O’Grady, K.E., Das, B., Highfield, D.A., & Wilson, 
M. E. (2009). Scaling-up interim methadone maintenance: Treatment for 
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•	 using	a	strengths-based	assessment	process	to	identify	personal,	family,	and	community/
cultural assets that can be mobilized to support recovery initiation and maintenance;
•	 viewing	assessment	as	a	continual	versus	single-point-in-time	intake	process	(based	on	the	
understanding that service needs change across the developmental stages of recovery); and 
•	 making	the	transition	from	professionally	directed	treatment	plans	to	patient-directed	recovery	
plans.273
Traditional assessment processes (and level-of-care and modality-placement decisions) in 
addiction treatment have relied primarily on an assessment of addiction severity (its acuity and 
chronicity) and complexity (co-occurring problems and obstacles to recovery). Recovery manage-
ment approaches to MM balance this emphasis on pathology assessment with an assessment 
of recovery capital in decisions related to placement, readiness for take-home privileges, and 
responses to a patient’s interests or preferences related to tapering. For example, a patient 
presenting with high problem severity, but exceptionally high recovery capital may require lower 
treatment intensity and shorter duration than the patient presenting with lower problem severity 
but little or no recovery capital.274 Assessing recovery capital and delivering services aimed at 
mobilizing and increasing internal and external recovery capital are essential strategies within 
recovery management approaches to the treatment of opioid dependence.
Neither the assessment nor counseling processes within MM programs have historically focused 
on needs of the children of MM patients, parenting concerns of MM patients, or the needs of the 
family as a whole.275 We envision a future in which MM programs will offer a wide menu of child-, 
parent-, and family-focused recovery support services (See later discussion). 
coMposition of the seRvice teaM 
Treatment of chronic diseases, in contrast to the treatment of acute disease or trauma, involves 
a broader multidisciplinary team and a greater emphasis on peer support for long-term recovery 
management. The typical staffing pattern of MM programs in the United States is made up of 
medical staff (physicians, physician’s assistants, nurses, and nurse practitioners), counseling staff, 
and ancillary professionals (pharmacists, psychologists, and social workers).276 We anticipate 
significant changes in the composition and duties of staff of MM programs that pursue greater 
recovery orientation, including expanded: 
273. Borkman, T. (1998). Is recovery planning any different from treatment 
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Scientific rationale and promising practices. Pittsburgh, PA: Northeast 
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based drug treatment practice and the child welfare system: The example 
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•	 roles	of	addiction	medicine	specialists	in	patient/family/community	education;
•	 involvement	of	primary	care	physicians	in	MM	treatment,	including	co-location	of	MM	clinics	
and primary health care clinics (potential conduits for opening office-based treatment sites);
•	 use	of	case	managers,	freeing	counselors	to	do	scheduled	recovery-focused	counseling;
•	 involvement	of	therapists	trained	in	clinical	work	with	families	and	children;	
•	 use	of	current	and	former	patients	in	medication-assisted	recovery	as	staff	and	volunteers	
within the MM milieu, e.g., as patient educators, recovery coaches, and advocates; and 
•	 use	of	indigenous	healers	drawn	from	diverse	cultural	communities,	e.g.,	leaders	of	faith-
based recovery ministries. 
These staffing changes are congruent with the RM focus on recovery as a process of enhanced 
global health and positive community re-integration and its emphasis on the potential contributions 
of peer-based recovery support services (P-BRSS) in long-term recovery from opioid addiction. 
Medical staff members play a central role in service delivery during a patient’s involvement in MM, 
but physician roles in MM focus primarily on conducting physical examinations, setting dosing 
levels, and performing administrative activities. Similarly, nursing time in OTPs is consumed 
primarily in dispensing medication for a high volume of patients. Most OTP physicians and nurses 
are not, or are only peripherally, involved in broader aspects of care delivery, nor are they involved 
in the sustained monitoring and support of patients following cessation of MM.277 Some MM 
patients who reviewed a summary of this monograph were quite critical of the lack of physician 
involvement in their care.
I have NEVER MET the doctor whose name is on my methadone take home 
bottles. Never once in 15 years. There is no medicine going on in the MMT 
system.278
One of the principles of RM is that every patient in recovery needs a sustained relationship with 
a primary care physician. Ideally, these physicians are involved as partners in the addiction 
treatment process, play a central role in the long-term management of health and wellness, and 
conduct ongoing post-treatment recovery check-ups. 
277. Loth, C., Schippers, G.M., Hart, H., & van de Wijngaart, G. (2007). 
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We anticipate greater involvement of primary care physicians in MM treatment, experiments in co-
location of MM clinics and primary health care clinics, and an increased number of experiments 
delivering methadone treatment through the auspices of primary care physicians. Integrating 
addiction medicine and primary medicine may be particularly important for older MM patients who 
face risks of premature death from such co-occurring conditions as nicotine dependence and 
diabetes.279 The high rate of psychiatric co-morbidity of MM patients and their generally low quality 
of life would also suggest a potentially greater role for psychologists and social workers in MM 
programs.280 
As a byproduct of the professionalization of addiction counseling, the percentage of addiction 
counselors with a history of personal recovery decreased from more than 70% in the late 1960s 
to 30% in 2009.281 Recovery representation is even lower in the MM arena, in spite of the fact that 
many MM patients recommended the use of recovering counselors in surveys asking them to 
identify the ideal characteristics of an MM program.282 Calsyn and colleagues’283 study of staffing 
patterns in MM programs found that less than half of MM programs had any staff in recovery, and 
only 10% of all MM staff in the United States self-identified as being in recovery. We anticipate 
a number of innovative, MM-specific peer recovery support initiatives in the near future that will 
forever reshape the milieu of methadone maintenance in the United States.284 We anticipate a day 
when current and former MM patients in stable recovery are ever-present within OTPs via their 
roles as service staff, members of governing boards and patient advisory councils, and through 
formal volunteer programs and alumni associations. 
From the standpoint of long-term recovery management, peer-based recovery support services 
can play a critical role in outreach (pre-recovery identification and recovery priming), recovery ini-
tiation and stabilization, transition to recovery maintenance, and enhancing the quality of personal 
and family life in long-term recovery (with or without continued methadone pharmacotherapy). 
Some OTPs, such as Beth Israel Medical Center in New York City, recruited patients who had 
been optimally dose—stabilized for years to be trained and credentialed as addiction counselors. 
Other OTPs are exploring the use of non-clinical peer-based recovery support services. Of 
particular note is the development of a peer-based recovery support services model for patients 
in methadone treatment via the CSAT-funded Medication Assisted Recovery Services (MARS) 
project in New York City.285
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the seRvice Relationship 
Relationships between patients with chronic diseases and their service providers are markedly 
different than interactions surrounding the treatment of acute disorders. The treatment of acute 
disorders places the physician and care team in a position of elevated power and responsibility 
to “fix” the problem presented by the patient. In contrast, the patient with a chronic disease bears 
central responsibility for managing his or her own recovery in consultation with his or her profes-
sional care providers. Physicians and the broader care team provide ongoing adjustments in 
medical management (e.g., medications) and respond to acute crises, but they play equally impor-
tant roles as educators, consultants, and recovery coaches. In these latter roles, they provide to 
each patient a rich menu of information and support services. As we shall see, the scope, depth, 
and duration of resources provided to patients managing other chronic diseases are far greater 
than those of the resources offered to current and former methadone patients. 
The service relationships within chronic disease management are particularly distinctive in terms 
of their duration (measured in years or decades), the high degree of intimacy that develops 
between service providers and the patient and family, and the broader focus of the relationship—
the global health and functioning of the patient and family rather than treatment of a particular 
health defect. One would think that service relationships within OTPs would reflect this type of 
relationship, given MM’s foundational belief that opioid dependence is a chronic disease requiring 
sustained and active management. 
The importance of the therapeutic alliance in the treatment of addiction is clearly evident in the 
early publications of the developers of MM. Dr. Marie Nyswander declared that the most important 
thing in the life of a drug addict is “to be understood.” She called upon treatment providers to 
“convey an interest in every aspect of the patient’s life.”286 Dr. Nyswander’s capacity for such alli-
ances with her patients was legendary, and Dr. Dole was fond of suggesting that it was impossible 
to rehabilitate any patient without getting to know the patient as a human being.287
I made a practice of spending two or three hours almost every day just sitting 
and talking with the addicts in a somewhat aimless way. I was just trying to get a 
sense of their way of thinking, their values, their experiences. They educated me 
about a world that was out of my reach, one that I had never been in and would 
never enter.288
286. Nyswander, M. (1956). The drug addict as a patient. New York: Grune 
& Stratton.
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Like teachers in a one-room school, we knew each patient personally.289
Dr. Mary Jeanne Kreek also extolled the importance of listening to patients as the most important 
quality of those working in MM treatment. 
Less easily measured than blood levels of the pharmacotherapeutic agent, urine 
content of a drug of abuse, receptor or peptide ligand levels, or the myriad of 
social and psychological indices measured by well-validated instruments of 
psychology and psychiatry are those qualities that make any individual staff 
member an excellent and human care giver.290 
MM in its earliest years was grounded in a relationship free of contempt and in attitudes of 
personal respect and professional humility.291 The climate of partnership between the original MM 
pioneers and their patients was so strong that critics suggested their outcomes were a product of 
the supportive milieu rather than of methadone. “There’s something very special about the climate 
at Rockefeller” was proffered by such detractors as a criticism rather than a compliment.292 
MM pioneers grieved the loss of such relationships as MM was widely diffused in the United 
States and beyond.
The most any chemical agent can do for an addict is to relieve his compulsive 
drive for illicit narcotics. To give him hope and self-respect requires human 
warmth; to become a productive citizen he needs the effective support of 
persons who can help him find a job and protect him from discrimination. It is in 
these human qualities that the [methadone maintenance] programs of the past 
five years have failed.293
… to succeed in bringing disadvantaged addicts to a productive way of life, a 
treatment program must enable its patients to feel pride and hope and to accept 
responsibility. This is often not achieved in present-day [methadone mainte-
nance] treatment programs. Without mutual respect, an adversary relationship 
develops between patients and staff, reinforced by arbitrary rules and the indif-
ference of persons in authority. Patients held in contempt by the staff continue to 
act like addicts… 294
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Service relationships within MM treatment have been inordinately shaped by the regulatory 
environment and the growing business orientation of OTPs. 
The “Catch-22” in which the methadone patient, methadone treatment staff, and 
methadone clinic as an institution are trapped grew out of the conflicting inter-
ests that emerged as methadone maintenance was mainstreamed as a treat-
ment modality. On the one hand, there were the needs of the methadone patient 
and the need for a long-term service relationship based on empathy, trust, and 
respect. On the other hand, there were concerns about public safety via the 
potential for methadone diversion. This tension between a milieu of engagement 
and empowerment versus a milieu of distrust and control left those being served 
caught between the status of a patient and the status of a prisoner/probationer 
and left the physician/nurse/counselor caught between their aspirations to serve 
as healers and onerous, regulatory-imposed policing functions. The result is 
a demedicalized system of methadone maintenance in which people entering 
methadone maintenance are treated more like criminals (or recalcitrant children) 
than patients, within a relational world more dominated by surveillance and 
control than compassion and choice.295 
The MM model is based on control and dehumanizes its “clients” with prac-
tices such as observed urinalysis.296
I have been on MMT for over 11 yrs now and I can’t even remember the last 
time I had a dirty UA. I have always been a model patient, never caused any 
problems, or made any formal complaints (even though there were many times I 
would have if I had not feared retaliation by the clinic owner and doctor).297
To seek help at an OTP requires willingness to surrender central control of one’s life to the OTP 
staff. The person entering the OTP is typically desperate and at the end of his/her rope, having 
burned all bridges to civility and support in the non-addict world. By entering methadone mainte-
nance pharmacotherapy, patients surrender control over their drug use and their lives to absolute 
strangers. If that trust is affirmed during the induction period, the patient is likely to remain recep-
tive to maintenance pharmacotherapy. As relationships with clinical staff deepen, the patient is 
likely to reveal his or her life experience and aspirations to the OTP staff. Establishment of a strong 
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alliance with the patient, beginning with the achievement of optimal dose stabilization in collabora-
tion with the patient, lays the foundation for the larger and more enduring process of biopsycho-
social recovery. Recovery-focused helping relationships are distinguished by a shared vision of 
long-term recovery, a recovery-focused partnership/consultant relationship, and an emphasis on 
continuity of relational support over time. 
ROMM requires abandoning the view that the individual is the sole source of the problem and that 
the credentialed professional is the source of the solution. The gross power inequities between the 
patient and OTP clinic must be acknowledged, abuses of such power admitted, and new service 
relationships formed on a long-term recovery partnership model. Substandard and exploitive 
care must be exposed and confronted, amends must be made where possible, and policies and 
practices that punish patient honesty must be abandoned. 
There are several measures within MM that can be used to gauge changes in the quality of 
service relationships over time. These indicators include: 1) measures of therapeutic alliance; 2) 
surveys of patient attitudes toward OTP staff and OTP services; 3) ethnographic studies of MM 
patients and the OTP milieu; 4) patient dropout rates during early treatment (first 30 days); 5) rates 
of dropout during dose and recovery stabilization (first 6 months); 6) discharge status, particularly 
the rates of administrative discharge and patient termination of services against medical advice; 
and 7) recovery rates of patients assigned to different counselors or service units. 
Positive indicators that an OTP is moving toward recovery-oriented service relationships include 
increased levels of recovery representation at OTP governance, leadership, and service-delivery 
levels; respect for patient opinions and preferences via a choice philosophy;298 reduced incidence 
of administrative discharges and changes in administrative discharge policies; elevating patient 
hopes and personal goals (e.g., helping patients weigh the pros and cons of SSI disability support 
and, where appropriate, achieve productive employment); transitioning patients from profession-
ally developed treatment plans to patient-developed recovery plans; and emphasizing continuity of 
patient/family contact and support across the stages of long-term recovery. 
Ensuring continuity of contact and support might be the Achilles heel of ROMM and the larger 
movement toward an RM model for all addiction treatment. Such continuity of support in a primary 
recovery support relationship cannot be ensured in a workforce undergoing constant turnover. 
Surveys of the addiction treatment workforce reveal high rates (25-50%) of staff turnover and high 
298. White, W. (2008e). Toward a philosophy of choice: A new era of ad-
diction treatment. Counselor, 9(1), 38-43.
— 84 —
percentages of staff members reporting their intention to leave their current positions in the next five 
years.299 There are reports of counselor turnover rates in OTPs as high as 400% per year.300 
Staff turnover is definitely a problem. I got used to the counselor I had when I 
first started methadone maintenance treatment. I told her all my history, all the 
dirty details and things I hadn’t been able to talk about before. Without me even 
knowing it was going to happen, she was gone, no goodbye—nothing. Then I 
had to try and go through all the same stuff again with a new counselor, and for 
what? Four months later, that one was gone too.301 
Ensuring continuity of contact and support within a long-term recovery management framework 
will require strategies for stabilization of the professional workforce and reliance on others (e.g., 
volunteers, recovery mutual aid sponsors) to provide such continuity. It is our hope that revitalized, 
recovery-focused OTPs will make these settings a more fulfilling place to work for physicians, 
nurses, counselors, other staff, and volunteers. 
seRvice Quality/duRation
Concerns about the quality of MM include six issues: methadone dosing philosophies, the char-
acter of addiction counseling, service scope, service duration, discharge status, and the service 
milieu. All are critical to treatment retention and long-term recovery outcomes.  
dosing philosophy/pRotocol
Once a patient is admitted into MM treatment, the induction process involves identifying the saf-
est, most appropriate initial dose of methadone. The induction dosing process is fraught with risk. 
The medication must fulfill the primary objective of alleviating a patient’s withdrawal symptoms 
(if the dose is inadequate, the patient is likely to seek illicit sources of relief), but there is a coun-
tervailing danger of lethal toxicity if the medication dose is too high. Ideally, the physician works 
with each patient, informing the patient of the need to share accurate and complete information 
regarding past and current use of opioids in order to determine the safest, most effective dose 
induction schedule for the patient.
 Methadone dose is a critical factor in ongoing patient retention and in long-term recovery out-
comes,302 and optimal methadone doses can vary widely from patient to patient based on multiple 
299. Kaplan, L. (2003). Substance abuse treatment workforce envi-
ronmental scan. Rockville, MD: Center for Substance Abuse Treatment. 
McLellan, A.T., Carise, D., & Kleber, H.D. (2003). The national addiction 
treatment infrastructure: Can it support the public’s demand for quality of 
care? Journal of Substance Abuse Treatment, 78, 125-129. Murphy, D.M., 
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DOI: 10.1002/14651858.CD002208. 
— 85 —
factors, including genotypes that influence the rate of methadone metabolism.303 The likelihood of 
continued use of heroin and other drugs following enrollment in MM decreases as the daily dose 
of methadone increases and tolerance is either matched (to the person’s prior illicit opioid dose) or 
built up (to a point where cross-tolerance/blockade to other opioids is established). A significant 
portion of heroin and other drug use in low-dose MM programs stems from therapeutic (e.g., 
self-medication of withdrawal symptoms) rather than hedonic motivations.304 Methadone dose 
and positive attitudes toward the option of sustained MM treatment are the most critical factors 
influencing MM retention, which in turn influences long-term recovery outcomes.305 
The history of MM is filled with intense debates about the superiority of high doses versus low 
doses of methadone. Anyone with extended tenure in the field of methadone maintenance treat-
ment will recall concerns about “under-dosing,” “sub-therapeutic dosing,” and “dosing ceilings.” 
Prevailing practice has moved through four stages: 1) high doses (80-120mgd) and long duration 
in the founding model of MM, 2) arbitrary- and low-dose ceilings (40-60mgd) and time limits on 
the duration of MM during the 1970s and 1980s, 3) emergence of private clinics known for ex-
ceptionally high-dose MM (above 120mgd), and 4) recent trends driven by scientific research and 
cumulative clinical experience that more closely approximate the founding model.306 At each dose 
level of MM, there are patients who do well; the critical factor in this dimension of MM treatment is 
the need for clinically individualized doses and the recognition that doses may need to be adjusted 
over time based on the physical, emotional, and social stressors experienced by the patient.307 
The key benefits of methadone as a pharmacotherapeutic agent in the management of chronic 
opioid addiction include: (1) cessation of withdrawal symptoms; (2) elimination of drug craving; (3) 
blocking the euphorigenic effects of other opiates and opiate derivatives; (4) physiological normal-
ization (lack of impairment from intoxication or sedation); and (5) physiological stability due to slow 
onset, long-acting metabolites (half life of 24-36 hours), and slow elimination due to deep storage 
in body tissues. Methadone maintenance pharmacotherapy first seeks to eliminate opioid with-
drawal symptoms and, by either building or matching tolerance, to identify the patient’s optimal 
dose—the particular methadone dose that maximizes the benefits of methadone in managing the 
disease of opioid addiction in the individual. Optimal dose stabilization is achieved by maintain-
ing the same benefits from the same optimal dose over time, without interruption. Once optimal 
dose stabilization is achieved, the patient is neither in a state of withdrawal nor opioid impaired; is 
considered opioid abstinent (in that the euphorigenic effects of other opioids are blocked); does 
303. Tennant, F. (2010). Cytochrome P450 Abnormalities in Patients Who 
Require High-Dose Opioids, The American Journal on the Addiction, 19(4), 
p. 370. 
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not suffer from opioid cravings; and, most important, has acquired the state of stability that is at 
the heart of the recovery initiation process. Again, these benefits are dependent on each patient’s 
receipt of individualized and optimal doses of methadone. 
Caplehorn and colleagues308 found that patients in abstinence-oriented MM programs (low-dose/
low duration philosophy) were more likely to leave treatment (26% more likely in first 6 months and 
39% more likely between 18 and 24 months) than patients in maintenance-oriented programs 
(high-dose/long duration philosophy). Subsequent studies (reviewed below) have affirmed the 
superiority of higher methadone doses in enhancing treatment retention and outcomes. 
MM is unique in the annals of medicine as the only arena in which patients have been denied 
medication or had their medication dosage lowered as a punishment for clinic rule infractions.309 
The use of medication as a coercive tool has no place in a recovery-oriented approach to the 
treatment of opioid addiction. 
addiction counseling
Recovery outcomes vary significantly across OTPs,310 and a portion of that variability is attributable 
to counselor factors.311 OTPs historically have been staffed with medical personnel charged with 
the mechanics of MM induction/dosing and counseling staff whose charge has been to facilitate 
the psychosocial rehabilitation process. Efforts have been made to formulate the special principles 
and activities that distinguish addiction counseling within the MM treatment setting.312 However, 
patients in most OTPs are not afforded the type of counseling that their counterparts receive in 
other addiction treatment modalities. 
Regularly scheduled counseling sessions guided by a theoretical framework of change and 
overseen by regular clinical supervision, with careful attention to the counseling process and 
counselor-patient relationship, are uncommon in many OTPs, and most MM patients are not offered 
a menu of individual, group, marital, or family counseling services.313 This is not to say that the MM 
counselor does not wish to provide more counseling or that the counselor has an insignificant role in 
MM treatment outcomes, but such effects often occur in spite of rather than because of the way the 
counselor’s role is defined in the OTP. MM counselors function more closely to what would be called 
case managers in other treatment settings. The “counseling” itself is more likely to involve activi-
ties such as monitoring urine drops, monitoring patients’ behavior in “the line” and at the “dosing 
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window,” enforcing clinic rules (e.g., ban on loitering), fielding requests for changes in medication 
dosage, arranging “guest doses” at other clinics for traveling patients, responding to non-payment of 
fees, and completing the endless paperwork required to maintain clinic regulatory compliance.
Most of the time, you only see your counselor to sign your treatment plan every 
3 months. They copy down what they had from the last time, change a few 
sentences and the dates, and there you have your current treatment plan. I think 
there should be psychotherapy going on along with MMT, and I thought that is 
what the counselor was supposed to be for. Not to mention, the clinics I have 
gone to have all only had ONE counselor for the whole clinic!314 
The lack of adequate counseling services is likely to emerge as a source of legal vulnerability for 
OTPs, as indicated by a recent lawsuit alleging that a major provider of methadone treatment in 
the U.S. failed to provide the counseling services that it had promised.315 
Studies to-date confirm an important relationship between MM staff attitudes about MM and 
retention in treatment.316 Studies have also found that clinical outcomes of MM patients differ 
considerably depending on the counselors to whom they are assigned, with neither level of 
formal education nor recovery status of the counselor predicting the best treatment outcomes.317 
Quantity of counseling also matters. Simpson and colleagues318 found that increased numbers 
and/or lengths of counseling sessions for MM patients led to a series of critical effects: decreased 
in-treatment drug use, increased retention in treatment, and enhanced long-term recovery out-
comes. MM patients who communicated with the authors about this monograph often contrasted 
their experiences with counselors at different clinics.
Basically it comes down to this: if I were to relapse and pee dirty for cocaine 
right now, my current clinic staff would CONGRATULATE themselves on a job 
well done—because they caught me. At [my former clinic], my counselor would 
feel like SHE failed me somehow and she would have been angry and worried 
FOR ME—not AT me.319 
Prolonged heroin use and its associated lifestyle poisons personal character and interpersonal re-
lationships. As a result, recovery involves not just a cessation of heroin use but also a reconstruc-
tion of personal values, personal identity, and relationship to family, friends, and community.320 
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The biological rationale for MM and the focus on the pharmacotherapeutic aspects of MM have 
minimized attention to these broader aspects of recovery. These factors have also provided little 
framework for patients to consider spiritual (including life meaning and purpose) dimensions of the 
recovery process. Kurtz,321 in his historical studies of Alcoholics Anonymous and in his writings on 
spirituality,322 describes seven experiences that are at the core of the addiction recovery process: 
•	 release	(a	shedding	of	mistruths	about	oneself;	surrender;	experience	of	breaking	free	or	be-
ing freed; a lessening or loss of burdens); 
•	 gratitude	(receptiveness,	appreciation,	and	thanksgiving);
•	 humility	(acceptance	of	imperfection,	being	free	of	comparisons,	honesty,	balance);
•	 tolerance	(experience	of	mutual	vulnerability;	openness	to	difference;	compassion);	
•	 forgiveness	(shedding	the	past;	letting	go	of	resentment,	anger,	and	sadness);
•	 awe	and	wonder	(being	humbled	before	something	of	great	power	and	beauty);	and	
•	 compassion	(recognizing	the	woundedness	of	others;	desire	to	share	awe	and	joy	with	oth-
ers; affirmation of life in the face of pain and loss). 
Rarely have mainstream MM patients had such issues explored in a counseling process. They 
have not been afforded the scope and intensity of educational and counseling experiences 
routinely provided to those in other addiction treatment modalities. 
There are several matters over which the methadone counselor has either exclusive or considerable 
control that can adversely affect the life of a methadone patient. These include how often and at 
what time the patient must come to the OTP for daily dosing and whether, or under which, circum-
stances the patient can earn “take-home” medication bottles and how many they can earn. Denying 
a patient take-home medication, insisting the patient attend the OTP daily, and limiting the time or 
hours in which the patient can receive his/her daily dose profoundly affects the patient’s self-esteem 
and his or her capacity to take on or to fulfill family, work, school, and travel obligations. Patients can 
request take-home privileges for special occasions, vacations, or in the case of a hardship, through 
a system in which there is much counselor discretion but little patient recourse in response to denial. 
Patients who find the courage to challenge staff decisions or actions often do so in fear of retaliatory 
action. The counselor relationship carries the most weight in such decision-making. 
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Under the current MM system, patients achieve substantial improvements related to heroin use 
and lifestyle stability, but many continue to experience difficulties with a variety of drugs (e.g., 
opioids, cocaine, benzodiazepines, alcohol) and remain economically dependent and socially 
unproductive—still isolated and socially estranged from the mainstream of community life.323 The 
founders of methadone maintenance were quite explicit about its limitation in addressing drug 
problems other than heroin (or other opioid) addiction.
…methadone has no unique value in the treatment of non-opiate addictions—
alcohol, cocaine, sedatives and tranquilizers—or smoking. The therapeutic 
environment of a good methadone clinic can help in dealing with these compli-
cating problems, but credit for improvement in these areas must go mainly to 
persistent, supportive counseling.324
MM patients have not been afforded the intensity of education and counseling to address these 
larger issues of global health and functioning that mark other addiction treatment modalities—in 
part because of the high ratios of patients to counselors that typify OTPs. 
Changing the counseling relationship to a sustained partnership grounded in the need to manage 
a chronic disease over the patient’s lifetime will require orienting patients in the fundamentals of 
long-term recovery from opioid addiction. Patients will need to understand such concepts as 
chronic disease, optimum dose stabilization, recovery management, recovery partnership, patient-
centered care, and recovery planning. Rather than being passive recipients of new models of care, 
patients in ROMM will be required to become fully engaged in shaping these new approaches to 
long-term recovery management. This orientation, education, and participation process should 
provide new inspiration and confidence for patients who have been quieted by shame, misinfor-
mation, and fear of reprisal for speaking out about the inadequacy of current treatment services. 
In the same vein, it will be important to acknowledge that not all patients need continued counsel-
ing and that periodic recovery checkups might replace required counseling when the latter serves 
only as a meaningless ritual of regulatory compliance for patients who have reached a high degree 
of recovery stability. We are arguing simultaneously for more and less counseling in the OTP milieu 
based on the needs of the particular patient. 
323. Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: 
Lessons learned, lessons forgotten, lessons ignored. Mount Sinai Journal 
of Medicine, 68, 62-74. 
324. Dole, V.P. (1994b). What we have learned from three decades of 
methadone maintenance treatment. Drug and Alcohol Review, 13, 3-4.
— 90 —
scope of ancillaRy seRvices
Ancillary services in methadone treatment include resources for identifying and treating co-oc-
curring medical, psychiatric, and illicit substance use problems; vocational/employment services; 
legal services; and peer-based recovery support services. Several studies have been conducted 
to assess whether or not the scope of ancillary services influences post-treatment recovery 
outcomes. 
•	 McLellan	and	colleagues325 found that MM patients who received enhanced services (medi-
cal/psychiatric care, family counseling, and employment services) achieved better treatment 
outcomes than patients who received only methadone or methadone plus counseling.
•	 McLellan	and	colleagues326 found that patients who received supplemental social services 
(case management, medical screening, housing assistance, parenting classes, and employ-
ment services) achieved better outcomes (less substance use, fewer medical/psychiatric 
problems, and better social functioning) than patients who received only core MM services. 
•	 Friedmann	and	colleagues327 found that ancillary on-site medical services enhanced post-
treatment substance use outcomes. 
•	 Berkman	and	Wechsberg328 confirmed that a higher percentage of MM patients received 
ancillary services when these services were provided on-site at the MM clinic rather than 
provided through off-site referral.329 
•	 Kraft	and	colleagues330 conducted a study of varying intensity levels of ancillary services in 
MM and found that abstinence rates were highest for those receiving the highest intensity of 
supplemental services, but that methadone plus counseling was the most clinically effective 
and cost-effective threshold of service provision. 
•	 Avants	and	colleagues331 compared two 12-week formats for delivering intensified MM 
services and found that outpatient MM amplified with ancillary services generated the same 
outcomes as a more intense day treatment format, and for less than half the cost.
The need for legal and other advocacy services is rarely mentioned in the professional literature on 
MM, despite the many legal issues faced by patients seeking MM and the variety of discrimination 
issues that they face. Such services would be a welcomed addition to the OTP service menu. 
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Some early treatment systems, such as the Illinois Drug Abuse Program, provided such legal 
services as an ancillary service for MM patients.332 
Expanding the range of services provided is congruent with the ROMM understanding that 
recovery encompasses global health and positive community integration. Further reflecting this 
understanding is ROMM’s family orientation. Family-focused services have not been a part of 
mainstream MM treatment services, with only the youngest of MM patients likely to have their 
family members consistently involved in the treatment process.333 Research in the past decade 
confirms three critical findings in this area: 1) family relationships are profoundly influenced by ad-
diction,334 2) these relationships exert a critical influence on recovery outcomes,335 and 3) drug-free 
family members can be mobilized to participate in the treatment of MM patients.336 
Pilot efforts to provide more family-focused services within OTPs have been evaluated positively. 
Dawe and colleagues337 evaluated the Parents under Pressure program and found that a family-
focused service intervention attached to MM enhanced parental functioning, improved parent-
child relationships, reduced the risk of child abuse, reduced behavior problems of children of MM 
patients, and decreased parental substance use. Fals-Stewart, O’Farrell, and Birchler338 tested the 
value of individual versus couples-focused MM counseling services and found that those patients 
receiving behavioral couples therapy experienced less substance use and enhanced quality 
of family relationships. Greif and Drechsler339 have outlined how parenting training groups can 
address some of the parenting issues faced by MM patients, e.g., difficulty providing consistent 
daily structure, guilt from past acts of neglect, sabotage of parenting by one’s own parents, anger 
from children due to addiction/recovery history, and the special challenges of raising adolescents. 
Grella and colleagues found that mothers treated in programs with a high level of family-focused 
services were twice as likely to experience successful reunification with their children as mothers 
treated in programs rated low in such services.340 Given the widespread community misun-
derstandings about methadone maintenance treatment, educational and support services for 
parents, siblings, intimate partners, children, and friends of the MM patient would seem to be 
particularly indicated to prevent sabotage of the patient’s recovery efforts and to mobilize support 
for recovery initiation and maintenance. 
One of the issues of considerable importance in ROMM is the need to provide treatment that has 
the potential of breaking intergenerational cycles of alcohol and other drug problems.341 Haggerty 
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and colleagues342 evaluated a program (Families Facing the Future) that provided parent training 
workshops and home-based family support services. They found that such services reduced the 
risk of substance use disorders among the male children of MM patients. We envision a day when a 
full range of family-, parent-, and child-focused services will be an integral component of mainstream 
methadone maintenance. Such services might include recovery-focused family education classes, 
family counseling, family support groups, parenting training, in-home family support services, family 
night social events, a children’s program (counseling, prevention, and early intervention), and inclu-
sion of family members in leadership roles in patient councils and alumni associations.
seRvice duRation
MM was conceptualized as a chronic disease by founders who envisioned that many if not most 
people treated for chronic heroin addiction would require prolonged if not lifelong methadone 
pharmacotherapy, analogous to the way in which many patients with diabetes or hypertension 
receive prolonged medication support. This conclusion was based on the finding in the earliest 
study of MM patient outcomes that less than 10% of patients were found to be “doing well” after 
cessation of methadone pharmacotherapy.343 Through this and subsequent studies, MM was 
defined as corrective rather than curative. 
It may be necessary for [MM] patients to remain in treatment for indefinite 
periods of time, possibly for the duration of their lives.344
…we don’t see the need of getting people off [methadone maintenance] treat-
ment any more than you’d try to get people off treatment from insulin…345
From the beginning, there were some MM patients who sustained abstinence-based recoveries 
following cessation of MM, but Dr. Dole cautioned that “an obsessive preoccupation with absti-
nence is self-defeating, leading to low-dose programs (which fail to stabilize the patient), prema-
ture discharge from treatment and low self-esteem if long-term abstinence seems unattainable.”346 
He further noted that:
…methadone patients are not necessarily committed to a lifelong dependence on 
the medication… The key to this result [sustained abstinence following termination 
of methadone maintenance] is the realization that the most important objective in 
treatment of an addict is support of good health and normal function. This may 
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or may not require continuation of maintenance pharmacotherapy… Available 
data suggest that the longer a patient continues in a maintenance program that 
provides adequate doses (e.g., five years or more), the greater his or her prob-
ability of permanent abstinence after termination of treatment… the neurochemical 
adaptations produced by thousands of heroin injections… are capable of gradual 
repair in some cases under the steady conditions of methadone maintenance.347
Dole also noted that the potential for post-MM abstinence was linked to the issue of methadone dose.
A wrong belief exists in the general public and in the medical profession, and 
even, I’m sorry to say, in methadone programs around the world. This is the 
illusion that by giving a very low dose [of methadone], you facilitate the evolution 
of this treatment to complete abstinence. The opposite is really the truth.348
As reflected in Dole’s observations, sustained recovery after tapering requires the achievement of 
two time-dependent processes within MM: 1) neurophysiological healing of the brain, and 2) a larger 
process of healing the physical, psychological, and social impairments produced by chronic heroin 
addiction. When such healing has not taken place, successful tapering from MM is unlikely. Unfortu-
nately, we currently know a great deal more about the neuropathology and psychosocial pathologies 
of addiction than we know about the processes of neurophysiological and psychosocial healing in 
long-term addiction recovery.349 The duration of MM declined throughout the 1970s and 1980s in 
tandem with the growing professional, family, and community expectations that MM should be as 
short as possible. Opioid addiction then became the only chronic disease in which patients were 
shamed and stigmatized for long-term medication adherence and denied pride in the achievement 
of sustained recovery stabilization—in marked contrast to the experience of those celebrating the 
length of their recoveries in AA, NA, and treatment alumni association meetings. 
There have been contentious debates for more than four decades about how long a patient should 
be maintained on methadone, but the reality is that most patients admitted to MM voluntarily or 
involuntarily leave in less than a year, frequently relapse following their discharge, and are often 
readmitted to MM or other treatment in what becomes a long, complex career of serial episodes of 
acute, treatment-facilitated stabilization. In spite of theoretical foundations supporting the efficacy of 
prolonged if not lifelong MM for most patients, studies beginning in the 1980s found that 80-100% 
of MM patients expect to taper from methadone at some time in the future and to continue their 
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recovery without medication.350 Great anxiety, if not outright phobia, is common as the time to initiate 
tapering approaches as a result of a personal goal or one imposed by one’s treatment program.351 
These anxieties are related to folklore about the difficulty of tapering, prior failed efforts at tapering, 
and lack of contact with patients who have successfully sustained recovery after tapering.352 Such 
emotional distress may account for the fact that the majority of patients who begin to taper do not 
complete the tapering process and either return to maintenance treatment or drop out of treat-
ment.353 The rates of success have improved with the advent of new pharmacological adjuncts to 
aid the tapering process. 
The majority of patients who are discharged from MM eventually return to heroin or other illicit 
opioid use,354 with first-year rates of resumed opioid use approaching or exceeding 50%, followed 
by a longer-term progressive decay in abstinence rates.355 Also striking is the speed at which 
relapse occurs. In a follow-up study of tapered MM patients by Gossop and colleagues,356 42% of 
those who relapsed did so within one week of reaching zero dose of methadone, and 71% of this 
group relapsed within six weeks. Post-treatment abstinence rates from heroin range from 8% to 
33% (based primarily on self-report and varying by length of follow-up period),357 and treatment 
re-admission rates are high.358 
The best single predictors of post-MM abstinence from heroin are longer periods of time in 
treatment, discharge status of treatment completion as planned, and employment during and after 
treatment.359 The latter is of particular significance in light of data revealing that only 26% of MM 
patients discharged from treatment in 2005 were employed at the time of discharge (46% were 
identified as not in the labor force, and 27% were identified as unemployed—rates similar to those 
of all patients discharged from addiction treatment in the U.S.).360 
Patients who remained continuously in MM or who completed a sustained period of MM have 
post-treatment recovery outcomes superior to those of patients completing only methadone-
assisted detoxification and patients who cycle in and out of MM.361 The shorter the first treatment 
period in MM, the greater the likelihood of treatment readmission.362 Based on post-treatment 
recovery outcomes, the minimum clinically optimal amount of time in MM has been defined as one 
year of continuous MM treatment,363 with some researchers concluding that two years constitutes 
the minimum optimal MM treatment duration.364 Clinical outcomes deteriorate with decreased 
length of time in treatment, with patients who spent less than three months in MM treatment 
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experiencing only minimal long-term improvement.365 Hubbard and colleagues366 found that MM 
had substantially higher retention rates (68% after three months) than outpatient counseling 
without methadone (36%) or residential programs without methadone (45%).
In spite of the importance of treatment retention and duration, one-year retention rates in most 
programs are less than 50%,367 but this can vary considerably by program. Kreek368 has reported 
retention rates ranging from 60-85% in “good programs”—those providing optimum methadone 
doses, on-site counseling, and ancillary medical and psychiatric services. In 2005, the average 
length of time in treatment for patients discharged from opioid replacement therapy in the United 
States was 245 days.369 The majority of MM patients who spend less than a year in their first 
treatment episode will return to treatment for multiple treatment episodes.370 Problems related to 
the retention of stabilized patients include pressure from self and others to “get off methadone”; 
resentment toward program rules that are perceived as restrictive, paternalistic, and humiliating371; 
and legislative or regulatory efforts to set arbitrary limits on the length of time a patient can remain 
in methadone maintenance.372 
Most MM patients cycle in and out of treatment via 5 stages: 1) enter treatment in a state of crisis, 
2) extract substantial benefits from treatment, 3) leave treatment during a period of recovery stabil-
ity, 4) resume opioid use and clinically deteriorate following treatment discharge, and 5) re-enter 
treatment in crisis but with less severity than in earlier admissions.373 Of patients discharged from 
OTPs in the United States in 2005, 77% had been in treatment before and 24% had five or more 
prior treatment episodes.374 Recycling in and out of treatment is a dominant pattern in MM,375 as it 
is in the larger addiction treatment arena.376 
In conclusion, discharge from MM is accompanied by significantly increased risk or resump-
tion of illicit opioid use and death.377 Like medication-based treatments for other chronic health 
conditions, methadone is effective as a medication only as long as it continues to be used as 
prescribed. MM policies that lower patient retention rates, even when done with the noblest 
of intentions (promoting abstinence from all opioids, including methadone), heighten patient 
risk for re-addiction, infectious disease, resumption of addiction-related criminality, arrest and 
incarceration, and death.378 Tapering from MM is most conducive to long-term recovery outcomes 
when it is voluntary, recommended by MM staff based on rehabilitation progress, phased over 
an extended period of time, and accompanied by increased professional and peer support 
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services.379 Even with such supports, post-treatment relapse rates are high.380 A key predictor of 
the degree of effectiveness of MM (like that of other addiction treatment modalities) is duration of 
active participation in treatment, with longer periods of retention associated with better long-term 
recovery outcomes.381 Promising practices to increase MM retention include higher, individualized 
methadone doses to ensure optimum stabilization, training and supervision to strengthen the 
counselor-patient relationship, expanding the service menu, and exposing patients to successful 
patients and former patients in stable, successful long-term recovery.382
A rarely discussed issue related to patient retention in MM is that of fees charged to patients. 
There are three types of OTPs in terms of payment for medication and other services: 1) for-profit 
OTPs, such as the large networks of CRC and Colonial clinics, whose fees are fully paid by a 
combination of the patient and his/her insurance company; 2) hybrid clinics that charge fees but 
on a sliding scale based on the patient’s ability to pay; and 3) OTPs whose costs are fully covered 
by Medicaid or various state services, with no direct costs incurred by the patients. Of the 1,132 
OTPs in the United States surveyed in 2008, only 34% of OTPs offered free treatment for patients 
who could not pay for their treatment, and only 51% offered a sliding fee scale.383
During times of personal and widespread financial distress, the issue of fees can undermine 
patient retention. Patients who are “financially noncompliant” are at high risk of voluntarily or 
involuntarily terminating MM—the latter christened “fee-tox” by MM patients.384 It is most often 
the working poor who are shut out of methadone because of inability to pay. Strategies with the 
potential of addressing the fee-tox issue include: 1) establishing funds that would award patients 
low-interest loans to sustain their treatment while they rebuilt their financial stability, 2) lowering 
fees for financially distressed patients, and 3) extending the tapering period in hopes that the 
patient will be able to catch up on the balance due. MM patients who communicated with the 
authors about this monograph were particularly incensed by those clinics they perceived to be 
more concerned with financial outcomes than recovery outcomes. 
The clinic I go to is a true “business” in every sense of the word. It is not anything 
close to “therapeutic,” it’s just shoveling out methadone and we keep taking it. 
They think money, talk money, and probably even “dream” money… Until the day 
all clinics are ran as “therapy” centers, things will never change.385  
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The private clinics I have attended charge anywhere from $80-$95 a week in 
addition to separate charges for all other services and they do not take private 
insurance or Medicaid and are CASH ONLY. If you are late on fees, they will 
detox you within a matter of weeks. They take no excuses for getting behind 
and do not let you “charge” and catch up at a later date, even if you are having a 
financial hardship. They can go up on their prices any time they want; they can 
give you a decrease on your dose anytime they want. They can make you jump 
through all these hoops like a show dog and you just have to take it!386 
dischaRge status and RecoveRy outcoMes
A discharge status of treatment completion signals that both the MM patient and OTP staff 
members have collaborated on a planned process of tapering from methadone and have a plan 
for sustained recovery self-management following the cessation of methadone pharmacotherapy. 
The process involves substantial progress in psychosocial rehabilitation as well as successful 
tapering off methadone. Treatment completion has generally served as an intermediary measure 
of treatment outcome, with patients who have completed treatment having better post-treatment 
outcomes than those discharged for other reasons (e.g., dropping out, administrative discharge, 
incarceration, or transfer).387 
The scientific and clinical literature on MM is filled with reports on the MM patient induction 
process, but it is striking how little focus has been paid to the process of patient disengagement 
from MM (beyond a focus on dosing protocols for tapering). Of MM patients discharged from 
outpatient opioid replacement therapy in the United States in 2005, only 11% completed treatment 
as planned; 45% dropped out; 17% were transferred to other programs; 13% were terminated 
by the program; and 15% were discharged for other reasons.388 Opioid replacement therapy has 
the lowest completion rate of all addiction treatment modalities.389 Much greater attention needs 
to be focused on the process through which patients disengage from participation in MM and the 
supports that best sustain recovery without the aid of medication or, when needed, speed the 
re-initiation of medication-assisted recovery. 
Patients may be “administratively discharged” (also referred to as “involuntary discharge” or 
“therapeutic termination”) from OTPs for continued drug use, violence or threats of violence, failure 
to pay fees, selling drugs, loitering, or repeated violation of program rules. We find the practice 
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of discharging patients for continued drug use particularly onerous. There is no other health care 
sector where one can be punished and extruded for exhibiting a symptom of the disorder being 
treated. In other settings, symptom continuation or a resurgence in symptoms calls for reas-
sessment and refinement of treatment procedures, rather than the expulsion of the patient from 
treatment.390 Dr. Robert Newman describes this paradox:
Patients also face termination [of MM] for a host of other reasons that are with-
out parallel in the medical management of disease. For instance, renal dialysis 
would never be stopped because a patient smoked marijuana, or crack, or used 
other illicit substances. Nor would those suffering from hypertension, diabetes, 
arthritis, glaucoma, schizophrenia or any other illness be abandoned because 
they used drugs. How ironic, then, that most methadone programs, whose 
express mission is to treat addiction, refuse to tolerate patients who demonstrate 
signs and symptoms of drug use…Medical care should not be withheld except 
for strictly medical reasons.391 
The risks of administrative discharge from MM are compounded in programs that impose manda-
tory waiting periods before patients who were administratively discharged can be considered 
for readmission. In some OTP studies, the rate of administrative (involuntary) discharge exceeds 
50% of all discharges.392 Of the total discharges from OTPs in 2005, 13% were administrative 
discharges.393 Disciplinary discharges appear to be more prevalent when OTPs have limited 
capacity, have high counselor caseloads, and experience pressure for admission of persons from 
their waiting lists.394 
At least one study claimed evidence of reduced drug use and increased retention in programs that 
expel patients exceeding particular levels of drug use,395 but these benefits usually accrue at the ex-
pense of “terminating” those patients most in need of sustained and intense clinical management.396 
Involuntary discharge from MM is associated with rapid clinical deterioration, e.g., re-addiction, 
criminal activity, disease exposure/transmission, and alienation from family and community.397 There 
is no evidence of “therapeutic” effects of administrative discharge for the patient being discharged, 
in spite of anecdotal reports of such effects.398 Patients who are administratively discharged from 
MM are at increased risk of post-treatment relapse and death;399 patients subjected to involuntary 
tapering and termination have the worst post-discharge recovery outcomes.400
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Ward and colleagues401 reviewed the issue of administrative discharge from MM programs and con-
cluded that non-punitive approaches were more effective. Belding, McLellan, Zanis, & Incmikoski’s402 
study of MM “non-responders” suggested three broad strategies to address continued opioid and 
other drug use: 1) increasing methadone doses to optimal levels (43% of their non-responders were 
below 80 mgd), 2) increasing internal motivation for cessation of drug use via counseling, and 3) 
creating external contingencies that rewarded positive treatment participation. 
the MM Milieu: cultuRe of addiction oR cultuRe of RecoveRy? 
The current clinic structure keeps recovering addicts in contact with people who 
are still using—a fatal flaw because the MM program is itself immersed within the 
drug scene, not a step away from it. One gets off the dope line and into another 
line—behind the same folks.403 
There are several key points related to the relationship between the addiction treatment milieu and 
recovery outcomes. 
•	 For	persons	enmeshed	in	illicit	drug	cultures,	the	transition	from	addiction	to	recovery	is	a	
journey between two physical and social worlds—from a culture of addiction to a culture of 
recovery, each with its own distinct cultural trappings, e.g., language, values, dress, symbols, 
rituals, roles, social pecking orders, etc.
•	 Patients	who	are	deeply	enmeshed	in	illicit	drug	cultures	bring	the	trappings	of	these	cultures	
with them when they enter the treatment milieu.
•	 The	best	single	predictor	of	continued	drug	use	during	MM	is	the	presence	of	drug	users	
within the social and intimate relationships of the patient.404
•	 Effective	addiction	treatment	involves	facilitating	the	patient’s	physical	and	social	disengage-
ment from the culture of addiction and shedding of the trappings of that culture, as well as 
guiding the patient into a relationship with an alternative culture of recovery. 
•	 The	presentation	of	drug	culture	trappings	in	the	treatment	milieu	reinforces	continued	drug	
use and undermines recovery initiation and maintenance; the presence of trappings of the 
recovery culture enhances recovery initiation and maintenance.
401. Ward, J., Mattick, R.P., & Hall, W. (1998). How long is long enough? 
Answers to questions about the duration of methadone maintenance 
treatment. In J. Ward, R.P. Mattick, & W. Hall (Eds.), Methadone mainte-
nance treatment and other opioid replacement therapies (pp. 305-336). 
Amsterdam: Harwood Academic. 
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•	 There	is	a	daily	struggle	for	dominance	between	these	two	cultures	within	addiction	treat-
ment milieus.
•	 Relapse	and	recovery	rates—good	and	bad—are	as	often	influenced	by	the	cultural	milieu	of	
treatment as by the intrapersonal factors of the patients.405
Treatment quality in MM has focused primarily on medication-related issues at the exclusion of the 
larger treatment milieu. As Dr. Edward Senay suggests, 
… dispensing methadone is not synonymous with treatment. It is methadone plus 
an institutional or organization transference which is responsible for the success 
of methadone maintenance programs… The role of methadone is an important 
element in a whole, but it is a major error to confuse the element with the whole.406
A distinctive dimension of recovery-oriented methadone maintenance (ROMM) is its emphasis 
on a therapeutic milieu that suppresses illicit drug cultures and provides a portal of entry into an 
alternative community of recovery. ROMM is distinguished by a:
•	 recovery-focused	institutional	identity,	e.g.,	a	recovery	center	that	sees	medication	as	an	aid	
in the goal of recovery rather than defining itself institutionally as a methadone clinic;
•	 presence	of	recovery	(hope,	honesty,	and	mutual	help)	so	palpable	that	it	is	socially	contagious;
•	 physical	plant	that	conveys	respect	via	its	safety,	privacy,	attractiveness,	and	comfort;
•	 distinctive	recovery-focused	culture	reflected	in	language,	literature,	art,	symbols,	music,	and	
daily rituals; and 
•	 the	visible	presence	of	recovering	people	(e.g.,	recovering	people	serving	as	board	members,	
staff, volunteers, and peer mentors) who offer living proof of the transformative power of long-
term recovery.
the locus of seRvice deliveRy 
I haven’t given a positive heroin urine in almost 20 years and I cannot go pick up 
a monthly prescription of my “medication.” If I were psychotic and hearing voices 
and declared a schizophrenic, I WOULD be given a monthly prescription for 
powerful drugs and the freedom to pick up those drugs at a pharmacy. Yet I am 
not to be trusted because I am still viewed as a “junkie.”407
405. White, W. (1996). Pathways from the culture of addiction to the 
culture of recovery. Center City, MN: Hazelden.
406. Senay, E.C. (1971). Methadone: Some myths and hypotheses. 
Journal of Psychedelic Drugs, 4(2), 182-185. 
407. MM patient email to authors, 2010
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Treatment of acute illness most often involves placing a patient in a medical facility where he or 
she can be treated by a professional; the management of chronic illness focuses instead on nest-
ing a recovery management process within each patient’s natural environment. This distinction is 
important to the future of MM. 
The focus of MM, like that of most addiction treatment modalities, has been on getting patients to 
the treatment facility (with methadone used in MM as the primary incentive for sustained patient-
clinic contact). ROMM anticipates a greater focus on delivery of recovery support services outside 
the clinic and the greater integration of medication and other recovery support services within 
non-stigmatizing community environments. A possible omen of this shift is the vision of abolish-
ing specialized MM clinics and integrating MM into organizations that are currently providing a 
comprehensive menu of treatment and recovery support services. Such a vision is now guiding 
the reorganization of addiction treatment in the State of New York.408 We anticipate the evolution of 
OTPs from silo-like businesses toward integrated, recovery-oriented systems of care. We envision 
the expansion of medical maintenance in the United States (methadone and related recovery 
support services provided through a primary care physician) and the integration of medication 
and other recovery support services within other health and human service institutions within the 
community. The expansion of pre-treatment and post-treatment recovery support services will 
also create new home-based and neighborhood-based models of service delivery. 
ROMM also is based on the concept of the community as patient—the idea that neighborhoods 
and whole communities can be severely wounded by addiction and be in need of community-
level intervention and sustained recovery support. Also of import is the idea that recovery 
flourishes in supportive communities. ROMM seeks to shape community perceptions, attitudes, 
and actions that welcome and offer support and inclusion for people in long-term medication-
assisted recovery. Long-term recovery outcomes are as often contingent upon community 
factors (e.g., attitudes toward methadone, methadone treatment, and methadone patients) as 
they are on intrapersonal factors.409 
asseRtive linkage to RecoveRy coMMunity ResouRces 
Peer-support has emerged as a primary recovery management strategy in the treatment of 
chronic illness. In the addiction context, there are two noteworthy trends. First, is the growth of 
peer recovery support via the ever-growing network of addiction recovery mutual aid groups, the 
408. OASAS Commissioner announces plans for one outpatient system 
of addiction services [Press release]. (2009). State of New York Office of 
Alcoholism and Substance Abuse Services. Retrieved from http://www.
oasas.state.ny.us/pio/press/pr-4-27-09methadone.cfm. 
409. White, W. (2009c). The mobilization of community resources to sup-
port long-term addiction recovery. Journal of Substance Abuse Treatment, 
36, 146-158. 
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philosophical (secular, spiritual, religious) diversification of these groups, the emergence of a new 
addiction recovery advocacy movement, new recovery community institutions (recovery homes, 
schools, industries, ministries, community centers), and the emergence of new peer-based 
service roles, e.g., that of the recovery coach.410 Second is the growing body of scientific evidence 
that participation in peer-based recovery support societies and other recovery community institu-
tions significantly elevates the prognosis for long-term recovery.411 Community integration strate-
gies may be particularly important for injection drug users, who often have prolonged histories of 
“institutional disaffiliation” and enmeshment in subterranean drug cultures.412 
Methadone pioneers Drs. Vincent Dole and Marie Nyswander both had an interest in addiction 
recovery mutual aid societies. Dr. Nyswander served on the Board of Directors of the National 
Advisory Commission on Narcotics—the governing body of East Coast Narcotics Anonymous 
in the 1950s—and Dole served as a non-alcoholic trustee of Alcoholics Anonymous. Given this 
interest, one would think that mutual aid involvement would have been part of the original MM 
model. There are two likely reasons for its exclusion: 1) the fragile organizational status of NA at 
the time MM was being pioneered (there were only 4 NA meetings in New York City in 1965) and 
2) the general antipathy toward “mainline addicts” in AA.413 
The potential benefits of recovery mutual aid societies for patients in addiction treatment have 
not been fulfilled due to ineffective (passive) linkage procedures, ill-timed linkage (following rather 
than during treatment), failure to offer choices related to recovery support frameworks, and 
failure to match each patient to a person/meeting most likely to enhance the process of mutual 
identification and engagement.414 The use of recovery mutual aid groups to enhance the recovery 
outcomes of MM patients has been further limited by:
•	 weak-to-nonexistent	relationships	between	MM	programs	and	local	recovery	mutual	aid	
groups, 
•	 the	stigma	attached	to	methadone	(equation	of	methadone	and	heroin)	within	Narcotics	
Anonymous (e.g., common prohibitions against MM patients speaking at meetings, chairing 
meetings, chairing a service committee), which leads to avoidance of such groups or keeping 
one’s MM status secret,415 
•	 until	the	founding	of	Methadone	Anonymous	(1991),	the	lack	of	a	recovery	mutual	aid	society	
explicitly for people in medication-assisted recovery from heroin addiction,416 and 
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•	 the	lack	of	a	model	for	peer-based	recovery	support	services	for	patients	in	medication-as-
sisted recovery, until the creation of the CSAT-funded Medication Assisted Recovery Services 
project in New York City in 2006. 
ROMM has two long-term recovery support goals: 1) integrating people in medication-assisted 
recovery into existing communities of recovery and 2) building a recovery community and long-
term recovery support services for people in medication-assisted recovery and their families. 
I have participated in 12-Step type recovery programs and I find them a neces-
sary part of treatment. It is a shame that NA and 12-Step groups feel about 
MMT patients like they do because I think if there was a way to combine the two 
therapies, there would be more successful recovering opiate addicts out there.417 
Promising practices within recovery-oriented methadone maintenance include active liaison 
between MM clinics and the service committees of local recovery mutual aid societies, encour-
aging/supporting the development of local Methadone Anonymous group meetings and other 
groups specifically for persons in medication-assisted recovery, assertive linkage of patients to the 
resources of local communities of recovery (including medication-friendly recovery support meet-
ings), using volunteer or paid peer recovery coaches to facilitate patient connections to recovery 
community resources, coaching patients on how to address medication issues at recovery 
support meetings, hosting on-site peer recovery support meetings at MM clinics, sponsoring 
educational events on medication-assisted recovery for recovery community members, inclusion 
of indigenous healers and healing practices within MM clinics, using patient/alumni councils to 
visibly celebrate patient recovery milestones, and participating visibly in local recovery celebration 
events.418 The key is to expose every patient entering MM to “living proof” of the reality and variet-
ies/styles of long-term medication-assisted recovery. 
post-tReatMent RecoveRy checkups, stage-appRopRiate RecoveRy 
education and suppoRt, and when needed, eaRly Re-inteRvention 
Perhaps the most distinctive feature of chronic disease management is the prolonged if not 
lifelong duration of professional monitoring and support. In suggesting that addiction treatment 
should emulate this feature, Humphreys419 referred to this as a shift in the focus in addiction treat-
ment from one of intensity (high intensity acute stabilization) to one of extensity (low intensity but 
417. Feedback from MM patient to authors, May 2010. 
418. White, W., & Kurtz, E. (2006b). Linking addiction treatment and 
communities of recovery: A primer for addiction counselors and recovery 
coaches. Pittsburgh, PA: Institute for Research, Education and Training in 
Addictions.
419. Humphreys, K. (2006). Closing remarks: Swimming to the horizon—
reflections on a special series. Addiction, 101, 1238-1240.
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prolonged recovery support). The rationale for such assertive approaches to continuing care in the 
OTP context is worth restating. In spite of the theoretical potential of lifelong methadone mainte-
nance, most patients cease MM treatment, often before they have reached the optimum time in 
MM. The therapeutic effects of MM erode for most patients following discharge from treatment.420 
Most patients who terminate MM resume opioid use/addiction—most within the first days and 
weeks of methadone cessation.421 MM patients who leave treatment against medical advice or for 
program rule infractions are at particularly high risk for post-treatment relapse. Studies of long-
term heroin addiction “careers” do not support the contention that persons chronically addicted 
to heroin eventually “mature out” of addiction as a function of aging; heroin addiction has the 
potential of being a lifelong condition.422 The death rate for out-of-treatment methadone patients is 
8-20 times that of in-treatment methadone patients.423
The recovery stability point (duration of current sobriety that predicts lifetime sobriety—the point 
at which the risk of future lifetime relapse drops below 15%) is higher for opioid addiction than for 
alcohol dependence—the latter being in the range of 3 to 5 years.424 Five years’ abstinence from 
heroin is a good benchmark for recovery stability,425 but 14-25% of heroin addicts who achieve five 
or more years’ abstinence will later return to opioid use.426 Others addicted to heroin cease heroin 
use for extensive periods but fail to achieve this 5-year stability benchmark.427 As we noted earlier, 
most people addicted to opioids experience prolonged addiction careers marked by cycles of 
treatment, periods of abstinence, relapse, and treatment re-entry.428 Such data confirm the need 
for intense monitoring throughout early recovery and sustained if not lifelong recovery checkups 
combined with early re-intervention as needed for rapid restabilization. 
Patients who have dropped out of MM and subsequently relapsed can be re-engaged through 
assertive models of outreach,429 and patients who relapse following discharge from treatment 
show marked improvements following re-admission to treatment,430 but the longer the delay in 
treatment re-entry, the more likely it is that such improvements will be compromised.431 The level 
of improvement following re-entry to MM approximates that achieved during earlier treatment: as 
currently designed, there is no evidence of cumulative, progressive improvement across multiple 
episodes of MM treatment.432 There is evidence that patients experiencing multiple MM treatment 
episodes stay in treatment longer in later episodes of treatment, creating opportunities for greater 
recovery stability.433 
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Studies of persons in long-term recovery from heroin addiction and persons who are continuing 
their heroin addiction careers confirm that negative affect and lack of coping skills are major risk 
factors for relapse and that self efficacy, social support, and participation in pro-social activities 
serve as the major protective factors for sustaining recovery.434 Recovery checkups and other as-
sertive approaches to continuing care following addiction treatment elevate short- and long-term 
recovery outcomes,435 but systematic, long-term monitoring and support of patients who have 
ceased MM treatment are not common practices within OTPs. 
Findings such as the above on the post-discharge status of methadone patients led Dr. Edward 
Senay436 to recommend 25 years ago that all MM patients should have continued professional 
treatment for at least a year after tapering to a zero dose of methadone. The percentage of MM 
patients who receive such support is not even routinely measured in OTPs, but the authors 
suspect that percentage would be quite low. We envision a future in which a system of recovery 
check-ups; peer-based recovery support; stage-appropriate recovery education; assertive linkage 
to communities of recovery; and, when needed, early re-intervention will be standard practices 
in OTPs and that such practices will reduce post-treatment mortality and enhance the long-term 
recovery outcomes of MM patients. We would suggest as a beginning point for design of such 
services that MM patients be provided periodic recovery checkups for at least five years follow-
ing achievement of a zero dose and/or any disengagement from treatment, with the frequency 
of contact determined by time (high intensity through the first 90 days of disengagement) and a 
personalized schedule of contact reflecting patient-identified circumstances in the future that are 
likely to pose elevated risks of drug use. 
RecoveRy-oRiented Methadone Maintenance: fuRtheR Reflections 
on outcoMe MeasuRes 
Methadone maintenance treatment has been evaluated using two broad benchmarks: 1) changes 
in behaviors that generate harm and costs to society (e.g., crime, disease transmission, unem-
ployment, abuse/neglect/abandonment of children), and (as in the evaluation of other treatment 
modalities) 2) the percentage of clients who maintain abstinence or no longer meet diagnostic 
criteria for opioid dependence following discharge from treatment. 
The first benchmark reflects legitimate public health concerns, although it is noteworthy that 
these have been collected and emphasized at the exclusion of measures of the effects of MM on 
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personal/family recovery (including measures of global health and quality of life). As a professional 
field, we know a great deal about what methadone maintenance treatment can eliminate from the 
lives of patients, but we know very little from the standpoint of science about what it adds. In fact, 
we know very little about the stages and styles of long-term medication-assisted recovery. It is 
regrettable that information on long-term MM-assisted recovery has not been collected and used 
to shape a menu of stage-specific recovery support services. 
Historically, multiple stakeholders other than MM patients have sat at the tables at which the 
criteria for evaluating MM have been defined. It is time MM patients and their family members 
are seated at these tables. There are thousands of stabilized MM patients in the United States 
who are invisible and silent. It is time they and their families were empowered to tell their recovery 
stories and help us as addiction professionals extract lessons from those stories that can elevate 
the quality of MM treatment and recovery support services.
The second benchmark, evaluating MM based on abstinence from all opioids following cessation 
of MM, is a fundamentally flawed approach. Dr. Robert Newman437 explains: 
… the assessment of methadone’s effectiveness in the treatment of addicts 
continues to focus on the study of former patients who are no longer receiving 
treatment—a focus no more logical than gauging the effectiveness of birth-
control pills by counting the number of pregnancies that occur after administra-
tion is discontinued…Methadone is dismissed by many and damned by others 
because it does not “cure” patients or render them immune from such societal 
ills as unemployment, alcoholism, marijuana smoking, and criminality. In other 
words, methadone maintenance has come to be evaluated by virtually every 
criterion except a decline in heroin use. 
Evaluating MM on in-treatment and post-treatment abstinence from alcohol and non-opioid drugs 
is similarly flawed if OTPs are not designed and funded to provide services beyond methadone 
pharmacotherapy that are capable of treating co-occurring drug dependencies. 
We propose that OTPs and all other addiction treatment programs be evaluated based on the 
same criteria and that such criteria be drawn from the Betty Ford Institute Consensus Panel 
definition of recovery—a definition that through its core components of sobriety, global health, and 
citizenship encompasses personal, family, and community interests. Using these criteria might 
437. Newman, R.G. (1987). Methadone treatment: Defining and evaluating 
success. New England Journal of Medicine, 317, 447-450.
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lead to enriching MM with a much broader array of professional and peer-based recovery support 
services and extend such support to patients far beyond the potential cessation of methadone 
pharmacotherapy. The same criteria would focus attention on intermediate outcome measures 
(related to sobriety, global health, and community reintegration) and process measures (attrac-
tion, access, engagement, retention, service duration, etc.) that have a strong nexus to long-term 
personal and family recovery outcomes. Such an approach is consistent with McLellan and 
colleagues’438 call to shift the evaluation of addiction treatment from a model of evaluating discrete 
episodes via post-treatment follow-up to a process of concurrent recovery monitoring and evaluat-
ing unique combinations and sequences of service elements on long-term addiction, treatment, 
and recovery careers.439 
a BRief note on evidence-Based pRactices in RoMM
We have tried to the extent possible to ground our recommendations in this article within the 
peer-reviewed scientific literature, but it is important to acknowledge that every MM program sees 
patients whose needs are never reflected in the randomized clinical trials that the field so worships. 
These are the patients who present with multiple drug choices, multiple co-occurring disorders, 
and multiple personal and environmental obstacles to long-term recovery. These patients are the 
first to be excluded from clinical trials and the first to be extruded from mainstream OTPs. We know 
almost nothing about the prevalence, pathways, and styles of long-term recovery for such patients 
or the kinds of clinical and support interventions that help facilitate such recoveries. Lacking such a 
scientific roadmap, we would be well served to find ways to listen to these patients and their families 
and forge models of care that respond to the complexity of their needs. We cannot assume that 
what we have learned about the treatment of MM patients in clinical trials applies to those patients 
with more complex needs. Of all patients entering OTPs today, these are the patients most in need 
of the kind of long-term recovery partnership we have described in this article.440 
suMMaRy
This article has outlined a vision of recovery-oriented methadone maintenance (ROMM). Put 
simply, ROMM seeks to: 
•	 focus on recovery from addiction rather than remission of a drug-specific disorder (e.g., opioid 
dependence);
438. McLellan, A.T., McKay, J.R., Forman, R., Cacciola, J., & Kemp, 
J. (2005). Reconsidering the evaluation of addiction treatment: From 
retrospective follow-up to concurrent recovery monitoring. Addiction, 100, 
447-458.
439. White, W. (2008c). Recovery management and recovery-oriented 
systems of care: Scientific rationale and promising practices. Pittsburgh, 
PA: Northeast Addiction Technology Transfer Center, Great Lakes Addiction 
Technology Transfer Center, Philadelphia Department of Behavioral Health 
& Mental Retardation Services. 
440. Senay, E. (2010). Personal communication, February 16, 2010.
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•	 attract people at an earlier stage of addiction via programs of assertive community education, 
screening, and outreach;
•	 ensure rapid service access for individuals and families seeking help;
•	 resolve obstacles to admission, initial stabilization, and continued participation in MM treatment; 
•	 achieve safe, optimum dose stabilization through individualized patient care that is responsive 
to patients’ needs and respectful of patients’ preferences and values;
•	 engage and retain individuals and families in a recovery-focused service relationship marked 
by mutual respect, hope, and emotional authenticity; 
•	 assess patient/family needs using assessment protocols that are global, family-centered, 
strengths-based, and continual;
•	 transition each patient from a professionally directed treatment plan to a patient-directed 
recovery plan;
•	 shift the service relationship from a professional expert model to a long-term recovery partner-
ship/consultation model;
•	 ensure minimum (at least one year of stabilization) and optimum (individualized) duration of 
treatment via focused retention strategies, assertive responses to early signs of disengage-
ment, and use of patient surveys to identify and resolve grievances that might contribute to 
disengagement;
•	 shift the treatment focus from that of an episode of care to the management of long-term ad-
diction/treatment/recovery careers;
•	 ensure that MM patients are afforded educational and counseling services on a par with those 
offered to patients in other addiction treatment modalities. 
•	 expand the service menu to include medical/psychiatric/social services, non-clinical, peer-
based recovery support services, and spiritual and culturally indigenous healing activities;
•	 extend the locus of service delivery beyond the OTP clinic to non-stigmatized service sites 
and neighborhood-based, church-based, work-based, and home-based recovery support 
services; 
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•	 assertively link patients/families to recovery community support resources (including 12-Step 
groups, other recovery mutual aid societies, and grassroots recovery advocacy and support 
organizations), and identify and establish partnerships with non-traditional sources of patient 
support within the community (e.g., faith-based recovery ministries); 
•	 engage the community via a positive program presence in the community, anti-stigma and 
community education campaigns about medication-assisted recovery, and recovery commu-
nity development activities; 
•	 provide individualized plans for post-treatment monitoring and support, stage-appropriate edu-
cation, support, and early re-intervention for all patients regardless of discharge status; and 
•	 evaluate MM treatment using proximal and distal indicators of long-term personal and family 
recovery. 
Achieving these changes in practice will be contingent on re-aligning the philosophy of MM toward 
a greater focus on long-term personal and family recovery (as opposed to a narrower focus on 
reduction of social harm), and it will require re-aligning the context of MM (policy, regulatory, 
funding, and community environment) to support this recovery vision. Facilitating such a transfor-
mation will in turn require enhancing the organization infrastructures of OTPs in such critical areas 
as capitalization, leadership/workforce development and stabilization, technological capabilities, 
institution-community relationships, and advocacy capabilities. As discussions proceed on the 
potential for OTP systems transformation, care should be taken to explore the risks of unintended 
consequences within such a transformation process.441 We will need to address critical questions, 
including:
•	 Is	there	a	risk	that	opioid-addicted	persons	not	desirous	of	recovery	as	defined	in	this	mono-
graph will be punished, denied services or otherwise abandoned for their lack of readiness to 
accept this goal? Might new recovery rhetoric be used to justify punitive treatment of “recov-
ery-resistant” patients?
•	 Could	approaches	to	recovery-oriented	methadone	maintenance	be	used	to	foist	services	on	
patients who do not need or want or cannot afford such services? 
•	 Might	this	recovery	orientation	add	a	new	layer	of	regulatory	demands	on	OTPs	that	in	the	
long run will add administrative burdens and further depersonalize service relationships? 
441. A special thanks to Dr. Robert Newman for raising this concern.
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Might these new recovery-focused regulatory demands actually decrease the individualization 
of care within the OTP? (Our fear here is of new mandates for particular types of services for 
all patients.) 
•	 Is	there	not	a	danger	that	the	assertive	outreach	programs	advocated	in	this	monograph	
might quickly overwhelm national OTP capacities?
•	 What	effects	will	increased	patient	retention	have	on	community	treatment	capacity?
•	 Will	the	financial	resources	required	to	deliver	a	service-enriched	model	of	methadone	mainte-
nance reduce the numbers of people served by the OTPs and inadvertently widen the gap 
between treatment needs and treatment capacity?
•	 Might	the	emphasis	on	patient-directed	recovery	plans	and	peer-based	recovery	support	
services inadvertently lead to the deprofessionalization of addiction treatment?
•	 Are	there	circumstances	in	which	patients	might	be	harmed	within	the	context	of	peer-based	
recovery support services? What kinds of screening, selection, training, supervision practices 
and ethical guidelines will be needed to minimize this risk?
•	 Might	the	integration	of	medication-assisted	treatment	and	recovery	support	services	into	
health, human services, and other community organizations lead to the eventual destruction 
of OTPs and the broader addictions field as a specialized arena of care? 
•	 Will	the	resources	that	will	be	required	to	provide	sustained	continuing	care	following	cessa-
tion of MM reduce OTP capacity for acute stabilization and maintenance? 
We feel that the best way of avoiding such risks is to ensure that one particular voice is always at 
the table and prominent in the coming discussions of recovery-oriented methadone maintenance. 
For the past 45 years, the design of methadone maintenance treatment in the United States has 
rested in the hands of policy-makers, scientists, and treatment professionals. The voice of the 
patient in shaping MM has grown from a whisper to the early stirrings of a patient advocacy move-
ment. In preparing this monograph, we talked with many MM patients, including a particularly 
hidden population of MM patients: those who have achieved prolonged recovery, health, produc-
tivity, and service. What we found through these latter conversations is a population of current and 
former MM patients who are strong, capable, and willing and ready to participate and help lead 
such systems-transformation processes. They represent an unknown portion of MM patients in 
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the U.S., and they have achieved a high quality of life in recovery, sometimes in spite of treatment 
milieus in which recovery was rarely discussed. 
I think it is WAY past time for MMT patients to speak up and stop allowing those 
who do not have a clue to make the rules and regs for methadone treatment. I 
am tired of the clinics taking advantage of patients and treating us like they do, 
and I will do whatever is needed to help change these things.442
Many MM patients will not become excited about a heightened recovery orientation of their clinic until 
they are first engaged in education and discussion about recovery—what recovery means in the MM 
context, pathways and styles of recovery, its prevalence, and its rewards. Perhaps the greatest failure 
of methadone maintenance is represented in the high proportion of MM patients who understand 
methadone maintenance as a treatment for opioid addiction but lack an understanding of medication-
assisted long-term recovery. OTPs will have come of age when their emphasis shifts from the personal 
and social injuries that MM subtracts from patients’ lives to a focus on what recovery-oriented metha-
done maintenance can add to the quality of personal, family, and community lives.
Patients will embrace a vision of recovery only to the extent that the realities of their daily lives and 
their needs and aspirations are reflected in that vision. Patients thus need to be co-creators of 
the vision rather than just passive recipients. That vision will most easily flow from the collective 
experiences of current and former MM patients whose quality of personal and family life has been 
elevated through their recovery journeys. We believe that the visioning process needs to start 
with conversations between patients who have survived the demands of the clinic system and 
have built lives of sustained recovery, and patients who are beginning treatment, often with little 
understanding of, or hope for, long-term recovery. We think the recovery vision we speak of can 
emerge from such connections. 
The seeds for a vibrant MM patient advocacy and peer support movement have been sown for 
decades by individual patients and early advocacy efforts.443 The time for the full emergence of 
that movement has arrived, and as it comes of age, this movement will profoundly shape the 
future of medication-assisted treatment and recovery in the United States. One of the most signifi-
cant challenges to be faced is the social and professional stigma attached to medication-assisted 
treatment and recovery, particularly methadone-assisted treatment and recovery. That will be the 
subject of the final article in this monograph. 
442. MM patient feedback to authors, May 2010. 
443. Woods, J. (2001). Methadone advocacy: The voice of the patient. The 
Mount Sinai Journal of Medicine, 68, 75-78.
— 112 —
RecoveRy-oRiented Methadone Maintenance
IV: Long-Term Strategies to Reduce the Stigma Attached 
to Addiction, Treatment, and Recovery within the City of 
Philadelphia
William L. White, MA
The guiding vision of our work must be to create a city and a world in which “people 
with a history of alcohol or drug problems, people in recovery, and people at risk for 
these problems are valued and treated with dignity, and where stigma, accompany-
ing attitudes, discrimination, and other barriers to recovery are eliminated.”444
intRoduction
When Dr. Arthur Evans, Jr. assumed leadership of the Philadelphia Department of Behavioral Health 
and Mental Retardation Services in 2004, he initiated a broad community-visioning exercise that 
ignited a “recovery-focused systems transformation” process. Systems transformation involves aligning 
concepts, contexts (policies, regulatory guidelines, funding mechanisms), and service practices to: 
1) identify and engage individuals and families affected by alcohol and other drug (AOD) problems, 
2) help these individuals and families initiate and sustain a process of long-term recovery, and 3) 
enhance the quality of personal/family life in long-term recovery. The emerging vision in Philadelphia 
was to create a city and a world in which “people with a history of alcohol or drug problems, people in 
recovery, and people at risk for these problems are valued and treated with dignity, and where stigma, 
accompanying attitudes, discrimination, and other barriers to recovery are eliminated.”445 
The purpose of this article is twofold. First, it provides an overview of key findings drawn from 
historical and scientific research on social/professional stigma related to addiction to illicit drugs, with 
a particular focus on the stigma experienced by people in medication-assisted treatment and long-
term medication-assisted recovery. Second, it outlines a menu of potential strategies that could be 
implemented by the Philadelphia Department of Behavioral Health and Mental Retardation Services 
and its many community partners to reduce this stigma. The document was prepared with input 
444. Substance Abuse and Mental Health Services Administration (SAM-
HSA). (2002). National Recovery Month helps reduce stigma. Substance 
Abuse and Mental Health Services Administration. Retrieved June 17, 
2009 from http://www.hazelden.org/web/public/ade20909.page.
445. Substance Abuse and Mental Health Services Administration (SAM-
HSA). (2002). National Recovery Month helps reduce stigma. Substance 
Abuse and Mental Health Services Administration. Retrieved June 17, 
2009 from http://www.hazelden.org/web/public/ade20909.page.
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from local and national addiction treatment professionals and recovery advocates and is intended as 
a starting point for further discussions and strategy-development meetings that will be facilitated by 
the Philadelphia Department of Behavioral Health and Mental Retardation Services. 
stigMa Basics
Stigma Defined
Stigma is the experience of being “deeply discredited” due to one’s “undesired differentness.” 
To be stigmatized is to be held in contempt, shunned, or rendered socially invisible because of 
a socially disapproved status.446 It involves processes of labeling, stereotyping, social rejection, 
exclusion, and extrusion—the essential ingredients of discrimination.447 
There are three types of personal stigma: 
•	 Enacted	stigma	(direct	experience	of	social	ostracism	and	discrimination)
•	 Perceived	stigma	(perception	of	stigmatized	attitudes	held	by	others	toward	oneself)	
•	 Self-stigma	(personal	feelings	of	shame	and	self-loathing	related	to	regret	over	misdeeds	and	
“lost time” in one’s life due to addiction).448 
Self-stigma, or internalized stigma, results from the internalization of community attitudes by the 
person being discredited. 
Stigma and Addiction
There is an extensive body of literature documenting the stigma attached to alcohol and other 
drug problems.449 No physical or psychiatric condition is more often or more deeply associated 
with social disapproval and discrimination than alcohol and/or other drug dependence.450 The 
social stigma attached to addiction constitutes a major obstacle to personal and family recovery, 
contributes to the marginalization of addiction professionals and their organizations, and limits the 
type and magnitude of cultural resources allocated to alcohol- and other drug-related problems.451
Stigma and Recovery
Addiction-related social stigma extends to people who have achieved stable recovery from 
addiction.452 In fact, people in recovery may have a greater fear of stigma and experience stigma 
more intensely precisely because of their recovery status and all that they now have to lose.453 The 
446. Goffman, E. (1963). Stigma: Notes on the management of spoiled 
identity. Englewood Cliffs: Prentice-Hall.
447. Sayce, L. (1998). Stigma, discrimination and social exclusion: What’s 
in a word? Journal of Mental Health, 7, 331-343. van Olphen, J., Eliason, 
M.J., Freudenberg, N., & Barnes, M. (2009). Nowhere to go: How stigma 
limits the options of female drug users after release from jail. Substance 
Abuse Treatment Prevention and Policy, 4. Retrieved from http://www.
substanceabusepolicy.com/content/pdf/1747-597X-4-10.pdf. 
448. Luoma, J.B., Twohig, M.P., Waltz, T., Hayes, S.C., Roget, N., Padilla, 
M., et al. (2007). An investigation of stigma in individuals receiving 
treatment for substance abuse. Addictive Behaviors, 32(7), 1331-1346. 
Vigilant, L.G. (2004). The stigma paradox in methadone maintenance: 
Naïve and positive consequences of a “treatment punishment” approach to 
opiate addiction. Humanity and Society, 28(4), 403-418. 
449. Dean, J.C., & Rud, F. (1984). The drug addict and the stigma of 
addiction. International Journal of Addictions, 19(8), 859-869. McLaughlin, 
D., & Long, A. (1996). An extended literature review of health profession-
als’ perceptions of illicit drugs and their clients who use them. Journal of 
Psychiatric and Mental Health Nursing, 3(5), 283-288. Sobell, L.C., Sobell, 
M.B., & Toneatto, T. (1992). Recovery from alcohol problems without 
treatment. In N. Heather, W.R. Miller, & J. Greeley (Eds), Self control and 
addictive behaviors (pp. 198-242). New York: Maxwell Macmillian.
450. Corrigan, P.W., Watson, A.C., & Miller, F. E. (2006). Blame, shame and 
contamination: The impact of mental illness and drug dependence stigma 
on family members. Journal of Family Psychology, 20(2), 239-246.
451. Woll, P. (2005). Healing the stigma of addiction: A guide for treatment 
professionals. Chicago, IL: Great Lakes Addiction Technology Transfer 
Center.
452. Tootle, D.M. (1987). Social acceptance of the recovering alcoholic in 
the workplace: A research note. Journal of Drug Issues, 17, 273-279. 
453. Woods, J. (2009). Personal communication, July 27, 2009.
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intensity of stigma varies by problem intensity and different styles of recovery. Stigma attached 
to natural recovery may be less severe, due to the perception of it as more noble (pulling oneself 
up by the bootstraps) and to the possibility that people might perceive the naturally recovering 
person as having had less severe problems. At the same time, natural recovery is often viewed by 
the public as less credible and durable than recovery from severe AOD problems initiated through 
professional treatment.454
Courtesy Stigma
The social stigma attached to addiction can be experienced by families, organizations (e.g., addic-
tion treatment programs), neighborhoods, and whole communities.455 Goffman456 referred to this 
stigma-by-association as “courtesy stigma.”457 
The social stigma attached to families affected by addiction carries the implication that the family 
somehow failed to prevent this problem, contributed to its onset, and/or played a role in inciting or 
failing to prevent relapse episodes. Children may be socially shunned due to the perception that 
they have been contaminated by the addiction of their parents or siblings.458 
Many family member behaviors that historically have been defined as “enabling” or “co-dependent” 
are better understood as attempts to protect the family from the stain of social stigma.459 The “cour-
tesy stigma” experienced by family members as embarrassment and shame is often displaced on 
the family member experiencing AOD problems in the form of anger and exclusion. Family members 
thus sacrifice their own family member to escape or lessen their own social condemnation. 
Addiction-related courtesy stigma can also extend to particular organizations, neighborhoods, 
and communities. Professionals who work with stigmatized groups may also be affected by this 
same stigma through, for example, the stigma’s effects on addiction professionals’ percption of 
themselves in relation to other fields and disciplines, and on the ways in which they are perceived 
by others. A particular neighborhood can be stigmatized when AOD problems become part of its 
public identity through repeated portrayal of the neighborhood’s challenges with no references 
to its strengths. Examples of ways in which whole communities can be stigmatized by addiction-
related stigma include the historical portrayal of the surge in cocaine use in the late 19th and 
early 20th centuries, and again in the 1980s, as a distinctly African American problem460 and the 
centuries-long misrepresentation (“firewater myths”) of the nature of alcohol problems in Native 
American communities.461 
454. Cunningham, J.A., Sobell, L.C., & Chow, V.M. (1993). What’s in a 
label? The effects of substance types and labels on treatment consider-
ations and stigma. Journal of Studies on Alcohol, 54(6), 693-699.
455. Luoma, J.B., Twohig, M.P., Waltz, T., Hayes, S.C., Roget, N., Padilla, 
M., et al. (2007). An investigation of stigma in individuals receiving 
treatment for substance abuse. Addictive Behaviors, 32(7), 1331-1346.
456. Goffman, E. (1963). Stigma: Notes on the management of spoiled 
identity. Englewood Cliffs:  Prentice-Hall. 
457. Also see: Barton, J.A. (1991). Parental adaptation to adolescent drug 
abuse: An ethnographic study of role formulation in response to courtesy 
stigma. Public Health Nursing, 8(1), 39-45. 
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on family members. Journal of Family Psychology, 20(2), 239-246.
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Stigma and Choice
Addiction has been alternately defined as a problem of vulnerability (an involuntary medical/
psychiatric disease) and a problem of culpability (a voluntary, self-inflicted moral lapse/character 
defect/vice/habit). The former model provides pathways of return to health; the latter proscribes 
sequestration and punishment as blame for moral/criminal liability, as a means of rehabilitation, 
and/or as a method of suppressing excessive substance use in the community.462 Stigma rises for 
some but not all disorders in which the individual is perceived as having personally contributed to 
the onset of the disorder. People with substance use disorders are less likely to be offered help by 
other citizens than are people with mental illnesses or physical disabilities.463 The stigma attached 
to drug dependence, and arguments for and against the personal or social harm or value of 
such stigma, hinge to a great degree on widely varying views on the degree to which those with 
significant alcohol and other drug problems have voluntary control over their drug use. 
Stigma and Motivation for Drug Use
American attitudes toward addiction have varied based on the motivation for drug use, with relief 
of pain viewed as more excusable than the search for unearned pleasure.464 Where pain-related 
addiction elicits compassion, addiction that results from the search for pleasure elicits condemna-
tion and social marginalization. At the same time, cultural phobia related to opioid addiction and 
fear that addiction-related stigma will be attached to prescription opioid use has resulted in the 
underuse of opioid medication in the treatment of acute and chronic pain, from both physician 
hesitation to prescribe opioids and patient ambivalence about taking opioid medications.465 Per-
haps the best example of this is patients’ resistance to their physicians’ suggestions that they take 
methadone for chronic pain because of the patients’ association with methadone as “that junkie 
drug.” This is further exacerbated by public and professional confusion on the difference between 
physical dependence on an opioid medication and opioid addiction (See later discussion). 
Stigma and “Badness”
American social policies on licit and illicit drugs have long been bifurcated by the notion of good 
drugs and bad drugs, with drugs in the latter category rated across degrees of badness. Good 
drugs have been celebrated, commercialized, and taxed as a source of government revenue with 
control mechanisms relying primarily on the social and legal definitions of who can use, when use 
can occur, where use can occur, how much can be consumed, and under what conditions use 
462. Acker, C.J. (1993). Stigma or legitimation? A historical examination of 
the social potentials of addiction disease models. Journal of Psychoactive 
Drugs, 25(3), 193-205. Husak, D.N. (2004). The moral relevance of 
addiction. Substance Use and Misuse, 39(3), 399-436.
463. Corrigan, P.W., Kuwabara, S.A., & O’Shaughnessy, J. (2009). The 
public stigma of mental illness and drug addiction: Findings from a strati-
fied random sample. Journal of Social Work, 9(2), 139-147.
464. Husak, D.N. (2004). The moral relevance of addiction. Substance Use 
and Misuse, 39(3), 399-436.
465. Woods, J. (2009). Personal communication, July 27, 2009.
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can and cannot occur. Bad drugs (and their users) have been demonized and prohibited, with 
the space between good and bad occupied by tolerated drugs (discouraged but not prohibited, 
e.g., tobacco) and instrumental drugs (approved for use only under special circumstances, e.g., 
prescription drugs). Historically, heroin and crack cocaine have been the most severely stigma-
tized substances and injection drug use the most severely stigmatized method of ingestion.466 The 
manner in which stigma triggered by public panic can demonize users and suppress treatment 
seeking is well illustrated by the “moral panic” linked to crack cocaine in the 1980s and the more 
recent panic related to surges in methamphetamine use.467 The attribution of “badness” (social 
stigma) has for most of the past century been most intense for those persons who regularly 
self-inject heroin.468 
By extension, greater addiction recovery-related stigma is extended to people in opioid treatment 
modalities. This stigma is particularly severe for persons whose treatment and recovery is sup-
ported by methadone, in spite of the well established scientific legitimacy and effectiveness of 
methadone treatment.469 In one of the most recent studies of methadone-related stigma, 98% of 
MAT patients surveyed reported that “stigma is an essential feature of methadone maintenance 
treatment.”470 For many opiate addicts, the stigma attached to medication-assisted treatment 
(MAT) is internalized from the culture at large and from illicit opioid street cultures long before 
treatment becomes a possibility or a necessity. Members of the illicit opioid street culture are also 
aware of methadone-related stigma and discrimination—spanning employment, child custody, 
access to other forms of addiction treatment, and even denial of certain privileges within the 
recovery community, e.g., right to speak at a recovery fellowship meeting, chair a meeting, head a 
service committee, or be credited with “clean time” while taking methadone.471 
Multidimensional Stigma
The weight of addiction-related social stigma is not equally applied. Its burdens fall heaviest on those 
with the fewest resources to resist it, e.g., those for whom stigma is layered across multiple condi-
tions (addiction, mental illness, HIV/AIDS, incarceration, minority status, poverty, homelessness, 
aging) and when these conditions are perceived as conflicting with gender-linked role responsibili-
ties, e.g., those of addicted pregnant women/mothers.472 Persons experiencing such layered, 
multidimensional stigma are less likely to seek addiction treatment than persons experiencing a 
single discredited condition.473 The social stigma attached to addiction begins primarily at the point 
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of admission to treatment (a social signal of problem severity) and intensifies with multiple treatment 
episodes (a social signal of treatment failure).474 One MAT patient distinguished the “inner shame” 
experienced during active addiction from the “public shame when you’re in the clinic.”475
Stigma in the Professional Context
The majority of health care professionals hold negative, stereotyped views of illicit drug users. 
These views are shaped for the most part, not by their professional training, but by each profes-
sional’s past experimentation with or lack of experimentation with illicit drugs.476 
Stigma, Treatment-Seeking, and Long-Term Health
Stigma can elicit social isolation, reduce help-seeking, and compromise long-term physical and 
mental health status.477 Social stigma is a major factor in preventing individuals from seeking and 
completing addiction treatment478 and from utilizing harm-reduction services such as needle 
exchange programs.479 Social stigma increases the service needs of persons with substance use 
disorders, but, by fostering social rejection and discrimination, that same stigma decreases ac-
cess to such services.480 Treatment seeking is also reduced by the perception that drug treatment 
program staff will “treat you like a little, nasty dope fiend.”481 
Chronic Illness, Stigma, and Methadone Maintenance
Acute illness is something you have (“I have a cold”); chronic illness is something you are (“I am 
a diabetic”). With acute illnesses, one experiences the onset of the illness, one is professionally 
treated or self-treated, and one recovers without a lasting imprint on personal or social identity. 
Chronic illness bears a greater stigma burden, in part because of the uncertainty with which the 
concept of recovery is applicable to a condition that is prolonged; is not in a technical sense 
“cured”; and will require sustained self-management and, in many cases, periodic professional 
treatment. Chronic illness can inflict social death, a loss of self, and a struggle to define a “time 
horizon” for recovery.482 
Vigilant483 attributes the stigma attached to methadone maintenance to the imperfect medicaliza-
tion of chronic opioid addiction and its treatment. By “imperfect,” Vigilant means that: 1) heroin 
addiction and its treatment have been trapped between medical and moral/criminal models of 
problem definition and resolution; 2) methadone maintenance has never achieved full legitimacy 
as a medical treatment in the eyes of the public, health care professionals, and the recovery 
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community, in spite of the scientific studies supporting it; 3) the person enrolled in methadone 
maintenance has never received full status as a “patient”; and 4) the methadone clinic has yet to 
be viewed as a place of healing on a par with hospitals or outpatient medical clinics. 
Vigilant further argues that heroin addicts entering methadone treatment are christened “patients,” 
but the treatment protocol—required daily clinic visits, forced sequestration of addicts together in 
a closed group regardless of recovery motivation and status, restrictive and inflexible medication 
pickup schedules, public exposure while standing in line for medication, observed urination for 
drug testing, mandatory counseling, sanctions for violations of treatment rules—is more akin to 
the status of “inmates” of “total institutions” than protocol befitting a medical patient.484 Methadone 
clinics have not achieved the social status of medical clinics because they have not been allowed 
to operate like medical clinics. Methadone patients have not achieved their full status as “patients” 
because they have not been treated as patients.   
The “Catch-22” in which the methadone patient, methadone treatment staff, and methadone clinic 
as an institution are trapped grew out of the conflicting interests that emerged as methadone 
maintenance was mainstreamed as a treatment modality. On the one hand, there were the needs 
of the methadone patient and the need for a long-term service relationship based on empathy, 
trust, and respect. On the other hand, there were concerns about public safety via the potential 
for methadone diversion. This tension between a milieu of engagement and empowerment and a 
milieu of distrust and control left those being served caught between the status of a patient and 
the status of a prisoner/probationer, and left physicians/nurses/counselors caught between their 
aspirations to serve as healers and onerous, regulatory-imposed policing functions.485 The result 
is a demedicalized system in which people entering methadone maintenance are treated more 
like criminals (or recalcitrant children) than patients, within a relational world more dominated by 
surveillance and control than compassion and choice.486 
… clients often felt that the relationship between themselves and their counsel-
ors was less focused on therapy than power; less about psychological growth, 
getting help, and a sense of well-being than about social control, conforming to 
rules and regulations, and punishment.487
Such focus on control rather than care may be even more greatly exaggerated for female patients, 
484. Vigilant, L.G. (2001). “Liquid handcuffs”: The phenomenology of 
recovering on methadone maintenance. Boston College Dissertations and 
Theses.
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486. Fraser, S., & Valentine, K. (2008). Substance and substitution: 
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487. Hunt, G., & Rosenbaum, M. (1998). ‘Hustling’ within the clinic: 
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leaving unattended many obstacles to participation and recovery, e.g., child care, transportation, 
caretaking responsibilities, sabotage from addicted partners, threats of partner violence, and 
difficulty paying for treatment.488 
The professional status of methadone treatment has suffered from the absence of theoretical 
models of addiction treatment and recovery that integrate the prevailing preoccupation with the 
mechanics of the medicine (e.g., concern with dosages, pick-up schedules, drug testing, take-
home privileges, tapering procedures) and control of the milieu (e.g., concern with loitering) with a 
focus on the broader physical, cognitive, emotional, relational, occupational, and spiritual aspects 
of long-term recovery.489 The lack of such theoretical models and the performance expectations 
emanating from such models breeds clinics in which patients’ contact with their counselors is 
rare, brief, and superficial, and in which ancillary services are minimal. As a result, methadone 
patients are all too often rendered and perceived as “passive figures onto which a treatment 
modality [methadone] is applied.”490 Missing is the image of the methadone patient as his or her 
own engineer of an enduring process of global (whole life) recovery. 
Types of Stigma Attached to Methadone Maintenance
Vigilant’s491 study of the phenomenology of methadone-assisted recovery revealed five types of 
stigma unique to methadone treatment: 
1.  Methadone treatment stigma: the stigma attached to treatment for opiate addiction; 
methadone treatment as a social signal of problem severity; stigma attached to methadone 
as a treatment modality by the culture at large and by major segments of the professional and 
recovery communities. (Methadone-related stigma is far greater for women than men, due to 
the perceived connection between heroin addiction and prostitution).
2.  Dose stigma: the stigma attached within the clinic culture to those on high doses of metha-
done—a status often interpreted by other patients as indicating a lack of interest in recovery.
3.  Stigma of personal regret: shame of looking back on the devastation to self, family, and 
community caused by heroin addiction.
4.  Stigma-related loss of associational ties: shrinking of the social network to the recovery/clinic 
community, in order to avoid the social stigma attached to addiction and methadone treatment. 
488. Fraser, J. (1997). Methadone clinic culture: The everyday realities of 
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5.  Loss-of-control stigma: shame related to the excessive demands of the clinic, its domina-
tion of one’s life and forced participation in shaming rituals (e.g., observed urination to confirm 
that urine for drug testing is “fresh” and not being surreptitiously substituted). 
Dr. Robert Newman492 places Viglant’s work within an important historical perspective. New-
man argues that the original model of methadone maintenance was corrupted as it was main-
streamed.493 Methadone treatment during this transition phase shifted to lower methadone doses, 
shorter lengths of methadone treatment participation, and decreased emphasis on services for 
collateral problems (e.g., counseling, employment, housing) that are critical to recovery stabiliza-
tion and maintenance. These changes violated the original theoretical framework of methadone 
maintenance to the extent that Newman drew the following provocative conclusion: 
Methadone maintenance treatment, with its unique, proven record of both ef-
fectiveness and safety, no longer exists. One can only hope that it is not too late 
to reassess that which has been cast aside, and to resurrect a form of treatment 
which has helped so many, and which could help many more.494 
Payte495 suggests that the history of methadone maintenance treatment stands as an argument 
for professional activism: 
It is no longer sufficient to take care of patients. Treatment providers must also 
become teachers, public relations workers, politicians, and advocates for all 
patients who want and need treatment.496
Personal Responses to Stigma
There is a high degree of variability in the ways in which persons in methadone maintenance 
respond to stigma. Patients with more positive self-concepts and more social resources are better 
able to counter stigma and assert the positive benefits of MAT. Those with lower self-esteem and 
fewer social resources are less capable of resisting stigma and tend to self-define methadone treat-
ment as another addiction (internalized stigma).497 Personal strategies to deal with stigma include:
•	 Secrecy/concealment	(e.g.,	concealing	one’s	methadone	treatment	status	at	AA	and	NA	
meetings)
•	 Social	withdrawal	(e.g.,	avoiding	new	friendships,	avoiding	recovery	support	meetings)
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•	 Preventive disclosure (selective disclosure to test acceptability) 
•	 Compensation	(using	personal	strengths	in	another	area	to	counter	the	imposed	stigma)	
•	 Strategic	interpretation	(comparing	oneself	to	others	within	the	stigmatized	group	rather	than	
to those in the larger community) 
•	 Political	activism.498
People with diminished internal assets and diminished social capital experience difficulty resisting a 
stigmatizing label and challenging the personal/organizational entities that are applying the label.499
Stigma and Cultures of Addiction
Social stigma contributes to the propensity of persons with drug dependencies to become en-
meshed in illicit drug subcultures.500 Individuals who share the “spoiled identity” of addiction have 
historically organized their own countercultures marked by distinct language, values, roles, rules 
(behavioral codes), relationships, and rituals.501 These subcultures provide shelter from stigma; 
access to drug supplies; social support for sustained drug use; meaningful roles, activities, and 
relationships; and mutual protection. 
Within these cultures, drug users protect their own identities by stigmatizing other drug users 
viewed as having less control of their drug use.502 Such attitudes can be played out within the 
social pecking order of drug treatment milieus. “Street cultures” are also embedded with myths 
designed to inhibit treatment-seeking, contribute to ambivalence about treatment, and increase 
the likelihood of treatment disengagement, including a number of myths about methadone (e.g., 
“it rots your teeth and bones”).503
Many individuals enmeshed in such cultures progressively diminish their contact with the main-
stream culture and become as dependent on the culture of addiction as they have been on the 
drugs in their lives. As drug-related personal impairment escalates, individuals may experience 
rejection and isolation from both the mainstream society and the illicit drug cultures that have shel-
tered them.504 If recovery and community reintegration are to be achieved and sustained, addiction 
treatment, recovery mutual aid societies, and other helping structures must facilitate a journey from 
the culture of addiction, or from this marginalized isolation, to a culture of recovery. Stigma is a major 
obstacle to successfully traversing the physical, psychological, and social space between these two 
worlds.505 Methadone advocate Walter Ginter recently reflected on this journey: 
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Methadone patients are caught between these two cultures. Even if recovery 
is their goal, they must stand in line at the clinic each day with people who are 
as interested in the best crack spot as they are about recovery. Under such a 
handicap, it is amazing that many patients find their way to medication-assisted 
recovery. When they do, it is more likely to be in spite of the treatment system 
than because of it. We have to find a way to separate the culture of addiction 
from the culture of recovery in our OTP’s [opioid treatment programs]. It is 
unreasonable to expect patients to find recovery until we do.506
Ginter’s observation elicits the image of “life in the queue”—the social influences that pervade 
interactions in the dosing line of the methadone clinic. The long-term addiction/recovery scales 
may well be tipped as much by the milieu as by methadone as a medication in the treatment of 
addiction.507
Strategies to Address Social Stigma
Three broad social strategies have been used to address stigma related to behavioral health 
disorders: 1) protest, 2) education, and 3) contact.508 One major strategy, seeking to inculcate the 
belief that alcohol and drug addiction is a disease, may help alleviate personal shame509 but has 
not been consistently shown to produce sympathetic attitudes toward those with severe alcohol 
and other drug problems.510 Public surveys reveal that those who agree that alcohol and drug ad-
diction is a disease are more likely to see these problems as severe and intractable and to doubt 
reports of successful recovery.511
One of the most effective strategies to reduce social stigma is to increase interpersonal contact 
between mainstream citizens and members of the stigmatized group.512 Contact between 
stigmatized and non-stigmatized groups as a vehicle of stigma reduction is most effective when 
the contact is between people of equal status (mutual identification); is personal, voluntary, and 
cooperative; and is mutually judged to be a positive experience.513 Encounters marked by such 
characteristics break down in-group/out-group boundaries of “us” and “them.” 
Social stigma is influenced by social proximity and distance. For example, community attitudes 
toward Oxford Houses are most positive among neighbors who live closest to these houses.514 
Reducing social distance and increasing interpersonal contact are important goals of any 
anti-stigma campaign. Individuals can express negative feelings toward a particular group 
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while simultaneously having positive regard for individuals of that group. As such relationships 
increase, the sentiment toward the group weakens and dissipates. Strategies that focus on 
increasing public awareness of multiple pathways of long-term recovery and exposing people 
to others who have resolved these problems may be more effective in countering social stigma 
than promoting a particular conceptualization of the nature of addiction.515 
histoRical/sociological peRspectives
The social stigma attached to certain patterns of psychoactive drug use has a long history in the 
United States and is inseparable from cultural strain related to such issues as race, religion, social 
class, gender roles, and intergenerational conflict. The social reform campaigns that have demon-
ized certain drugs and classes of drug users shared common conceptual themes: 
•	 The	drug	is	associated	with	a	hated	subgroup	of	the	society	or	a	foreign	enemy.
•	 The	drug	is	identified	as	solely	responsible	for	many	problems	in	the	culture,	e.g.,	crime,	vio-
lence, insanity.
•	 The	survival	of	the	culture	is	pictured	as	being	dependent	on	the	prohibition	of	the	drug.
•	 The	concept	of	“controlled”	use	is	destroyed	and	replaced	by	a	“domino	theory”	of	chemical	
progression.
•	 The	drug	is	associated	with	the	corruption	of	young	children,	particularly	their	sexual	corruption.
•	 Both	the	user	and	the	supplier	of	the	drug	are	defined	as	fiends,	always	in	search	of	new	
victims; use of the drug is considered “contagious.”
•	 Policy	options	are	presented	only	in	terms	of	total	prohibition	or	total	access.
•	 Anyone	questioning	any	of	the	above	assumptions	is	bitterly	attacked	and	characterized	as	
part of the problem that needs to be eliminated.516
These themes shape what Lindesmith517 referred to as “dope fiend mythology”—a “body of super-
stition, half-truths and misinformation” that claims that narcotic drug use causes moral degeneracy 
and violent crime (rape and murder) and that drug “pushers” and drug users have a voracious 
appetite for infecting non-users.518 Modern studies of the historical origins of these myths have 
placed their beginnings within the Federal Bureau of Narcotics’ early and mid-twentieth-century 
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anti-drug campaigns,519 but similar myths were also promulgated by the leaders of nineteenth-
century anti-alcohol, anti-tobacco, anti-opium, and anti-cocaine campaigns.520 These myths about 
the nature of various drugs and the nature of the drug user constitute the conceptual foundation of 
addiction-related stigma. 
The social stigma attached to methadone is rooted in a larger anti-medication bias within 
the history of addiction treatment.
That bias is rooted in the fact that many new drugs announced as breakthroughs in the treatment of 
alcohol and other addiction were later found to create problems in their own right. Alcohol, opium, 
morphine, cocaine, cannabis, barbiturate and non-barbiturate sedatives, amphetamines and other 
psychostimulants, LSD, and the so-called “minor” tranquilizers have all been claimed to have cura-
tive properties in the treatment of addiction.521 The history of such iatrogenic insults bodes caution 
and close scientific scrutiny of any new drug claimed as a treatment for drug addiction.522 But that 
same history also suggests that newly developed drugs of unsurpassed effectiveness might be 
socially and professionally rejected because of this traditional anti-medication bias. 
Social stigma toward alcohol and other drug (AOD) addiction may be defined as an 
obstacle to problem resolution or as a strategy of problem resolution.
The stigmatization and criminalization of alcohol and other drug problems in the United States 
has grown over more than two centuries, as an outcome of a series of “drug panics” and resulting 
social reform campaigns.523 These campaigns have generated policies of isolation, control, and 
punishment of drug users.524 Stigmatization is not an accidental by-product of these campaigns. It 
is a reflection of policies that “unashamedly aim to make the predicament of the addict as dreadful 
as possible in order to discourage others from engaging in drug experimentation.”525 An outcome 
of this complex social history is that many addiction professionals and recovery advocates see the 
stigma produced by “zero tolerance” policies as a problem to be alleviated, whereas preventionists 
see the stigma produced by such policies as a valuable community asset.526 A key question thus 
remains, “How do addiction treatment professionals, recovery advocates, and preventionists avoid 
working at cross-purposes in their educational efforts in local communities?” Efforts to reduce 
addiction-related stigma must engage multiple community groups in ways that alter community 
perception of the sources and solutions to alcohol and other drug problems.
519. Reasons, C.E. (1972). Dope, fiends and myths. Paper presented at 
American Sociological Association’s Annual Meeting (New Orleans, LA, 
August). Reasons, C.E. (1976). Images of crime and the criminal: The dope 
fiend mythology. Journal of Research in Crime and Delinquency, 13(2), 
133-144.
520. White, W. (1979). Themes in chemical prohibition. In Drugs in 
perspective. Rockville, MD: National Drug Abuse Center/National Institute 
on Drug Abuse.
521. White, W. (1998). Slaying the dragon: The history of addiction 
treatment and recovery in America. Bloomington, IL: Chestnut Health 
Systems.
522. White, W.L. & Kleber, H.D. (2008). Preventing harm in the name of 
help: A guide for addiction professionals, Counselor, 9(6), 10-17. 
523. Jonnes, J. (1996). Hep-cats, narcs, and pipe dreams. New York: 
Scribner. Musto, D. (1973). The American disease: Origins of narcotic 
controls, New Haven: Yale University Press.
524. White, W. (1979). Themes in chemical prohibition. In Drugs in 
perspective. Rockville, MD: National Drug Abuse Center/National Institute 
on Drug Abuse.
525. Husak, D.N. (2004). The moral relevance of addiction. Substance Use 
and Misuse, 39(3), 399-436.
526. There are those who take an extreme position on this, arguing that 
addiction is a moral problem, addicts are “bad people,” stigma attached 
to addiction is good and should be increased, the internalized stigma 
attached to addiction directs most addict violence within the drug culture, 
and that any lowering of that stigma might create a re-direction of that 
violence outward toward normal citizens. Dalrymple, T. (2007). Junk 
Medicine: Doctors, lies and the addiction bureaucracy. Great Britain: Har-
riman House, Ltd. 
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Efforts to increase or reduce stigma attached to illicit drug use may have intended or 
unintended side-effects.527
Two examples illustrate this point. First, efforts to decrease illicit drug use by portraying the drug 
user as physically diseased, morally depraved, and criminally dangerous may inadvertently de-
crease help-seeking behavior by creating caricatured images of addiction with which few people 
experiencing AOD problems identify. Such efforts may also promote patterns of social exclusion 
and discrimination within local communities that block the ability of drug-dependent individuals 
to reenter mainstream community life. Second, community education efforts aimed at reducing 
stigma might increase drug use.528 This might occur if these campaigns inadvertently normalized 
illicit drug use, increased non-user curiosity about drug effects, conveyed the impressions that 
addiction treatment is an assured safety net (available and affordable) or that recovery is easily 
attainable, or glamorized the recovering addict as a heroic figure within cultural contexts in which 
few heroic models are available. 
Any campaign to counter addiction/treatment/recovery-related stigma must ask two 
related questions: 1) “What is the source of stigma?” and “Who profits from stigma?”529
Efforts by one group to define another group as deviant can serve psychological, political, and 
economic interests. Simply put, stigmatizing others often serves to increase the self-esteem of the 
stigmatizer.530 It elevates oneself as more worthy than the demeaned “other” and defines oneself 
as an upholder of community health and morality. Social scapegoating of others increases during 
periods in which personal esteem, security, safety, and social value are threatened. Participation in, 
or support of, a campaign that defines a particular group as “outsiders” serves to confirm one’s own 
status as an “insider.” Addiction professionals seeking to reduce social stigma attached to addiction/
treatment/recovery must address such issues of esteem, security, safety, and social value. 
Stigma has political utility. Anti-drug campaigns often mask and reflect deeper conflicts of gender, 
race, social class, and generational conflict. Such issues have long been manipulated for political 
gain. Stigma is often the delayed fruit of anti-drug campaigns waged for the benefit of those seek-
ing to build or retain political power. Anti-stigma campaigns must address the question of how 
the community and its political leaders can benefit from changes in attitudes toward addiction/
treatment/recovery. 
527. Room, R. (2005). Stigma, social inequality and alcohol and drug use. 
Drug and Alcohol Review, 24(2), 143-155.
528. Gerber, J. (1973). Role of the ex-addict in drug abuse intervention. 
Drug Forum, 2(2), 105-106.
529. Weinstein, 2009, personal communication.
530. Tajfel, H., & Turner, J.C. (1979). An integrative theory of intergroup 
conflict. In W.G. Austin, & S. Worchel (Eds.), The social psychology of 
intergroup relations (pp. 33-48). Monterey, CA: Brooks/Cole. 
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Social stigma can be fed by individuals and institutions whose economic interests are served by 
such attitudes. Changes in attitudes can trigger shifts in cultural ownership of alcohol and other 
drug problems and, in that process, shift millions of dollars in ways that affect the destinies of 
individuals, organizations, and whole communities. For example, changes in community attitudes 
have in the past shifted millions of dollars between community-based addiction treatment and the 
criminal justice system. Such shifts influence the fate of professional careers, organizations, and 
in some cases, entire community economies. Similarly, what may be viewed as a problem of “not 
in my back yard” (NIMBY) prejudice by citizens of a particular neighborhood may actually reflect a 
manipulation of public opinion by hidden financial interests, e.g., developers who would profit from 
gentrification of a neighborhood targeted for a new addiction treatment facility.531 
Formal studies of public resistance to locating behavioral health (addiction or mental health) 
treatment clinics and recovery homes in a particular neighborhood have drawn several key 
conclusions. Facilities that notify neighbors before their entrance into the community experi-
ence greater initial resistance than those who do not, but achieve better long-term relationships 
with the local community—particularly when the facility has an active strategy of neighborhood 
relations, e.g., open houses and community service.532 Many facilities are well accepted in their 
communities, and acceptance is associated with public concepts of “social responsibility and 
collective care.”533 Acceptance is highest among community residents who are younger, are 
more economically and educationally advantaged, personally know someone in recovery, rely 
on education/experience rather than the media as the most important source of information, 
see facility residents as similar to other people, and believe local residents encountering behav-
ioral health problems should have access to local, community-based services.534 By enhancing 
positive recovery outcomes, larger facilities (eight or more residents) generate fewer neighbor-
hood complaints related to criminal or aggressive behavior.535 
Local opposition to the opening of a new methadone clinic has been linked to fear of increased 
drug use and crime, fear of potential effects on property values, objections to the profits made 
by private methadone clinics, and philosophical opposition to methadone as a treatment and as 
a perceived method of social control of communities of color.536 This opposition can be reduced 
by involvement of neighborhood leaders in site planning, placement of clinics in low-traffic areas, 
minimization of patient visibility (e.g., providing space for socializing to minimize loitering outside 
531. Joseph, H. (2009). Personal Communication (Interview), June 5, 
2009.
532. Zippay AL. (2007). Psychiatric Residences: Notification, NIMBY, and 
Neighborhood Relations. Psychiatric Services 58, 109–113. http://www.
psychservices.psychiatryonline.org/
533. Zippay, A. & Lee, S.K. (2008). Neighbors’ perceptions of community-
based psychiatric housing. Social Service Review 82(3), 395-417.
534. Iutcovich, M., Iutcovich, J., & Strikland, W .J. (1996). Group homes 
for the mentally ill? NIMBY! Social Insight, 11-15. Repper, J., & Brooker, C. 
(1996). Public attitudes toward mental health facilities in the community. 
Health and Social Care in the Community, 4(5), 290-299.
535. Jason, L.A., Groh, D.R., Durocher, M., Alvarez, J., Aase, D.M., & 
Ferrari, J.R. (2008). Counteracting “Not in My Backyard”: The positive 
effects of greater occupancy within mutual-help recovery homes. Journal 
of Community Psychology, 36, 947-958.
536. Genevie, L., Struening, E.L., KAllos, J.E., Gelier, I., Muhlin, G.L. & Ka-
plan, S. (1988). Urban community reaction to health facilities in residential 
areas: Lessons from the placement of methadone facilities in New York 
City. The International Journal of the Addictions, 23(6), 603-616. 
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the clinic, encouraging early morning pickups), and demonstration that methadone clinic patients 
can make a positive contribution to the community (e.g., community service programs).537 
There has been considerable rethinking of the NIMBY issue. First, NIMBY may represent, not local 
prejudice, but a local manifestation of a belief system that is deeply ingrained within the national 
culture—suggesting the need for national as well as local anti-stigma strategies.538 
It is essential that attempts are made to improve tolerance not only within local 
populations but also within the total population. This might be achieved through 
a broad based educational and awareness raising strategy which is properly 
funded by purchasers of health and social care.539
Second, as a local issue, NIMBY is being viewed as more than a manifestation of misinformation 
and prejudice. 
Siting conflicts should not be seen as resulting from the unreasonable and 
selfish attitudes of the local population, but as a real reflection of concerns about 
health, safety, quality of life, political interests, rights and moral issues… There is 
a need to break out of adversarial approaches toward cooperation.540 
Siting conflicts may be minimized if preceded by efforts to promote community consensus on 
such key propositions as the following:
•	 Each	family/neighborhood	has	a	responsibility	to	take	care	of	its	own.
•	 Each	neighborhood/community	is	responsible	for	developing	a	level	of	prevention,	early	
intervention, treatment, and recovery support services commensurate with the vulnerability to 
AOD problems in that neighborhood.
•	 Neighborhoods/communities	may	band	together	to	create	a	full	continuum	of	prevention,	
early intervention, treatment, and recovery support services available to all of their members, 
with all neighborhoods/communities having a voice (through their elected representatives) 
regarding the location of such resources.
•	 Neighborhoods/communities	have	a	right	to	be	involved	in	planning	decisions	related	to	the	
siting of new addiction treatment and recovery support resources. 
537. Genevie, L., Struening, E.L., KAllos, J.E., Gelier, I., Muhlin, G.L. & Ka-
plan, S. (1988). Urban community reaction to health facilities in residential 
areas: Lessons from the placement of methadone facilities in New York 
City. The International Journal of the Addictions, 23(6), 603-616. 
538. Tempalski, B., Friedman, R., Keem, M., Coopoer, H. & Friedman, S.R. 
(2007). NIMBY localism and national inequitable exclusion alliances: The 
case of syringe exchange programs in the United States, Geoforum, 38(6), 
1250-1263. 
539. Repper, J., & Brooker, C. (1996). Public attitudes toward mental 
health facilities in the community. Health and Social Care in the 
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Community, 4(5), 290-299.
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•	 Neighborhoods/communities	have	a	right	to	know	the	extent	to	which	individuals	served	
by a treatment or recovery support facility come from within or outside the neighborhood/
community. 
•	 Neighborhoods/communities	have	a	right	to	know	about	potential	problems	that	may	arise	
within treatment and recovery support facilities and how such problems will be managed. 
•	 Organizations	seeking	to	open	new	treatment	or	recovery	support	facilities	have	a	right	to	a	
fair hearing in which they can present ways in which that facility meets current legal/regulatory 
requirements and ways in which the facility will benefit the community via services, jobs, and 
economic resources.541 
The stigma attached to methadone treatment for opioid addiction is rooted in the unique 
history of this drug and its close association with heroin addiction.
Methadone maintenance as a treatment for heroin addiction has grown from a handful of patients 
in the mid-1960s to more than 260,000 patients in 2008 (plus an additional 140,000 opioid-
dependent patients being treated with buprenorphine).542 Early attacks on methadone in the late 
1960s and 1970s focused on what was perceived as “drug substitution” and concerns about 
methadone diversion and methadone-related deaths.543 Since that time, attitudes toward metha-
done are due in great part to the fact that the least stabilized medication-assisted treatment (MAT) 
patients and the worst MAT programs (e.g., poorest clinical, administrative, and fiscal practices) 
garner nearly all of the attention the media gives to the subject of methadone treatment. 
Widely disseminated myths and misconceptions about the drug methadone and methadone 
maintenance as an addiction treatment have flourished since its introduction and continue to 
affect discussions about methadone at personal, professional, public, and policy levels. In spite 
of the established scientific legitimacy and effectiveness of methadone maintenance treatment 
(see later citations), methadone patients are forced to hide their “dirty little secret” for fear of social 
rejection and discrimination.544 
Attitudes toward methadone as a mechanism of recovery support are unique in the broad arena 
of addiction treatment. For other areas of recovery support (e.g., participation in professional 
continuing care groups, peer-based recovery support meetings, daily recovery support rituals not 
involving medication), there is consistent praise for continuing or increasing these activities over 
541. White, W. (2009). Personal Communication to Dr. Arthur Evans
542. Kleber, H. (2008). Methadone maintenance 4 decades later: 
Thousands of lives saved but still controversial. Journal of the American 
Medical Association, 300(9), 2303-2305. 
543. Kleber, H. (2008). Methadone maintenance 4 decades later: 
Thousands of lives saved but still controversial. Journal of the American 
Medical Association, 300(9), 2303-2305.
544. Gryczynski, J. (2005). Patient views on methadone treatment as 
conveyed in an online support group. Presented at the annual meeting 
of the American Sociological Association, Philadelphia, PA. Murphy, S., & 
Irwin, J. (1992). “Living with the dirty secret”: Problems of disclosure for 
methadone maintenance clients. Journal of Psychoactive Drugs, 24(3), 
257-264.
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time. But for the person whose recovery is supported by methadone, there is encouragement to 
taper off methadone and congratulations when such tapering is complete, in spite of research 
finding high relapse rates following such tapering and the lack of expectation among patients or 
staff that tapering will be successful.545 Professional congratulations to the person who similarly 
reduced and ended his or her recovery support meeting participation would be unthinkable in 
most current recovery cultures.546 
The stigma attached to methadone is also shaped by the expectations of methadone treatment as 
a system of care. Methadone advocate Walter Ginter comments on such expectations:
Patients, former patients, staff, policy makers, and the public expect the metha-
done treatment program to treat addiction. While that is a reasonable expecta-
tion, it is not what Opioid Treatment Programs (OTPs) do. OTPs treat opiate 
dependence, and they do it very well. Most patients on an adequate dose of 
methadone do not continue to use opiates. However, opiate addiction is more than 
dependence on opiates; it is dependence combined with a series of behaviors. 
OTPs (with a few exceptions) do not treat the behavioral aspects of addiction. 
The behavioral aspects are not treated by a medication but rather by counseling, 
therapy, peer recovery supports, and 12-step groups. As long as well-intentioned 
people go around saying that “methadone is recovery,” it is going to continue to 
be misunderstood. Methadone is a medication, a tool, even a pathway, but it is not 
recovery. Recovery is a way of living one’s life. It doesn’t come in a bottle.547
Modern OTPs, under the influence of the American Association for the Treatment of Opioid De-
pendence, are making significant strides in moving from this narrow focus on metabolic stabiliza-
tion to the broader processes involved in addiction treatment and long-term addiction recovery.548 
Patients entering methadone treatment are as likely to be seeking respite as they are to be seek-
ing recovery.549 Entrance into addiction treatment can be a milestone in one’s addiction career as 
well as a potential milestone of recovery.550 It is the milieu of the clinic, the service relationships, 
and the broader menu of services in which methadone is nested that can tip the scales from the 
former to the latter. The social and professional perception of methadone treatment as consisting 
almost exclusively of the medication itself has contributed to the stigma attached to methadone 
and methadone maintenance treatment. 
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conceptual undeRpinnings of Mat-linked stigMa 
Social and professional stigma, particularly stigma associated with methadone treatment, is but-
tressed by a set of core assumptions or beliefs. Table 1 (beginning on the following page) outlines 
some of these key assumptions and beliefs and their current scientific status. 
Table 1: Stigma-Linked Beliefs and Their Scientific Status
Stigma-Linked BeLiefS the Science
1. Compulsive drug use is a 
choice, and such voluntary 
choices and their conse-
quences should not be masked 
within a disease rhetoric that 
fails to hold people accountable 
for their decisions and actions.
1. Volitional control over whether to use or not use a drug, and how much 
and for how long to use once use begins, progressively diminishes in vulner-
able populations as the brain is “hijacked” via the dysregulation of normal 
brain functioning produced by sustained drug exposure.551 
2. Methadone is a “crutch”: 
it provides symptomatic 
treatment but fails to treat the 
deeper emotional and relational 
disturbances that led to the 
initiation and maintenance of 
heroin addiction.552 
2. Opioid addiction is at its core more a physiological than psychological 
disorder,553 but recovery rates in MAT can be compromised by high rates 
of co-occurring medical and psychiatric disorders.554 MAT outcomes are 
enhanced when methadone is wrapped in a broader menu of medical, 
psychiatric, and social services.555 The primary rationale for MAT is the 
following: the physiological core of opioid dependence requires a core 
treatment of physiological stabilization; abstinence-based treatment of opioid 
dependence is limited in terms of attraction, retention, and post-treatment 
outcomes because it lacks this core physiological treatment.
551. Dackis, C., & O’Brien, C. (2005). Neurobiology of addiction: Treatment 
and public policy ramifications. Nature Neuroscience, 8(11), 1431-1436. 
Shaham, Y., & Hope, B. T. (2005). The role of neuroadaptations in relapse 
to drug seeking. Nature Neuroscience, 8(11), 1437-1439.
552. Beschner, G.M., & Walters, J.M. (1985). Just another habit? The 
heroin users’ perspective on treatment. In B. Hanson, G. Beschner, J.M. 
Walters, & E. Bovelle (Eds.), Life with heroin: Voices from the inner city. 
Lexington, MA: Lexington Books.
553. Kreek, M.J., & Reisinger, M. (1997). In J. Lowinson, P. Ruiz, R.B. Mill-
man, & J.G. Langrod (Eds.), Substance abuse: A comprehensive text (pp. 
822-853). Baltimore, MD: Williams and Wilkins. 
554. Cacciola, J.S., Alterman, A.I., Rutherford, M.J., McKay, J.R., & Milva-
ney, F.D. (2001). Drug and Alcohol Dependence, 61, 271-280.
555. Abbot, P.J., Moore, B., Delaney, H., & Weller, S. (1999). Retrospec-
tive analyses of additional services for methadone maintenance patients. 
Journal of Substance Abuse Treatment, 17(1-2), 129-137. Hesse, M., 
& Pedersen, M.U. (2008). Easy-access services in low-threshold opiate 
agonist maintenance. International Journal of Mental Health and Addiction, 
6(3), 316-324. McLellan, A. T., Arndt, I.O., Metzger, D.S., Woody, G.E., & 
O’Brien, C.P. (1993). The effects of psychosocial services in substance 
abuse treatment. Journal of the American Medical Association, 269, 
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Stigma-Linked BeLiefS the Science
3. Methadone simply 
replaces one drug/addiction 
for another: “methadone is like 
the alcoholic replacing Bourbon 
with Scotch.”556
3. Injected heroin produces intense euphoria, whereas oral consumption of 
appropriate doses of methadone in an opioid-tolerant patient produces a 
normalizing rather than a euphoric effect.557 Because of this, most patients 
on methadone view methadone as a “medication” rather than a “drug.”558 
Methadone and buprenorphine are best thought of as addiction-ameliorating 
medications rather than addiction-inducing drugs.559 Methadone, like other 
legal medications, is subjected to quality controls (assurance of proper and 
consistent dosage and purity) not available with illicit opioids. Self-reports 
of MMT patients switching from being a “slave to heroin” to a “slave to 
methadone”560 have more to do with the rigorous demands of the MMT clinic 
structure than with the pharmacological equivalency of heroin and methadone. 
4. Methadone maintenance 
diminishes one’s capacity to 
eventually achieve long-term 
abstinence from opiates. 
4. The effect of methadone on the duration of addiction careers is unclear. Mad-
dux and Desmond561 found rates of long-term abstinence (defined in this study 
as abstinence from all opiates including methadone) of persons following MMT 
(9-21%) similar to those for persons treated in drug-free treatment (10-19%). 
The data “do not suggest that methadone impedes eventual recovery.”562 In a 
study published the same year, Maddux and Desmond conducted a 10-year 
follow-up comparison of patients with less than one year and more than one year 
on methadone maintenance and concluded: “methadone maintenance for 1 year 
or longer impedes eventual recovery from opioid dependence.” They went on 
to say that “For many patients, however, the benefits of prolonged methadone 
maintenance could outweigh the possible cost of diminished likelihood of eventual 
recovery.”563 A definitive answer to the effects of methadone maintenance on 
long-term addiction and recovery careers remains unclear. Future studies must 
include those in stable medication-assisted treatment without secondary drug 
use, with indicators of progress toward global health and community integration 
within the definition of recovery.564
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Stigma-Linked BeLiefS the Science
5. Low doses and short periods 
of methadone maintenance 
result in better rates of long-
term recovery. 
5. There is a significant relationship between methadone dosage and the 
odds of continued heroin use during MAT.565 Two-thirds of methadone 
treatment patients receive inadequate daily dosages of methadone-dosages 
below 80 mg/day566—in spite of growing evidence that higher dosages are 
linked to greater reductions in the use of other opiates, greater reductions in 
secondary drug use (e.g. cocaine, benzodiazepines),and enhancements in 
global recovery outcomes.567 The effective duration of methadone mainte-
nance associated with the best long-term recovery outcomes is at least one 
year of participation.568 In 2002, the average length of time from admission 
to discharge in outpatient methadone maintenance was 175 days.569
6. MAT patients should be 
encouraged to end MAT as 
soon as possible. 
6. The majority of opioid-dependent persons leaving MAT, like their opioid-
dependent counterparts leaving drug-free treatment, quickly relapse, and 
up to two-thirds later return to treatment—often for repeated episodes of 
treatment.570 The choice to end MAT is a decision to be made by the patient in 
consultation with his or her physician, but it is best attempted after a substan-
tial period of stability in MAT and with increased support during and following 
the tapering and cessation periods. The inability of some people to successfully 
taper from methadone may result more from physiological differences than 
from inadequate levels of personal motivation or family/social support.
seMantic and visual iMages undeRpinning Mat-Related stigMa
Social and professional stigma attached to opiate addiction and medication-assisted treatment 
(MAT) is buttressed by language. It is manifested in language that demedicalizes the status of 
addiction and depersonalizes and demonizes those with the disorder. Words and phrases such 
as drug habit, drug abuse, dope fiend, junkie, smackhead, addict, dirty (versus clean), user, client 
(rather than patient), and substitution all reflect such demedicalized and objectifying language.571
565. Caplehorn, J.R.M., Bell, J., Kleinbaum, D.G., & Gebski, V.J. (1993). 
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www.facesandvoicesofrecovery.org. NAMA (1994). Client vs. patient. 
National Alliance of Methadone Advocates, inc, Policy Statement # 4, May, 
1994. Retrieved July 28, 2009 from http://www.methadone.org/nama-
documents/ps04client_v_patient.html.
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… these terms [substitution therapy, replacement therapy] do not confer legiti-
macy or status on treatment… indeed the opposite is the case. All are associ-
ated with a culture of inauthenticity, and as a result, their value is permanently in 
question. It might be that, endemic as this language of substitution has become, 
new terms should be found.572
The stigma attached to heroin addiction has been extended to methadone treatment and intensi-
fied through such language as methodonia, methodonian, and deathadone. Books with titles like 
Methadone: A Technological Fix573 are popular, and the titles of professional articles proclaim 
“Stoned on Methadone,” “Hooked: The Madness in Methadone Treatment,” “Methadone: The 
Forlorn Hope,” and “The Methdonians.” Film “documentaries” are promoted through such titles 
as “Methadonia,” and “Methadone: An American Way of Dealing,”574 and methadone treatment is 
commonly portrayed as ineffective through such popular films as “Sid and Nancy,” “Trainspotting,” 
and “Permanent Midnight.”575 The language of methadone maintenance (e.g., its designation as a 
“substitution therapy” or “replacement therapy”) has contributed to the stigma attached to MAT by 
reinforcing the proposition that MAT is nothing more than the replacement of an illegal high with a 
legal high.576 
As noted earlier, the social stigma attached to narcotic addiction has been internalized within 
American drug cultures. The pecking orders within these cultures are reinforced by one’s status 
as a righteous dope fiend, hope-to-die dope fiend, or gutter hype. Such pecking orders can be 
acted out within the addiction treatment milieu as well as within local drug cultures. 
stReet Myths and stigMa 
Stigma attached to methadone has also been infused within the illicit drug culture of the United 
States.577 Beginning on the following page, Table 2 illustrates some of the methadone-related 
myths that pervade the American drug culture and that serve to inhibit treatment-seeking behavior 
and contribute to early treatment termination. 
572. Fraser, S., & Valentine, K. (2008). Substance and substitution: Metha-
done subjects in liberal societies. New York: Macmillan. 
573. Nelkin, D. (1973). Methadone maintenance: A technological fix. New 
York: George Braziller.
574. Joseph, H. (1995). Medical methadone maintenance: The further 
concealment of a stigmatized condition. Unpublished doctoral dissertation, 
City University of New York.
575. Cape, G.S. (2003). Addiction, stigma, and movies. Acta Psychiatrica 
Scandinavica, 107(3), 163-169.
576. Maremmani, I., & Pacini, M. (2006). Combating the stigma: Discard-
ing the label “substitution treatment” in favour of “behavior-normalization 
treatment.” Heroin Addiction and Related Clinical Problems, 8(4), 5-8.
577. Beschner, G.M., & Walters, J.M. (1985). Just another habit? The 
heroin users’ perspective on treatment. In B. Hanson, G. Beschner, J.M. 
Walters, & E. Bovelle (Eds.), Life with heroin: Voices from the inner city. 
Lexington, MA: Lexington Books.
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Table 2: Myths and Facts
the myth the factS
1. The name Dolophine (a phar-
maceutical brand of methadone 
marketed by Eli Lilly) was 
named for Adolf Hitler.
1. The “dolo” in Dolophine comes from the Latin dolor, meaning “pain,” and 
the “phine” likely comes from morphine or is derived from “fin,” meaning 
“end”; the name reflects the search for an alternative for morphine in the 
treatment of pain.578
2. Methadone is addicting. 2. Prolonged use of methadone, like that of any opioid, induces physical 
dependence, but there is no evidence that it induces addiction. The definitional 
determinants of addiction have historically included three components: 1) tolerance, 
2) withdrawal, and 3) compulsive use in spite of adverse consequences. Methadone 
meets the first two criteria, but not the third. Since its widespread introduction, 
there has not been a significant population of people who compulsively pursue 
methadone as a primary drug choice, although the potential for emergence of 
such a population continues to be monitored.579 People maintained on methadone 
for prolonged periods may be physically dependent upon methadone, but their 
addiction is to heroin or other short-acting narcotics, not methadone. 
3. Methadone is harder to 
“kick” than heroin.
3. Acute withdrawal from methadone takes longer than acute withdrawal 
from heroin. 
4. Methadone is nothing more 
than a cheap, legal high for 
people who cannot obtain heroin. 
4. Methadone at optimal doses does not produce intoxication; it produces 
physiological stabilization without heroin’s brief cycles of withdrawal distress 
and impairment related to acute intoxication. 
5. Once on methadone, you 
can never get off of it.
5. Relapse rates are high following cessation of both heroin and methadone. 
Some individuals do initiate and maintain recovery with the aid of methadone 
and later stop using methadone as a recovery adjunct while maintaining 
successful long-term recovery. 
578. Payte, J.T. (1991). A brief history of methadone in the treatment 
of opiate dependence: A personal perspective. Journal of Psychoactive 
Drugs, 23(2), 103-107.
579. A few commentators suggested that this has recently begun to 
change and that trends in this area should be closely monitored. 
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the myth the factS
6. Methadone maintenance 
extends the total length of 
addiction careers.
6. There is no scientific evidence that MAT lengthens addiction careers; ad-
diction careers are instead influenced by factors such as age of onset of use, 
degree of problem severity/complexity, and the level of personal recovery 
capital (internal and external resources that can be mobilized to initiate and 
sustain recovery).
7. Methadone hurts your health, 
e.g., rots your bones and 
teeth.580
7. The safety of methadone, including its safety for pregnant women and 
the infants they deliver, has been established in innumerable scientific 
studies.581 Most side-effects reported by patients are not a function of 
methadone per se, but are due to “inadequate dosages which precipitate 
withdrawal symptoms, excessive amounts of methadone, undiagnosed 
medical problems, or the interaction of methadone with other drugs and/or 
alcohol.”582 Long-term health problems, specifically dental disease, result 
from years of avoiding medical/dental care and are often first identified when 
the person enters MAT.
8. Methadone makes you fat. 8. Weight gain is common among MAT patients and is a product of increased 
food intake and improvement in overall health. Weight stabilizes with 
improved nutrition and exercise.583 
9. MAT patients are at 
increased risk of developing 
alcohol problems.
9. Problems of secondary drug dependence are a risk factor for all persons 
in recovery from opioid addiction, but this risk is similar across modalities 
of treatment. These problems are elevated in MAT programs that use 
sub-optimal doses of methadone and do not clinically address the problem 
of co-occurring psychiatric illness and secondary drug use—particularly the 
“pill culture” (e.g., benzodiazepines) that permeates many methadone clinics. 
The lack of meaningful activities may also contribute to such secondary drug 
use among MAT patients.584
 
580. Beschner, G.M., & Walters, J.M. (1985). Just another habit? The 
heroin users’ perspective on treatment. In B. Hanson, G. Beschner, J.M. 
Walters, & E. Bovelle (Eds.), Life with heroin: Voices from the inner city. 
Lexington, MA: Lexington Books.
581. Kreek, M.J. (1983). Health consequences associated with the use 
of methadone. In J. R. Cooper, F. Altman, B.S. Brown, & D. Czechowicz 
(Eds.), Research on the treatment of narcotic addiction: State of the art 
(NIDA Research Monograph Series; DHHS Publication No. (ADM) 83-1281; 
pp. 456-482). Rockville, MD: National Institute on Drug Abuse. Kreek, M. 
J., & Vocci, F. (2002). History and current status of opioid maintenance 
treatments. Journal of Substance Abuse Treatment, 23(2), 93-105. Center 
for Substance Abuse Treatment (2005). Medication-assisted treatment for 
opioid addiction in opioid treatment programs (Treatment Improvement 
Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048). Rockville, 
MD: Substance Abuse and Mental Health Services Administration.
582. Goldsmith, D.S., Hunt, D.E., Litpon, D.S., & Strug, D.L. (1984). 
Methadone folklore: Beliefs about side effects and their impact on treat-
ment. Human Organization, 43(4), 330-340.
583. Marion, I.J. (2009). Methadone: Myths and Facts (Presentation 
slides). 
584. Best, D. (2009). Personal communication. 
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the myth the factS
10. Methadone blunts the 
emotions, e.g., references to 
“methadone mummies.”
10. MAT patients actually report increased capacity to acknowledge and 
express emotion.585 The blunting of emotion might result from excessive 
methadone doses or secondary use of other drugs, e.g., benzodiazepines. 
11. Methadone maintenance is 
for “losers.” It is for people who 
can no longer “take care of 
business” on the streets.586 
11. “This image of the methadone client as a ‘loser,’ without ‘heart,’ and un-
able to ‘make it on the streets anymore,’ is reinforced by the low visibility of 
methadone clients who are working regularly and/or have what both clients 
and users not in treatment describe as a ‘steady hustle,’ that is, regular, 
income-generating employment, either legal or illegal.”587
12. Methadone is a tool of 
political pacification of poor 
communities of color.
12. Methadone makes a positive contribution to poor communities of color 
via reduced heroin-related deaths, reduced transmission of HIV and other 
diseases, reduced crime, and the social and economic assets that stable 
MAT patients add to their communities. Anti-methadone attitudes within 
the African American community must be viewed within the context of a 
long history of victimization of this community by scientific and medical 
enterprises, e.g., withholding medical treatment from 399 African American 
sharecroppers in the Tuskegee Syphilis Study.588
Sources: Hunt, D.E., Litpon, D.S., Goldsmith, D.S., Strug, D.L., & Spunt, B. (1985). “It takes your heart”: The image 
of methadone maintenance in the addict world and the effect on recruitment into treatment. International Journal 
of the Addictions, 20(11-12), 1751-1171; Velton, E. (1992). Myths about methadone. National Alliance of Methadone 
Advocates, Education Series Number 3; Joseph, H., Stancliff, S. & Langrod, J. (2000). Methadone maintenance 
treatment: A review of historical and clinical issues. Mount Sinai Journal of Medicine, 67, 347-364.
Again, these myths inhibit help-seeking, contribute to ambivalence about treatment, and increase 
the likelihood of treatment disengagement of MAT patients.589
585. Flynn, P.M., Joe, G.W., Broome, K.M. Simpson, D.D., & Brown, B.S. 
(2003).  Recovery from opioid addiction in DATOS. Journal of Substance 
Abuse Treatment, 25(3), 177-186.  
586. Preble, E., & Casey, J. (1969). Taking care of business—The heroin 
user’s life on the street. The International Journal of the Addictions, 6(1), 
1-24. Preble, E., & Miller. T. (1977).  Methadone, wine and welfare.  In 
R.S. Weppner (Ed.),  Street ethnography (pp. 229-248). Beverly Hills: Sage 
Publications. 
587. Hunt, D.E., Litpon, D.S., Goldsmith, D.S., Strug, D.L., & Spunt, B. 
(1985). “It takes your heart”: The image of methadone maintenance in the 
addict world and the effect on recruitment into treatment. International 
Journal of the Addictions, 20(11-12), 1751-1171.
588. White, W., & Sanders, M. (2008). Recovery management and people 
of color: Redesigning addiction treatment for historically disempowered 
communities. Alcoholism Treatment Quarterly, 26(3), 365-395.
589. Hunt, D.E., Litpon, D.S., Goldsmith, D.S., Strug, D.L., & Spunt, B. 
(1985). “It takes your heart”: The image of methadone maintenance in the 
addict world and the effect on recruitment into treatment. International 
Journal of the Addictions, 20(11-12), 1751-1171. Rosenblum, A., Magura, 
S., & Joseph, H. (1991). Ambivalence toward methadone treatment among 
intravenous drug users. Journal of Psychoactive Drugs, 23(1), 21-27.
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exaMples of addiction/tReatMent/RecoveRy-Related stigMa/
discRiMination
Addiction-related stigma is manifested in a broad range of attitudes, behaviors, and policies. 
These general effects include:
•	 Social	shunning/distancing	
•	 Expression	of	disregard	and	contempt
•	 Denial	of	needed	medication	for	pain	(interpreting	expressions	of	pain	as	drug-seeking	
behavior)
•	 Disrespect	from	primary	health	care	providers	and	social	service	personnel	
•	 Denial	of	basic	medical	services
•	 Denial	of	liver	transplantation	
•	 Discrimination	via	denial	of	governmental	benefits	for	people	with	drug-related	felonies,	e.g.,	
student loans, public housing, small business loans 
•	 Denial	of	training/employment	opportunities
•	 Denial	of	housing	and	homelessness	services
Other effects of such stigma are reserved specifically for those persons whose treatment and 
recovery is supported by methadone. These more specific effects include: 
•	 Denial	of	methadone	support	or	medically-supervised	withdrawal	during	incarceration
•	 Denial	of	access	to	other	addiction	treatment	modalities	and	recovery	support	services,	e.g.,	
denial of access to many residential treatment facilities and recovery homes in spite of evi-
dence that persons on methadone can benefit on par with non-medicated patients from such 
services590 
•	 Denial	of	medication	for	pain	on	the	false	assumption	that	pain	is	relieved	by	the	existing	
methadone dose 
•	 Exposure	to	punitive,	as	opposed	to	supportive,	styles	of	counseling	
590. De Leon, G., Stains, G.L., Perlis, T.E., Sacks, S., McKendrick, 
K., Hilton, R., & Brady, R. (1995). Therapeutic community methods in 
methadone maintenance (Passages): An open clinical trial. Drug and 
Alcohol Dependence, 37, 45-57. Sorensen, J. L., Andrews, S., Delucchi, 
K. L., Greenberg, B., Guydish, J., Masson, C.L., et al. (2008). Methadone 
patients in the therapeutic community: A test of equivalency. Drug and 
Alcohol Dependence, 100(1), 100-109. 
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•	 Denial	of	the	right	to	speak	and	assume	leadership	roles	in	local	AA/NA	meetings
•	 Denial	of	detoxification	services	for	other	addictive	substances	in	acute	medical	facilities	(e.g.,	
medical management of alcohol withdrawal) while being maintained on one’s prescribed and 
stabilized dose of methadone591 
•	 Loss	of	child	custody	due	to	participation	in	MAT.
The stigma attached to addiction, and to the use of methadone as a medication in particular, has 
influenced key clinical practices within methadone treatment since its inception in the mid-1960s. 
Such practices, often “legislated” by oversight bodies, further contributed to the stigma associated 
with methadone treatment.592 These practices, some of which have declined due to changes in 
regulatory guidelines, include:
•	 Resistance	to	hiring	methadone	patients	as	counselors	(e.g.,	requirement	that	they	first	be	
tapered)
•	 Being	required	to	stand	in	line	in	a	publicly	visible	area	(e.g.,	public	sidewalk)	to	receive	metha-
done 
•	 Separate	bathrooms	for	staff	and	patients	(required	by	regulation	in	most	states)
•	 Refusing	to	admit	people	on	the	grounds	of	insufficient	motivation
•	 Informal	use	of	pejorative	labels	to	designate	readmitted	patients	(e.g.,	frequent flyers, re-
treads)
•	 Lowered	“horizons	of	possibilities”	(expectations)	communicated	to	patients	
•	 Suboptimal	methadone	doses
•	 Lowering	methadone	dose	or	disciplinary	discharge	as	a	punishment	for	clinic	rule	violations
•	 Discharging	patients	for	drug	use593 
•	 “Blind	dosing”	without	patients’	involvement	and	consent	
•	 Stigma	attached	to	having	a	high	dose	of	methadone	within	the	MAT	subculture	
•	 Staff	pressure	on	patients	to	taper	(medically	withdraw)	from	methadone	in	settings	with	an	
abstinence orientation toward MAT
591. Hettema, J., & Sorenson, J.L. (2009). Access to care for methadone 
maintenance patients in the United States. International Journal of Mental 
Health and Addiction. Online publication ahead of print. Retrieved from 
http://www.springerlink.com/content/c5v56125880u2p64/. Joe, G.W., 
Simpson, D.D, & Rowan-Szal, G.A. (2009). Interaction of counseling rap-
port and topics discussed in sessions with methadone treatment clients. 
Substance Use and Misuse, 44, 3-17. Joseph, H., Stancliff, S., & Langrod, 
J. (2000). Methadone maintenance treatment: A review of historical and 
clinical issues. Mount Sinai Journal of Medicine, 67, 347-364.
592. Anstice, S., Strike, C.J., & Brands, B. (2009). Supervised methadone 
consumption: Client issues and stigma. Substance Use and Misuse, 44(6), 
794-808. O’Brien, C.P. (2008). A 50 year old woman addicted to heron: 
Review of treatment for heroin addiction. Journal of the American Medical 
Association, 300, 414-321. 
593. NAMA (1994). Discharge from treatment for drug use. Policy state-
ment # 3. Retrieved May 25, 2009 from http://www.methadone.org/
namadocuments/ps03discharge_from.html.
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•	 Staff	discouragement	of	tapering	for	all	patients	out	of	fear	“they	won’t	make	it”	in	settings	
with a harm-reduction orientation toward MAT 
•	 Onerous	pickup	schedules	and	restricted	dispensing	hours	that	interfere	with	pro-social	roles,	
e.g., education, employment, parenting
•	 Supervised	consumption	of	methadone	and	frontally	observed	urine	drops	(required	by	regu-
lation)
•	 Arbitrary	limits	on	the	duration	of	methadone	maintenance
•	 Discouragement/prohibition	of	fraternization	among	MAT	patients
•	 Inadequate	funding/reimbursement	for	ancillary	health	and	social	services,	inadequate	educa-
tion and training of staff, and inadequate clinical supervision 
•	 Elaborate	and	medically	unprecedented	regulatory	requirements	governing	the	use	of	metha-
done as a medication in addiction treatment.594 
In the MAT context, these practices are often experienced by patients as a demonstration of the 
power held over them by professional staff. There are evidence-based training strategies and 
techniques that can lower stigma and its behavioral manifestations displayed by frontline addiction 
treatment service providers.595
Methadone-specific stigma can also affect methadone treatment organizations and their staff. 
Organizational effects can include community resistance to the opening of a new methadone 
treatment site, resistance to the relocation of an existing program, or political pressure to close an 
existing MAT site.
conceptual undeRpinnings of a caMpaign to eliMinate stigMa 
Related to Methadone
Anti-stigma campaigns in the addictions arena have historically focused on a core set of ideas.596 
These simply stated propositions serve as the skeletal foundation of professional and public 
education efforts and policy advocacy efforts. For example, the “modern alcoholism movement” 
launched in the 1940s laid the foundation for the rise of modern addiction treatment. This move-
ment was built on the five “kinetic” ideas:
594. Järvinen, M., & Andersen, D. (2009). The making of the chronic 
addict. Substance Use and Misuse, 44, 865-885. Rosenbaum, M. (1995). 
The demedicalization of methadone maintenance. Journal of Psychoactive 
Drugs, 27, 145-149.
595. Andrews, S.B., Sorenson, J.L., & Delucchi, K. (2004). Methadone 
stigma and the potential effect of sensitivity training for drug treatment 
staff. Presented at the annual meeting of the American Public Health 
Association, November 6-10, Washington, DC. Hayes, S.C., Bissett, R., 
Roget, N., Padilla, M., Kohlenberg, B.S., Fisher, G., et al. (2004). The 
impact of acceptance and commitment training and multicultural training 
on the stigmatizing attitudes and professional burnout of substance abuse 
counselors. Behavior Therapy, 35(4), 821-835.
596. Johnson, B. (1973). The alcoholism movement in America: A study in 
cultural innovation. Unpublished doctoral dissertation, University of Illinois, 
Urbana, Illinois.
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Modern Alcoholism Movement: Kinetic Ideas 
1.  Alcoholism is a disease.
2.  The alcoholic, therefore, is a sick person.
3.  The alcoholic can be helped.
4.  The alcoholic is worth helping.
5.  Alcoholism is our No. 4 public health problem, and our public responsibility.597 
New Recovery Advocacy Movement: Core Ideas 
The “new addiction recovery advocacy movement” is also based on a set of core ideas:
1.  Addiction recovery is a reality in the lives of hundreds of thousands of individuals and families 
throughout the United States. 
2.  There are many paths to recovery, and all are cause for celebration. 
3.  Recovering and recovered people are part of the solution to alcohol and other drug problems. 
4.  Recovery flourishes in supportive communities. 
5.  Recovery is voluntary. 
6.  Recovery gives back what addiction has taken from individuals, families, neighborhoods, and 
communities.598 
Any movement to destigmatize methadone treatment and the broader arena of medication-
assisted recovery will need its own set of core ideas. The propositions listed below constitute a 
menu of propositions from which such a set of ideas might be formulated and condensed to form 
operational slogans.
the natuRe of addictive disoRdeRs
•	 The	initial	decision	to	consume	or	not	consume	alcohol,	tobacco,	and	other	drugs	is,	in	most	
but not all circumstances, a voluntary choice.599
597. Anderson, D. (1942). Alcohol and public opinion. Quarterly Journal 
of Studies on Alcohol, 3(3), 376-392. Mann, M. (1944). Formation of a 
National Committee for Education on Alcoholism. Quarterly Journal of 
Studies on Alcohol, 5(2), 354-358. 
598. White, W. (2006). Let’s go make some history: Chronicles of the 
new addiction recovery advocacy movement. Washington, D.C.: Johnson 
Institute and Faces and Voices of Recovery. 
599. Dr. Karol Kaltenbach and others point out that multiple factors 
compromise the volitional intent involved in initial drug consumption: early 
age of onset, introduction of drug use by an older authority figure, coerced 
use as a dimension of sexual victimization, and drug-saturated peer 
environments can all compromise the voluntary quality of such choices. 
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•	 This	initial	choice	may	be	consciously	influenced	by	moral	or	religious	values,600 but more of-
ten reflects behavior directed at normal needs and experiences, e.g., pleasure seeking, social 
inclusion, personal identity, relief from physical/emotional discomfort or family distress. 
•	 The	long-term	consequences	flowing	from	continued	drug	exposure	have	more	to	do	with	
factors of personal and environmental vulnerability than with personal morality or strength of 
character. 
•	 Addiction	is	a	brain	disease	that	manifests	itself	in	the	loss	of	volitional	control	over	drug-
seeking, drug use, and its consequences. 
•	 This	loss	of	volitional	control	is	related	to	neurobiological	changes	in	the	brain	that	place	the	
need for the drug above other physical needs and social responsibilities. 
•	 Addiction	is	not	a	problem	easily	resolved	through	“willpower”;	addiction	is,	by	definition,	a	
failure of such power.
•	 Nearly	two-thirds	of	American	families	have	direct	experience	with	alcohol	or	drug	addic-
tion.601
natuRe of addiction RecoveRy
•	 Recovery	from	alcohol	and	drug	addiction	requires	personal	persistence	and	sustained	family	
and social support; recovery flourishes in supportive communities. 
•	 Recovery-supportive	communities	are	good	for	everyone;	all	citizens	reap	dividends	from	
successful long-term recovery. 
•	 Long-term	addiction	recovery	is	a	living	reality	for	hundreds	of	thousands	of	individuals	and	
families. 
•	 Recovery	from	alcohol	and	drug	addiction	requires	personal	persistence	and	sustained	family	
and social support; recovery flourishes in supportive communities.
•	 There	are	multiple	pathways	of	long-term	recovery,	and	all	are	cause	for	celebration.
•	 Providing	addiction	treatment	and	sustained	recovery	support	services	is	more	effective	and	
a more prudent use of community resources than the strategy of mass incarceration.
600. Husak, D.N. (2004). The moral relevance of addiction. Substance Use 
and Misuse, 39(3), 399-436.
601. Peter D. Hart Research Associates/Coldwater Corporation (2004). 
2004 Peter D. Hart Research Associates/Coldwater Corporation, Faces 
and Voices of Recovery public survey. Washington, DC: Faces and Voices 
of Recovery. 
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Medication and RecoveRy 
•	 Some	opioid-dependent	individuals	with	sustained	abstinence	from	short-acting	opioids	and	
social support may achieve long-term recovery (brain recovery and psychosocial recovery) 
without the aid of medications, while other drug-dependent individuals will require prolonged, 
if not lifelong, use of medications that reduce drug craving and facilitate full biopsychosocial/
spiritual functioning. 
•	 Stabilizing	medications	are	available	for	the	treatment	of	severe	opioid	addiction,	and	even	
more effective medications may become available in the future. 
•	 Opiate	addiction	is	a	“brain-related	medical	disorder”	that	is	treatable	with	effective	medica-
tions; other professionally directed medical, psychological, and social services; and peer-
based recovery support services.602
•	 Appropriate	daily	dosages	of	methadone	suppress	cellular	craving	for	narcotics,	prevent	
withdrawal symptoms (the opioid abstinence syndrome); block the effects of heroin use; and 
provide a platform or metabolic stability upon which full physical, emotional, and cognitive 
recovery can be achieved.603
•	 The	dosages	required	to	achieve	these	effects	vary	from	individual	to	individual.604
•	 Appropriate	oral	doses	of	methadone	do	not	produce	an	experience	of	sedation	or	euphoria	
in individuals who are opiate-tolerant;605 stabilized patients not using other substances are 
capable of experiencing the full range of emotional and physical pain.606
•	 Methadone	maintenance	combined	with	needed	ancillary	medical,	psychological,	and	social	
services is the most effective method of treating chronic heroin addiction.607 
•	 The	effectiveness	of	methadone	maintenance	treatment	has	been	reviewed	and	affirmed	by	
major health research and policy bodies, including the National Institute on Drug Abuse, the 
American Medical Association, the American Society of Addiction Medicine, the Institute of 
Medicine, the National Academy of Sciences, the National Institute on Health Consensus 
Panel, and the Office of National Drug Control Policy,608 as well as the World Health Organiza-
tion and other governmental health policy groups around the world. 
602. Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone 
maintenance treatment: A review of historical and clinical issues. Mount 
Sinai Journal of Medicine, 67, 347-364. White, W. (2009). The mobilization 
of community resources to support long-term addiction recovery. Journal 
of Substance Abuse Treatment, 36, 146-158. 
603. Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone 
maintenance treatment: A review of historical and clinical issues. Mount 
Sinai Journal of Medicine, 67, 347-364.
604. Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone 
maintenance treatment: A review of historical and clinical issues. Mount 
Sinai Journal of Medicine, 67, 347-364.
605. Marion, I.J. (2009). Methadone: Myths and Facts (Presentation 
slides); Murray, J.B. (1998). Effectiveness of methadone maintenance for 
heroin addiction. Psychological Reports, 83, 295-302. Zweben, J. (1991). 
Counseling issues in methadone treatment. Journal of Psychoactive Drugs, 
23(2), 177-190.
606. Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone 
maintenance treatment: A review of historical and clinical issues. Mount 
Sinai Journal of Medicine, 67, 347-364.
607. Rettig, R.A., & Yarmolinsky, A. (1995). Federal regulation of 
methadone treatment. Washington, D.C.: National Academy Press. 
National Consensus Development Panel on Effective Medical Treatment of 
Opiate Addiction. (1998). Effective medical treatment of opiate addiction. 
Journal of the American Medical Association, 280(22), 1936-1943.
608. White, W., & Coon, B. (2003). Methadone and the anti-medication 
bias in addiction treatment. Counselor, 4(5), 58-63. 
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•	 These	collective	reviews	conclude	that	orally	administered	methadone	can	be	provided	for	a	
prolonged period at stable dosages with a high degree of safety and without significant ef-
fects on psychomotor or cognitive functioning.609 
•	 Methadone	is	the	safest	medication	available	to	treat	heroin	addiction	in	pregnant	women.610
•	 These	reviews	also	confirm	that	MAT	delivered	at	optimal	dosages	by	competent	practitio-
ners: 1) decreases the death rate of opiate-dependent individuals by as much as 50%; 2) 
reduces the transmission of HIV (four-to-six-fold reductions), hepatitis B and C, and other in-
fections; 3) eliminates or reduces illicit opiate use (by minimizing narcotic craving and blocking 
the euphoric effects of other narcotics); 4) reduces criminal activity; 5) enhances productive 
behavior via employment and academic/vocational functioning; 6) improves global health and 
social functioning; and 7) is cost-effective.611 
•	 Methadone-related	deaths	are	related	primarily	to	the	diversion	of	methadone	prescriptions	
for pain rather than from methadone used as a treatment for addiction or illegally diverted 
from methadone clinics/patients.612 
•	 Methadone	as	a	pharmacological	adjunct	in	the	treatment	of	opioid	addiction,	like	insulin	in	
the treatment of diabetes, is a corrective therapy, not a curative therapy. It is effective only 
when it is consumed on a sustained daily basis. Relapse rates are high following cessation 
of methadone maintenance, and mortality rates rise following medical withdrawal.613 People 
should not be precipitously encouraged to end such treatment.614 Patients choosing to taper 
(end methadone maintenance) should receive increased program support, including edu-
cational guidance on the tapering decision, relapse prevention, and recovery strengthening 
techniques; support for changes in diet and exercise; continued professional and peer-based 
support; close post-tapering monitoring; and, if and when needed, early re-intervention and 
re-initiation of methadone maintenance.615 
•	 After	more	than	40	years’	experience	with	methadone	maintenance,	primary	addiction	to	
methadone within the illicit drug culture occurs but still constitutes a rare phenomenon. 
Methadone has value in the illicit drug culture primarily for the self-medication of opiate-de-
pendent individuals who cannot procure heroin or other short-acting opioids, or who cannot 
gain access to methadone maintenance programs.616 
609. Kreek, M.J., & Vocci, F. (2002). History and current status of opioid 
maintenance treatments. Journal of Substance Abuse Treatment, 23(2), 93-
105. National Consensus Development Panel on Effective Medical Treatment 
of Opiate Addiction. (1998). Effective medical treatment of opiate addiction. 
Journal of the American Medical Association, 280(22), 1936-1943.
610. Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone 
maintenance treatment: A review of historical and clinical issues. Mount 
Sinai Journal of Medicine, 67, 347-364. Kreek, M.J., & Vocci, F. (2002). 
History and current status of opioid maintenance treatments. Journal of 
Substance Abuse Treatment, 23(2), 93-105.
611. Clausen, T., Ancherson, K., & Waal, H. (2008). Mortality prior to, dur-
ing and after opioid maintenance treatment (OMT): A national prospective 
study. Drug and Alcohol Dependence, 94, 151-157. Corsi, K.F., Lehman, 
W.K. & Booth, R.E. (2009). The effect of methadone maintenance on posi-
tive outcomes for opiate injection drug users. Journal of Substance Abuse 
Treatment, 37, 120-126. Kreek, M.J., & Vocci, F. (2002). History and 
current status of opioid maintenance treatments. Journal of Substance 
Abuse Treatment, 23(2), 93-105. National Consensus Development Panel 
on Effective Medical Treatment of Opiate Addiction. (1998). Effective 
medical treatment of opiate addiction. Journal of the American Medical 
Association, 280(22), 1936-1943.
612. Paulozzi, L.J., Budnitz, D.S., & Xi, Y. (2006). Increasing deaths from 
opioid analgesics in the United States. Pharmacoepidemiology and Drug 
Safety, 15(9), 618-27. Sims, S.A., Snow, L.A., & Porucznik, C.A. (2006). 
Surveillance of methadone-related adverse drug events using multiple 
public health data sources. Journal of Biomedical Information, 40(4), 382-
389. Webster, L.R. (2005). Methadone-related deaths. Journal of Opioid 
Management, 1, 211-217.
613. Davoli, M., Bargagli. A.M., Perucci C.A., Schifano, P., Belleudi, V., 
Hickman, M., et al. (2007). Risk of fatal overdose during and after special-
ist drug treatment: The VEdeTTE study: A national multi-site prospective 
cohort study. Addiction, 102, 1954-1959. Joseph, H., Stancliff, S., & Lan-
grod, J. (2000). Methadone maintenance treatment: A review of historical 
and clinical issues. Mount Sinai Journal of Medicine, 67, 347-364.
614. Cooper, J.R. (1992). Ineffective use of psychoactive drugs: Methadone is 
no exception. Journal of the American Medical Association, 267(2), 281-282. 
615. Gold, M.L., Sorenson, J.L., McCanlies, N., Trier, M., & Dlugosch, G. 
(1988). Tapering from methadone maintenance: Attitudes of clients and staff. 
Journal of Substance Abuse Treatment, 5, 37-44. Joseph, H., Stancliff, S., & 
Langrod, J. (2000). Methadone maintenance treatment: A review of historical 
and clinical issues. Mount Sinai Journal of Medicine, 67, 347-364.
616. Hunt, D.E., Litpon, D.S., Goldsmith, D.S., Strug, D.L., & Spunt, B. 
(1985). “It takes your heart”: the image of methadone maintenance in the 
addict world and the effect on recruitment into treatment. International 
Journal of the Addictions, 20(11-12), 1751-1171. Joseph, H., Stancliff, S., 
& Langrod, J. (2000). Methadone maintenance treatment: A review of his-
torical and clinical issues. Mount Sinai Journal of Medicine, 67, 347-364.
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stigMa as a BaRRieR to RecoveRy
•	 The	stigma	attached	to	addiction,	treatment,	and	recovery	injures	those—the	patient	and	
family—directly affected by these experiences, as well as the larger community.617
•	 The	stigma	attached	to	addiction	perpetuates	the	very	problem	it	is	intended	to	discourage.	
•	 There	is	substantial	shame	embedded	in	the	experience	of	addiction;	people	in	need	of	ad-
diction treatment should not be shamed for seeking the very resources that may be critical 
to their long-term recovery. Yet entry into methadone maintenance, because of the attached 
stigma, is often experienced as failure as a person—and even failure as an addict.618
an addiction/tReatMent/RecoveRy caMpaign 
The stigma attached specifically to methadone maintenance is embedded at the community level 
within a larger body of negative attitudes toward illicit drug use, drug addiction, addiction treat-
ment, and addiction recovery. The best stigma-reduction campaign would aim at general attitudes 
toward addiction, treatment, and recovery, with a sub-campaign that specifically addresses 
stigma related to methadone and other medications. 
Guiding Vision: Create a city and a world in which “people with a history of alcohol or drug 
problems, people in recovery, and people at risk for these problems are valued and treated with 
dignity, and where stigma, accompanying attitudes, discrimination, and other barriers to recovery 
are eliminated.”619
Campaign Goals: To:
•	 Change	public	and	professional	views	on	methadone	maintenance	treatment	from	a	practice	
that just “substitutes one drug/addiction for another” to a scientifically validated medical prac-
tice capable of saving and transforming lives and enhancing the quality of community life.620 
•	 Change	the	view	of	methadone	maintenance	within	the	heroin	using	community	from	that	of	a	
passive process of “giving up” to an assertive lifestyle of active recovery.621 
•	 Put	a	face	and	voice	on	medication-assisted	recovery	by	conveying	the	stories	of	individuals	
and families in long-term addiction recovery and explaining the role MAT programs are playing 
in enhancing the health and safety of particular neighborhoods. 
617. Lavack, A. (2007). Using social marketing to de-stigmatize addic-
tions: A review. Addiction Research and Theory, 15(5), 479-492.
618. Hunt, D.E., Litpon, D.S., Goldsmith, D.S., Strug, D.L., & Spunt, B. 
(1985). “It takes your heart”: the image of methadone maintenance in the 
addict world and the effect on recruitment into treatment. International 
Journal of the Addictions, 20(11-12), 1751-1171.
619. Substance Abuse and Mental Health Services Administration (SAM-
HSA) (2002). National Recovery Month helps reduce stigma. Substance 
Abuse and Mental Health Services Administration. Retrieved June 17, 
2009 from http://www.hazelden.org/web/public/ade20909.page.
620. Joseph, H. (1995). Medical methadone maintenance: The further 
concealment of a stigmatized condition. Unpublished doctoral dissertation, 
City University of New York.
621. Hunt, D.E., Litpon, D.S., Goldsmith, D.S., Strug, D.L., & Spunt, B. 
(1985). “It takes your heart”: the image of methadone maintenance in the 
addict world and the effect on recruitment into treatment. International 
Journal of the Addictions, 20(11-12), 1751-1171.
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•	 Portray	the	contributions	of	people	in	medication-assisted	recovery	to	their	communities	
through their family support, educational, occupational, and community service activities.
•	 Encourage	participation	of	MAT	providers	in	local	community	activities	to	improve	the	public	
image of the methadone clinic/patient.
A Menu of Potential Strategies: Listed below is a menu of potential strategies that might be 
refined and implemented to achieve the goals outlined above. These potential strategies, devel-
oped by the Philadelphia Department of Behavioral Health and Mental Retardation Services, are 
offered as a starting point for local discussion. 
RecoveRy RepResentation and coMMunity MoBilization
1.  Ensure broad representation of people in medication-assisted recovery and professional rep-
resentation from medication-assisted treatment providers within policy advisory groups and 
technical work groups.
2.  Create an organizational structure to lead a campaign to define and promote methadone-
assisted recovery initiation and recovery maintenance (sobriety, global health, and citizenship) 
as a morally honorable pathway of long-term recovery. Try to elevate the legitimacy and vis-
ibility of the campaign via local political sponsorship, e.g., a mayoral commission.
3.  Encourage the inclusion of people in medication-assisted recovery in existing recovery support fel-
lowships and develop/support recovery fellowships specifically for people in medication-assisted 
recovery, e.g., Methadone Anonymous.622 (The encouragement and use of recovery support 
groups has significantly increased in MAT clinics in the United States, and the M.A.R.S. Project in 
New York City is receiving many requests for information about such support groups).623 
4.  Encourage the development of venues through which people in recovery (particularly current 
or former MAT patients) can perform acts of service to those seeking recovery, as well as 
broader acts of community service.
5.  Create a Mayor’s Task Force to assist in the planned relocation of existing treatment programs 
or site locations for new programs—proactive management of “Not in my backyard” (NIMBY) 
resistance by establishing principles for locating addiction treatment and recovery support 
resources. (This may be best addressed within a Task Force that explores siting issues for all 
622. Gilman, S.M., Galanter, M., & Dermatis, H. (2001). Methadone 
Anonymous: A 12-step program for methadone maintained heroin addicts. 
Substance Abuse, 22(4), 247-256. Glickman, L. Galanter, M., Dermatis, 
H., & Dingle, S. (2006). Recovery and spiritual transformation among peer 
leaders of a modified Methadone Anonymous group. Journal of Psychoac-
tive Drugs, 38(4), 531-533. Obuchowsky, M., & Zweben, J.E. (1987). 
Bridging the gap: The methadone client in 12-Step programs. Journal of 
Psychoactive Drugs, 19(3), 301-302. 
623. Ginter, W. (2009). Personal Communication (Interview), June 22, 
2009.
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health and social service programs.) Those principles identified earlier in this article might serve 
as beginning points for discussion. 
6.  Explore ways to use patient writing, art, drama, music, dance, and videography as vehicles of 
education on medication-assisted treatment and recovery. 
coMMunity education 
1.  Design, implement, and evaluate a public education campaign (similar to the drunk driving 
media campaigns of the 1980s and California’s Methadone Saves Lives campaign) through a 
Mayor’s task force that would include representatives from all major local media outlets.
•	 Put	mainstream	faces	and	voices	on	addiction,	treatment,	and	recovery.	
•	 Include	the	faces	of	family	members	whose	lives	have	been	influenced	by	addiction	
treatment and recovery.
•	 Embed	information	on	opioid	addiction	and	medication-assisted	recovery	in	main-
stream healthcare outlets, e.g., medical clinics, pharmacies, health fairs, etc. 
•	 Target	those	zip	codes	experiencing	the	most	severe	opioid	dependence	problems.	
2.  Establish interdisciplinary work groups who, as part of the Mayor’s task force, will be charged 
with: developing/disseminating articles, pamphlets, and training materials on medication-
assisted recovery aimed at reaching local lay and professional audiences; placing articles in 
media outlets; and immediately responding to inaccurate portrayals of medication-assisted 
treatment/recovery by the media.624
3.  Develop and support a corps of people who, through interviews and speeches, can put a 
positive face and voice on medication-assisted recovery; recruit people in medication-assist-
ed recovery for participation in Storytelling Training;625 organize speaking teams of profession-
als and recovery advocates who can speak to local groups; and develop information packets 
to support the work of these teams.
4.  Develop brief information packets and oral presentations that can be used by outreach work-
ers to challenge “street mythologies” on methadone and other medications used in the treat-
ment of addiction. 
624. Jones, D.J. (2002). Methadone patient advocacy—letters to the 
media helps change attitudes. Methadone Today, 6(9), 4. Joseph, H. 
(1995). Medical methadone maintenance: The further concealment of a 
stigmatized condition. Unpublished doctoral dissertation, City University of 
New York.
625. Storytelling Training is a skills-based training for persons in recovery 
to assist them in developing their recovery stories and gaining confidence 
in refining and presenting those stories in public and professional forums. 
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pRofessional education 
1.  Create opportunities for people throughout the treatment system to be exposed to the faces 
and voices of people in long-term medication-assisted recovery.
2.  Ensure that all staff and volunteers working within addiction treatment are educated about the 
effectiveness of medication-assisted treatment, myths versus scientific findings on methadone 
maintenance, the importance of proper dosing in medication-assisted treatment, comparative 
outcomes of medication-assisted and drug-free treatment, and post-treatment outcomes for 
both medication-assisted and drug-free treatment.626 On a monthly basis, provide a central-
ized orientation for all new staff entering the Philadelphia treatment system, with the above 
information included.627 
3.  Provide structured opportunities for staff exchanges between medication-assisted and 
drug-free treatment programs, exchanges that include opportunities for formal and informal 
interactions with staff and patients. Ensure admission policies/practices that allow people in 
medication-assisted treatment to receive collateral treatment and recovery support services 
from other addiction treatment and recovery support organizations, e.g. the integrated treat-
ment of methadone patients for co-occurring alcohol dependence within alcoholism treat-
ment programs.628
4.  Ensure that scientifically grounded information on medication-assisted recovery is included 
in local addiction studies programs and within the in-service training programs of all funded 
addiction treatment programs.
5.  Integrate information on medication-assisted addiction treatment into the curricula of local 
medical schools, and host an annual training for local physicians and psychiatrists on the use 
of medications in the treatment of addiction and best practices for pain management in pa-
tients being treated for addiction with methadone or buprenorphine. Provide information and 
resources on persons in medication-assisted recovery for use in psychology, social work, and 
allied health professional training programs. 
6.  Ensure that all managed care behavioral health organizations (MCBHOs) include an adequate 
number of panel providers with experience or training in the area of medication-assisted opi-
oid treatment and pain management.
626. Kang, S-Y, Magura, S., Nwakese, P., & Demsky, S. (1997). Counselor 
attitudes in methadone maintenance. Journal of Maintenance in the Addic-
tions, 1(2), 41-58.
627. Recent studies—Abraham, A.J., Ducharme, L. & Roman, P. (2009). 
Counselor attitudes toward pharmacotherapies for alcohol dependence, 
Journal of Studies of Alcohol and Drugs, 70, 628-635—suggest that 
counselors are quite receptive to pharmacological adjuncts in the 
treatment of alcohol dependence when given proper training on the use 
of such adjuncts. The extent to which these findings would extend to 
receptiveness to methadone with similar training is unclear.
628. Kipnis, S.S., Herron, A., Perez, J., & Joseph, H. (2001). Integrating 
the methadone patient in the traditional addiction inpatient rehabilitation 
program—problems and solutions. The Mount Sinai Journal of Medicine, 
68(1), 28-32.
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7.  Host a training on medication-assisted treatment for key criminal justice personnel to police 
(via police academy), jail staff, attorneys, and judges—particularly criminal court, drug court, 
and family court judges. This is of paramount importance to the well being pregnant and 
parenting women.629 
8.  Provide orientation to treatment and medication-assisted treatment to key city officials—both 
political leaders and department heads and supervisors. 
non-stigMatizing, RecoveRy-focused language 
1.  Conduct an audit of the core concepts and language of addiction treatment and recovery, 
purging language that perpetuates myths, misunderstandings, and stigma and replacing that 
language with words and phrases that convey respect and hope for multiple pathways of 
long-term recovery. 
2.  Purge language that grew out of moral models of addiction, e.g., dirty/clean. Clarify the mean-
ing of drug free, abstinence, sobriety, and recovery. Promote the Betty Ford Institute’s (BFI) 
three-component consensus definition of recovery: sobriety, global health, and citizenship, in 
which “formerly opioid-dependent individuals who take naltrexone, buprenorphine, or metha-
done as prescribed and are abstinent from alcohol and all other nonprescribed drugs would 
meet this definition of sobriety.”630 
3.  Use the BFI recovery definition in order to achieve conceptual clarity and expose the abstinence-
versus-methadone debate as a false dichotomy. The issue is not one of method but of mission: full 
recovery and a meaningful life in the community—by any means necessary. By the BFI definition 
of recovery, there are individuals who are abstinent from all psychoactive drugs who do not meet 
the criteria for recovery and individuals maintained on methadone who do meet those criteria. 
Recovery is more than the elimination of alcohol and drugs from an otherwise unchanged life, and 
recovery is more than medication-facilitated metabolic stabilization. The BFI definition of recovery 
may help address stigma and discrimination at both professional and public levels.
4.  Encourage members of Methadone Anonymous to advocate for a change in the name of 
the fellowship to something that does not equate methadone with heroin (e.g., Medication-
Assisted Recovery Anonymous). Many other anonymous fellowships include in their names 
the drug or activity to be given up, e.g., Narcotics Anonymous, Cocaine Anonymous, Crystal 
629. Dr. Karol Kaltenbach (2009). Personal communication.
630. Betty Ford Institute Consensus Panel. (2007). What is recovery? 
A working definition from the Betty Ford Institute. Journal of Substance 
Abuse Treatment, 33, 221-228. 
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Meth Anonymous, Gamblers Anonymous. This is not the explicit intent of Methadone Anony-
mous, but that is what is currently being conveyed via its name.631 
5.  Develop a policy statement on language and stigma for dissemination to all DBH/MRS-funded 
treatment programs.
6.  Cease describing methadone maintenance in terms that suggest the equivalency of heroin 
and methadone, such as substitution therapy or replacement therapy, and the use of the 
term detoxification to describe tapering (methadone is a medication, not a toxic substance). 
Replace such language with words and phrases that convey the link between methadone and 
long-term recovery, e.g., medication-assisted treatment and medication-assisted recovery.632
Dole and Nyswander would never prescribe a “substitute” for heroin. When Dole 
used the term “replacement therapy,” he meant it in a physiological sense—that 
there were impairments in the central nervous system caused by the continuous 
use of opiates and that methadone could correct but not cure these impair-
ments. He did not mean that methadone replaces heroin as a legal intoxicant. 
Methadone is a corrective medication, not a substitute for heroin.633 
tReatMent pRactices
1.  Change institutional identities of medication-assisted treatment providers from “methadone 
clinics” to “addiction recovery centers”—as is currently being attempted in the State of New 
York. This would signal the institutional mission of recovery and identify medication as one 
of many tools that can help people achieve that goal. Encourage patients to participate in a 
broad menu of professionally directed and peer-based recovery support activities at the clinic 
or at a closely located recovery support center. Build strong cultures of recovery—a recovery 
haven, refuge, sanctuary—within or in proximity to existing clinics. Expose the least stabilized 
patients to role models who have achieved successful stabilization and long-term recovery.634 
2.  Explore regulatory and funding policy changes that would allow addiction treatment and re-
covery support services to be provided in less stigmatized sites, e.g., mainstream health care 
delivery institutions, schools, churches, neighborhood centers, and other community service 
organizations.635 Expand medical methadone maintenance-methadone provided to the most 
stabilized patients via a monthly visit to a private health practitioner.636 
631. NAMA (1995). On the name of Methadone Anonymous. National 
Alliance of Methadone Advocates, inc, Policy Statement # 6, May, 1994. 
Retrieved July 28, 2009 from http://www.methadone.org/namadocu-
ments/ps06ma_name.html.
632. Maremmani, I., & Pacini, M. (2006). Combating the stigma: Discard-
ing the label “substitution treatment” in favour of “behavior-normalization 
treatment.” Heroin Addiction and Related Clinical Problems, 8(4), 5-8. 
Joseph, H. (2009). Personal Communication (Interview), June 5, 2009. 
Ginter, W. (2009). Personal Communication (Interview), June 22, 2009.
633. Joseph, H. (2009). Personal Communication (Interview), June 5, 
2009.
634. Until opioid treatment programs as a whole develop such vibrant 
cultures of recovery, they will be vulnerable to collective charge that they 
have done little more than transition their patients from an active life 
of hustling and getting high to a life of “methadone, wine and welfare”. 
Prebble, E., & Miller. T. (1977).  Methadone, wine and welfare.  In R. S. 
Weppner (Ed.), Street ethnography (pp. 229-248). Beverly Hills: Sage 
Publications. 
635. Radcliffe, P., & Stevens, A. (2008). Are drug treatment services 
only for ‘thieving junkie scumbags’? Drug users and the management of 
stigmatized identities. Social Science and Medicine, 67(7), 1065-1073.
636. King, V.L., Burke, C., Stoller, K.B., Neufeld, K.J., Peirce, J., Kolodner, 
K., et al. (2008). Implementing methadone medical maintenance in 
community-based clinics: Disseminating evidence-based treatment. 
Journal of Substance Abuse Treatment, 35, 312-321. Marion, I.J. (2009). 
Personal communication with author, June 24, 2009.
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3.  Prohibit the exclusion of persons on methadone or buprenorphine by any organization 
receiving funding. This would add authority to existing regulations prohibiting organizations 
receiving city/state/federal dollars to discriminate against MAT recipients. Any communication 
from public authorities regarding such prohibition should also include the reminder that MAT 
recipients are protected under the American Disabilities Act. 
4.  Improve the public image of methadone clinics by upgrading the exterior and maintenance of 
the physical plant; improve the quality of the clinic visit experience by upgrading the qual-
ity and maintenance of the interior physical plant of methadone clinics. Increase the use of 
“warm welcome” procedures, including casual dress by security personnel. 
5.  Facilitate greater integration between harm reduction (HR) projects (needle-exchange pro-
grams), medication-assisted treatment, and medication-focused recovery advocacy, e.g., pilot 
programs that infuse clearer recovery options into HR, such as recovery-focused outreach 
workers available at needle exchange sites. 
local, state, and fedeRal policy advocacy 
1.  Encourage the development of medication-assisted recovery advocacy groups, e.g., local 
chapters of the National Alliance for Medication-Assisted Recovery (NAMA Recovery), and/or 
the inclusion of people in medication-assisted recovery within existing or emerging recovery 
advocacy organizations. 
2.  Encourage medication-assisted treatment providers to continue their advocacy activities 
through state Associations for the Treatment of Opioid Dependence and the American As-
sociation for the Treatment of Opioid Attendance (AATOD) related to federal, state, and local 
policy/regulatory/funding/research issues. 
3.  Seek alignment of policies, funding guidelines, and mechanism and regulatory guidelines to 
support recovery-focused treatment of chronic opioid dependence. 
4.  Encourage individuals and organizations to seek full legal redress in response to acts of dis-
crimination related to medication-assisted treatment and recovery.
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evaluation
1.  Establish a baseline of community attitudes and practices—among citizens, addiction treat-
ment providers, allied health and human service providers, criminal justice personnel, child 
protection personnel, and members of recovery support fellowships—for use in evaluating this 
overall plan over time. 
The implementation of some of these strategies will require a vanguard of people in methadone-
assisted recovery to involve themselves in a larger recovery advocacy movement. Efforts must be 
made to encourage and support that vanguard. 
suMMaRy 
The social stigma attached to addiction, addiction treatment, and addiction recovery exists at 
cultural, institutional, interpersonal, and intrapersonal levels.637 This stigma is particularly intense 
for those with histories of heroin self-injection and who are in medication-assisted treatment. Ef-
forts to lower stigma and discrimination for those in addiction treatment and recovery, particularly 
those in MAT, will need to operate at all these levels. Commitment at the highest levels is essential 
to the mobilization of citizens to support policies and programs that support long-term personal 
and family recovery from alcohol and other drug problems, and to provide services to youth aimed 
at breaking intergenerational cycles of alcohol and other drug problem transmission in individuals, 
families, and neighborhoods. It is essential to engage multiple stakeholders in formulating strate-
gies to reduce social stigma related to addiction treatment and recovery and to take special action 
to reduce the stigma related to medication-assisted treatment and recovery. Through this process, 
we will use one guiding principle: There are multiple pathways of long-term addiction recovery, and 
all are cause for celebration. 
637. Woll, P. (2005). Healing the stigma of addiction: A guide for treatment 
professionals. Chicago, IL: Great Lakes Addiction Technology Transfer 
Center.
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